Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1068516,minimum level of detection,The minimum level of detection of the method was 40 ng ketoprofen/ml of plasma or 20 ng ketoprofen/ml of urine.,The pharmacokinetics of ketoprofen in man during and after repeated oral dosing (50 mg q.i.d.) with Orudis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1068516/),[ketopren·ng] / [ml],40,499,DB01009,Ketoprofen
,1068516,minimum level of detection,The minimum level of detection of the method was 40 ng ketoprofen/ml of plasma or 20 ng ketoprofen/ml of urine.,The pharmacokinetics of ketoprofen in man during and after repeated oral dosing (50 mg q.i.d.) with Orudis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1068516/),[ketopren·ng] / [ml],20,500,DB01009,Ketoprofen
,21395606,volumes of distribution,"The volumes of distribution of S-ketoprofen for the 6- and 21-day-old piglets were 241.7 (211.3-276.5) mL/kg and 155.0 (138.7-173.1) mL/kg, respectively, while the corresponding parameters for R-ketoprofen were 289.2 (250.3-334.2) mL/kg and 193.0 (168.7-220.8) mL/kg.",Enantioselective pharmacokinetics of ketoprofen in piglets: the significance of neonatal age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395606/),[ml] / [kg],241.7,1052,DB01009,Ketoprofen
,21395606,volumes of distribution,"The volumes of distribution of S-ketoprofen for the 6- and 21-day-old piglets were 241.7 (211.3-276.5) mL/kg and 155.0 (138.7-173.1) mL/kg, respectively, while the corresponding parameters for R-ketoprofen were 289.2 (250.3-334.2) mL/kg and 193.0 (168.7-220.8) mL/kg.",Enantioselective pharmacokinetics of ketoprofen in piglets: the significance of neonatal age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395606/),[ml] / [kg],155.0,1053,DB01009,Ketoprofen
,21395606,volumes of distribution,"The volumes of distribution of S-ketoprofen for the 6- and 21-day-old piglets were 241.7 (211.3-276.5) mL/kg and 155.0 (138.7-173.1) mL/kg, respectively, while the corresponding parameters for R-ketoprofen were 289.2 (250.3-334.2) mL/kg and 193.0 (168.7-220.8) mL/kg.",Enantioselective pharmacokinetics of ketoprofen in piglets: the significance of neonatal age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395606/),[ml] / [kg],289.2,1054,DB01009,Ketoprofen
,21395606,volumes of distribution,"The volumes of distribution of S-ketoprofen for the 6- and 21-day-old piglets were 241.7 (211.3-276.5) mL/kg and 155.0 (138.7-173.1) mL/kg, respectively, while the corresponding parameters for R-ketoprofen were 289.2 (250.3-334.2) mL/kg and 193.0 (168.7-220.8) mL/kg.",Enantioselective pharmacokinetics of ketoprofen in piglets: the significance of neonatal age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395606/),[ml] / [kg],193.0,1055,DB01009,Ketoprofen
,21395606,clearances,"The clearances of R-ketoprofen [948.4 (768.0-1171.2) mL/h/kg and 425 (319.1-566.0) mL/h/kg for the 6- and 21-day-old piglets, respectively] were significantly higher compared to the clearances of S-ketoprofen [57.3 (46.6-70.4) mL/h/kg and 33.8 (27.0-42.2) mL/h/kg for 6- and 21-day-old piglets, respectively].",Enantioselective pharmacokinetics of ketoprofen in piglets: the significance of neonatal age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395606/),[ml] / [h·kg],948.4,1056,DB01009,Ketoprofen
,21395606,clearances,"The clearances of R-ketoprofen [948.4 (768.0-1171.2) mL/h/kg and 425 (319.1-566.0) mL/h/kg for the 6- and 21-day-old piglets, respectively] were significantly higher compared to the clearances of S-ketoprofen [57.3 (46.6-70.4) mL/h/kg and 33.8 (27.0-42.2) mL/h/kg for 6- and 21-day-old piglets, respectively].",Enantioselective pharmacokinetics of ketoprofen in piglets: the significance of neonatal age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395606/),[ml] / [h·kg],425,1057,DB01009,Ketoprofen
,21395606,clearances,"The clearances of R-ketoprofen [948.4 (768.0-1171.2) mL/h/kg and 425 (319.1-566.0) mL/h/kg for the 6- and 21-day-old piglets, respectively] were significantly higher compared to the clearances of S-ketoprofen [57.3 (46.6-70.4) mL/h/kg and 33.8 (27.0-42.2) mL/h/kg for 6- and 21-day-old piglets, respectively].",Enantioselective pharmacokinetics of ketoprofen in piglets: the significance of neonatal age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395606/),[ml] / [h·kg],57.3,1058,DB01009,Ketoprofen
,21395606,clearances,"The clearances of R-ketoprofen [948.4 (768.0-1171.2) mL/h/kg and 425 (319.1-566.0) mL/h/kg for the 6- and 21-day-old piglets, respectively] were significantly higher compared to the clearances of S-ketoprofen [57.3 (46.6-70.4) mL/h/kg and 33.8 (27.0-42.2) mL/h/kg for 6- and 21-day-old piglets, respectively].",Enantioselective pharmacokinetics of ketoprofen in piglets: the significance of neonatal age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395606/),[ml] / [h·kg],33.8,1059,DB01009,Ketoprofen
,21395606,elimination half-life,"The elimination half-life of S-ketoprofen was 3.4h for both age groups, while the elimination half-life of R-ketoprofen was 0.2h for the 6-day-old and 0.4h for the 21-day-old piglets.",Enantioselective pharmacokinetics of ketoprofen in piglets: the significance of neonatal age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395606/),h,3.4,1060,DB01009,Ketoprofen
,21395606,elimination half-life,"The elimination half-life of S-ketoprofen was 3.4h for both age groups, while the elimination half-life of R-ketoprofen was 0.2h for the 6-day-old and 0.4h for the 21-day-old piglets.",Enantioselective pharmacokinetics of ketoprofen in piglets: the significance of neonatal age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395606/),h,0.2,1061,DB01009,Ketoprofen
,21395606,elimination half-life,"The elimination half-life of S-ketoprofen was 3.4h for both age groups, while the elimination half-life of R-ketoprofen was 0.2h for the 6-day-old and 0.4h for the 21-day-old piglets.",Enantioselective pharmacokinetics of ketoprofen in piglets: the significance of neonatal age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395606/),h,0.4,1062,DB01009,Ketoprofen
,21780552,UD50,"UD50 values of ketoprofen patch were 49.9 mg/kg and 48.9 mg/kg for the stomach and the small intestine, respectively, whereas UD50 values of oral ketoprofen were 3.6 mg/kg and 3.7 mg/kg, respectively.","Physical characteristics, pharmacological properties and clinical efficacy of the ketoprofen patch: a new patch formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21780552/),[mg] / [kg],49.9,1755,DB01009,Ketoprofen
,21780552,UD50,"UD50 values of ketoprofen patch were 49.9 mg/kg and 48.9 mg/kg for the stomach and the small intestine, respectively, whereas UD50 values of oral ketoprofen were 3.6 mg/kg and 3.7 mg/kg, respectively.","Physical characteristics, pharmacological properties and clinical efficacy of the ketoprofen patch: a new patch formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21780552/),[mg] / [kg],48.9,1756,DB01009,Ketoprofen
,21780552,UD50,"UD50 values of ketoprofen patch were 49.9 mg/kg and 48.9 mg/kg for the stomach and the small intestine, respectively, whereas UD50 values of oral ketoprofen were 3.6 mg/kg and 3.7 mg/kg, respectively.","Physical characteristics, pharmacological properties and clinical efficacy of the ketoprofen patch: a new patch formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21780552/),[mg] / [kg],3.6,1757,DB01009,Ketoprofen
,21780552,UD50,"UD50 values of ketoprofen patch were 49.9 mg/kg and 48.9 mg/kg for the stomach and the small intestine, respectively, whereas UD50 values of oral ketoprofen were 3.6 mg/kg and 3.7 mg/kg, respectively.","Physical characteristics, pharmacological properties and clinical efficacy of the ketoprofen patch: a new patch formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21780552/),[mg] / [kg],3.7,1758,DB01009,Ketoprofen
,8398601,recovery,"The recovery of total KT in bile was significantly higher after administration of (S)-KT than after (R)-KT [90.1 +/- 3.5% vs 68.8 +/- 8.2%, n = 3, P < 0.05].",Stereoselectivity of biliary excretion of 2-arylpropionates in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398601/),%,90.1,2051,DB01009,Ketoprofen
,8398601,recovery,"The recovery of total KT in bile was significantly higher after administration of (S)-KT than after (R)-KT [90.1 +/- 3.5% vs 68.8 +/- 8.2%, n = 3, P < 0.05].",Stereoselectivity of biliary excretion of 2-arylpropionates in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398601/),%,68.8,2052,DB01009,Ketoprofen
,8398601,terminal half-life,"In normal rats the terminal half-life of (R)-KT was significantly shorter than that of (S)-KT after administration of (R)-KT (2.2 +/- 0.6 h vs 14.3 +/- 4.9 h, n = 3, P < 0.05).",Stereoselectivity of biliary excretion of 2-arylpropionates in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398601/),h,2.2,2053,DB01009,Ketoprofen
,8398601,terminal half-life,"In normal rats the terminal half-life of (R)-KT was significantly shorter than that of (S)-KT after administration of (R)-KT (2.2 +/- 0.6 h vs 14.3 +/- 4.9 h, n = 3, P < 0.05).",Stereoselectivity of biliary excretion of 2-arylpropionates in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398601/),h,14.3,2054,DB01009,Ketoprofen
,3806417,distribution volumes,"The mean distribution volumes for R- and S-ketoprofen were 114 (7.4) and 294 (76) ml/kg, respectively.",Enantioselective disposition of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs. IV. Ketoprofen disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806417/),[ml] / [kg],114,2297,DB01009,Ketoprofen
,3806417,distribution volumes,"The mean distribution volumes for R- and S-ketoprofen were 114 (7.4) and 294 (76) ml/kg, respectively.",Enantioselective disposition of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs. IV. Ketoprofen disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806417/),[ml] / [kg],294,2298,DB01009,Ketoprofen
,3806417,clearance,The mean clearance of the R-enantiomer from plasma was 292 (40) ml/kg/hr compared to 36 (3.2) ml/kg/hr for the S-enantiomer.,Enantioselective disposition of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs. IV. Ketoprofen disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806417/),[ml] / [h·kg],292,2299,DB01009,Ketoprofen
,3806417,clearance,The mean clearance of the R-enantiomer from plasma was 292 (40) ml/kg/hr compared to 36 (3.2) ml/kg/hr for the S-enantiomer.,Enantioselective disposition of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs. IV. Ketoprofen disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806417/),[ml] / [h·kg],36,2300,DB01009,Ketoprofen
,16801987,area under the curve AUC0-x,"Following the i.v. bolus, mean (+/- SEM) area under the curve AUC0-x and clearance (CL) were 9005 +/- 422 ng.h/ml and 0.089 +/- 0.004 l/h/kg.",Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801987/),[h·ng] / [ml],9005,2742,DB01009,Ketoprofen
,16801987,clearance (CL),"Following the i.v. bolus, mean (+/- SEM) area under the curve AUC0-x and clearance (CL) were 9005 +/- 422 ng.h/ml and 0.089 +/- 0.004 l/h/kg.",Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801987/),[l] / [h·kg],0.089,2743,DB01009,Ketoprofen
,16801987,Volumes of distribution Vi,Volumes of distribution Vi and Vss averaged 0.060 +/- 0.006 l/kg and 0.104 +/- 0.003 l/kg.,Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801987/),[l] / [kg],0.060,2744,DB01009,Ketoprofen
,16801987,Vss,Volumes of distribution Vi and Vss averaged 0.060 +/- 0.006 l/kg and 0.104 +/- 0.003 l/kg.,Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801987/),[l] / [kg],0.104,2745,DB01009,Ketoprofen
,16801987,elimination half-life (t1/2e),Mean elimination half-life (t1/2e) and MRT were 1.05 +/- 0.04 h and 1.18 +/- 0.05 h.,Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801987/),h,1.05,2746,DB01009,Ketoprofen
,16801987,MRT,Mean elimination half-life (t1/2e) and MRT were 1.05 +/- 0.04 h and 1.18 +/- 0.05 h.,Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801987/),h,1.18,2747,DB01009,Ketoprofen
,16801987,tmax,"Following single i.m. 25 mg and 50 mg dexketoprofen, a rapid absorption was observed, with tmax values ranging from 0.17 h to 0.75 h.",Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801987/),h,0.17,2748,DB01009,Ketoprofen
,16801987,tmax,"Following single i.m. 25 mg and 50 mg dexketoprofen, a rapid absorption was observed, with tmax values ranging from 0.17 h to 0.75 h.",Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801987/),h,0.75,2749,DB01009,Ketoprofen
,16801987,Cmax,"The corresponding Cmax averaged 1851 +/- 182 ng/ml and 3813 +/- 169 ng/ml, and mean AUC0-x were 3033 +/- 193 ng.h/ml and 5878 +/- 228 ng.h/ml, respectively.",Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801987/),[ng] / [ml],1851,2750,DB01009,Ketoprofen
,16801987,Cmax,"The corresponding Cmax averaged 1851 +/- 182 ng/ml and 3813 +/- 169 ng/ml, and mean AUC0-x were 3033 +/- 193 ng.h/ml and 5878 +/- 228 ng.h/ml, respectively.",Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801987/),[ng] / [ml],3813,2751,DB01009,Ketoprofen
,16801987,AUC0-x,"The corresponding Cmax averaged 1851 +/- 182 ng/ml and 3813 +/- 169 ng/ml, and mean AUC0-x were 3033 +/- 193 ng.h/ml and 5878 +/- 228 ng.h/ml, respectively.",Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801987/),[h·ng] / [ml],3033,2752,DB01009,Ketoprofen
,16801987,AUC0-x,"The corresponding Cmax averaged 1851 +/- 182 ng/ml and 3813 +/- 169 ng/ml, and mean AUC0-x were 3033 +/- 193 ng.h/ml and 5878 +/- 228 ng.h/ml, respectively.",Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801987/),[h·ng] / [ml],5878,2753,DB01009,Ketoprofen
,11496958,apparent plateau,Plasma concentrations increased slowly and reached an apparent plateau of 7-40 ng/ml at 10-12h.,Comparison of tissue concentrations after intramuscular and topical administration of ketoprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11496958/),[ng] / [ml],7-40,5612,DB01009,Ketoprofen
,7262174,bioavailability,The bioavailability from the commercial capsule relative to that from the solution was 99.7% +/- 10.5% and that from the simple capsule was 102% +/- 10%.,Ketoprofen pharmacokinetics and bioavailability based on an improved sensitive and specific assay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7262174/),%,99.7,10687,DB01009,Ketoprofen
,7262174,bioavailability,The bioavailability from the commercial capsule relative to that from the solution was 99.7% +/- 10.5% and that from the simple capsule was 102% +/- 10%.,Ketoprofen pharmacokinetics and bioavailability based on an improved sensitive and specific assay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7262174/),%,102,10688,DB01009,Ketoprofen
,7262174,clearance (Cl/F,"A two-compartment open model was fitted to the solution data giving excellent prediction of the time-to-peak and clearance (Cl/F = 5.2 +/- 1.1l/h) as determined by eye and by log-trapezoidal rule, respectively.",Ketoprofen pharmacokinetics and bioavailability based on an improved sensitive and specific assay. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7262174/),[l] / [h],5.2,10689,DB01009,Ketoprofen
,15595229,oral maximum plasma concentration (Cmax),The median oral maximum plasma concentration (Cmax) exceeded the topical Cmax by nearly 200-fold (4.15 versus 0.021 microg/mL) (p = 0.001).,Relative bioavailability of ketoprofen 20% in a poloxamer-lecithin organogel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595229/),[μg] / [ml],4.15,11532,DB01009,Ketoprofen
,15595229,oral maximum plasma concentration (Cmax),The median oral maximum plasma concentration (Cmax) exceeded the topical Cmax by nearly 200-fold (4.15 versus 0.021 microg/mL) (p = 0.001).,Relative bioavailability of ketoprofen 20% in a poloxamer-lecithin organogel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595229/),[μg] / [ml],0.021,11533,DB01009,Ketoprofen
,15595229,Cmax,The median oral maximum plasma concentration (Cmax) exceeded the topical Cmax by nearly 200-fold (4.15 versus 0.021 microg/mL) (p = 0.001).,Relative bioavailability of ketoprofen 20% in a poloxamer-lecithin organogel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595229/),[μg] / [ml],4.15,11534,DB01009,Ketoprofen
,15595229,Cmax,The median oral maximum plasma concentration (Cmax) exceeded the topical Cmax by nearly 200-fold (4.15 versus 0.021 microg/mL) (p = 0.001).,Relative bioavailability of ketoprofen 20% in a poloxamer-lecithin organogel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595229/),[μg] / [ml],0.021,11535,DB01009,Ketoprofen
,15595229,relative bioavailability,"The median relative bioavailability of topical ketoprofen was 0.48%, with individual subjects' values ranging from 0.18% to 2.1%.",Relative bioavailability of ketoprofen 20% in a poloxamer-lecithin organogel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595229/),%,0.48,11536,DB01009,Ketoprofen
,15595229,relative bioavailability,"The median relative bioavailability of topical ketoprofen was 0.48%, with individual subjects' values ranging from 0.18% to 2.1%.",Relative bioavailability of ketoprofen 20% in a poloxamer-lecithin organogel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595229/),%,0.18,11537,DB01009,Ketoprofen
,15595229,relative bioavailability,"The median relative bioavailability of topical ketoprofen was 0.48%, with individual subjects' values ranging from 0.18% to 2.1%.",Relative bioavailability of ketoprofen 20% in a poloxamer-lecithin organogel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595229/),%,2.1,11538,DB01009,Ketoprofen
,14989364,elimination half-life (t1/2),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),,1.52,12712,DB01009,Ketoprofen
,14989364,elimination half-life (t1/2),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),,0.87,12713,DB01009,Ketoprofen
,14989364,elimination half-life (t1/2),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),,0.31,12714,DB01009,Ketoprofen
,14989364,elimination half-life (t1/2),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),,1.71,12715,DB01009,Ketoprofen
,14989364,elimination half-life (t1/2),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),,0.69,12716,DB01009,Ketoprofen
,14989364,elimination half-life (t1/2),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),,0.26,12717,DB01009,Ketoprofen
,14989364,mean residence time (MRT),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),h,0.45,12718,DB01009,Ketoprofen
,14989364,mean residence time (MRT),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),h,1.25,12719,DB01009,Ketoprofen
,14989364,mean residence time (MRT),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),h,2.20,12720,DB01009,Ketoprofen
,14989364,mean residence time (MRT),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),h,0.38,12721,DB01009,Ketoprofen
,14989364,mean residence time (MRT),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),h,0.99,12722,DB01009,Ketoprofen
,14989364,mean residence time (MRT),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),h,2.47,12723,DB01009,Ketoprofen
,14989364,area under the plasma concentration-time curve (AUC),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),[μg] / [h)·ml],0.87,12724,DB01009,Ketoprofen
,14989364,area under the plasma concentration-time curve (AUC),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),[μg] / [h)·ml],2.93,12725,DB01009,Ketoprofen
,14989364,area under the plasma concentration-time curve (AUC),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),[μg] / [h)·ml],3.24,12726,DB01009,Ketoprofen
,14989364,area under the plasma concentration-time curve (AUC),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),[μg] / [h)·ml],0.67,12727,DB01009,Ketoprofen
,14989364,area under the plasma concentration-time curve (AUC),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),[μg] / [h)·ml],2.78,12728,DB01009,Ketoprofen
,14989364,area under the plasma concentration-time curve (AUC),"Significant differences between the three categories of animals were obtained in elimination half-life (t1/2) (1.52, 0.87 and 0.31 and 1.71, 0.69 and 0.26 in newborn calves, cows in early lactation and cows in gestation, respectively), mean residence time (MRT) (0.45, 1.25, 2.20 and 0.38, 0.99, 2.47 h, in cows in gestation, cows in early lactation and newborn calves, respectively) and area under the plasma concentration-time curve (AUC) (0.87, 2.93, 3.24, and 0.67, 2.78, 5.13 (microg/h)/ml in cows in gestation, cows in early lactation and newborn calves, respectively, for the R-(-) and S-(+) enantiomer, respectively.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),[μg] / [h)·ml],5.13,12729,DB01009,Ketoprofen
,14989364,AUC,"In calves, there was a significant difference in AUC (3.24 vs 5.13 (microg/h)/ml between R-(-)- and S-(+)-ketoprofen.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),[μg] / [h)·ml],3.24,12730,DB01009,Ketoprofen
,14989364,AUC,"In calves, there was a significant difference in AUC (3.24 vs 5.13 (microg/h)/ml between R-(-)- and S-(+)-ketoprofen.",Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14989364/),[μg] / [h)·ml],5.13,12731,DB01009,Ketoprofen
,8300888,U,Urinary ketoprofen conjugate (S:R) ratio was 1.6 +/- .25 and 1.65 +/- .27 for arthritic and nonarthritic subjects.,"Ketoprofen pharmacokinetics in the elderly: influence of rheumatic disease, renal function, and dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8300888/),,1.6,13427,DB01009,Ketoprofen
,8300888,U,Urinary ketoprofen conjugate (S:R) ratio was 1.6 +/- .25 and 1.65 +/- .27 for arthritic and nonarthritic subjects.,"Ketoprofen pharmacokinetics in the elderly: influence of rheumatic disease, renal function, and dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8300888/),,1.65,13428,DB01009,Ketoprofen
,8300888,ketoprofen conjugate (S:R) ratio,Urinary ketoprofen conjugate (S:R) ratio was 1.6 +/- .25 and 1.65 +/- .27 for arthritic and nonarthritic subjects.,"Ketoprofen pharmacokinetics in the elderly: influence of rheumatic disease, renal function, and dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8300888/),,1.6,13429,DB01009,Ketoprofen
,8300888,ketoprofen conjugate (S:R) ratio,Urinary ketoprofen conjugate (S:R) ratio was 1.6 +/- .25 and 1.65 +/- .27 for arthritic and nonarthritic subjects.,"Ketoprofen pharmacokinetics in the elderly: influence of rheumatic disease, renal function, and dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8300888/),,1.65,13430,DB01009,Ketoprofen
,15379436,S:R ratio,(S)-(+)-KTP was the predominant enantiomer; the S:R ratio in the plasma increased from 2.58 +/- 0.38 at 15 min to 5.72 +/- 2.35 at 1 h.,A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),,2.58,13592,DB01009,Ketoprofen
,15379436,S:R ratio,(S)-(+)-KTP was the predominant enantiomer; the S:R ratio in the plasma increased from 2.58 +/- 0.38 at 15 min to 5.72 +/- 2.35 at 1 h.,A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),,5.72,13593,DB01009,Ketoprofen
,15379436,Tmax,"The mean (+/- SD) pharmacokinetic parameters for (S)-(+)-KTP were characterized as Tmax = 0.76 +/- 0.19 h, Cmax = 2.02 +/- 0.41 microg/ml, t1/2el = 1.65 +/- 0.48 h, AUC = 6.06 +/- 1.16 microg.h/ml, Vd/F = 0.39 +/- 0.07 L/kg, Cl/F = 170 +/- 39 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),h,0.76,13594,DB01009,Ketoprofen
,15379436,Cmax,"The mean (+/- SD) pharmacokinetic parameters for (S)-(+)-KTP were characterized as Tmax = 0.76 +/- 0.19 h, Cmax = 2.02 +/- 0.41 microg/ml, t1/2el = 1.65 +/- 0.48 h, AUC = 6.06 +/- 1.16 microg.h/ml, Vd/F = 0.39 +/- 0.07 L/kg, Cl/F = 170 +/- 39 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),[μg] / [ml],2.02,13595,DB01009,Ketoprofen
,15379436,t1/2el,"The mean (+/- SD) pharmacokinetic parameters for (S)-(+)-KTP were characterized as Tmax = 0.76 +/- 0.19 h, Cmax = 2.02 +/- 0.41 microg/ml, t1/2el = 1.65 +/- 0.48 h, AUC = 6.06 +/- 1.16 microg.h/ml, Vd/F = 0.39 +/- 0.07 L/kg, Cl/F = 170 +/- 39 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),h,1.65,13596,DB01009,Ketoprofen
,15379436,AUC,"The mean (+/- SD) pharmacokinetic parameters for (S)-(+)-KTP were characterized as Tmax = 0.76 +/- 0.19 h, Cmax = 2.02 +/- 0.41 microg/ml, t1/2el = 1.65 +/- 0.48 h, AUC = 6.06 +/- 1.16 microg.h/ml, Vd/F = 0.39 +/- 0.07 L/kg, Cl/F = 170 +/- 39 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),[h·μg] / [ml],6.06,13597,DB01009,Ketoprofen
,15379436,Vd/F,"The mean (+/- SD) pharmacokinetic parameters for (S)-(+)-KTP were characterized as Tmax = 0.76 +/- 0.19 h, Cmax = 2.02 +/- 0.41 microg/ml, t1/2el = 1.65 +/- 0.48 h, AUC = 6.06 +/- 1.16 microg.h/ml, Vd/F = 0.39 +/- 0.07 L/kg, Cl/F = 170 +/- 39 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),[l] / [kg],0.39,13598,DB01009,Ketoprofen
,15379436,Cl/F,"The mean (+/- SD) pharmacokinetic parameters for (S)-(+)-KTP were characterized as Tmax = 0.76 +/- 0.19 h, Cmax = 2.02 +/- 0.41 microg/ml, t1/2el = 1.65 +/- 0.48 h, AUC = 6.06 +/- 1.16 microg.h/ml, Vd/F = 0.39 +/- 0.07 L/kg, Cl/F = 170 +/- 39 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),[ml] / [h·kg],170,13599,DB01009,Ketoprofen
,15379436,Tmax,"The mean (+/- SD) pharmacokinetic parameters of MLX were Tmax = 8.5 +/- 1.91 h, Cmax = 0.82 +/- 0.29 microg/ml, t1/2lambda(z) = 12.13 +/- 2.15 h, AUCinf = 15.41 +/- 1.24 microg.h/ml, Vd/F = 0.23 +/- 0.03 L/ kg, and Cl/F = 10 +/- 1.4 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),h,8.5,13600,DB01009,Ketoprofen
,15379436,Cmax,"The mean (+/- SD) pharmacokinetic parameters of MLX were Tmax = 8.5 +/- 1.91 h, Cmax = 0.82 +/- 0.29 microg/ml, t1/2lambda(z) = 12.13 +/- 2.15 h, AUCinf = 15.41 +/- 1.24 microg.h/ml, Vd/F = 0.23 +/- 0.03 L/ kg, and Cl/F = 10 +/- 1.4 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),[μg] / [ml],0.82,13601,DB01009,Ketoprofen
,15379436,t1/2lambda(z),"The mean (+/- SD) pharmacokinetic parameters of MLX were Tmax = 8.5 +/- 1.91 h, Cmax = 0.82 +/- 0.29 microg/ml, t1/2lambda(z) = 12.13 +/- 2.15 h, AUCinf = 15.41 +/- 1.24 microg.h/ml, Vd/F = 0.23 +/- 0.03 L/ kg, and Cl/F = 10 +/- 1.4 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),h,12.13,13602,DB01009,Ketoprofen
,15379436,AUCinf,"The mean (+/- SD) pharmacokinetic parameters of MLX were Tmax = 8.5 +/- 1.91 h, Cmax = 0.82 +/- 0.29 microg/ml, t1/2lambda(z) = 12.13 +/- 2.15 h, AUCinf = 15.41 +/- 1.24 microg.h/ml, Vd/F = 0.23 +/- 0.03 L/ kg, and Cl/F = 10 +/- 1.4 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),[h·μg] / [ml],15.41,13603,DB01009,Ketoprofen
,15379436,Vd/F,"The mean (+/- SD) pharmacokinetic parameters of MLX were Tmax = 8.5 +/- 1.91 h, Cmax = 0.82 +/- 0.29 microg/ml, t1/2lambda(z) = 12.13 +/- 2.15 h, AUCinf = 15.41 +/- 1.24 microg.h/ml, Vd/F = 0.23 +/- 0.03 L/ kg, and Cl/F = 10 +/- 1.4 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),[l] / [kg],0.23,13604,DB01009,Ketoprofen
,15379436,Cl/F,"The mean (+/- SD) pharmacokinetic parameters of MLX were Tmax = 8.5 +/- 1.91 h, Cmax = 0.82 +/- 0.29 microg/ml, t1/2lambda(z) = 12.13 +/- 2.15 h, AUCinf = 15.41 +/- 1.24 microg.h/ml, Vd/F = 0.23 +/- 0.03 L/ kg, and Cl/F = 10 +/- 1.4 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),[ml] / [h·kg],10,13605,DB01009,Ketoprofen
,1810148,steady-state clearances,The mean (+/- SEM) steady-state clearances of (R)-ibuprofen (15.5 +/- 1.1 ml/min/kg) and (S)-ibuprofen (13.6 +/- 1.9 ml/min/kg) were not significantly different from each other (p greater than 0.05) and exceeded the plasma clearance of indocyanine green (4.3 +/- 0.4 ml/min/kg) in a separate group of rabbits (n = 6).,Pharmacokinetics of the enantiomers of ibuprofen in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810148/),[ml] / [kg·min],15.5,14985,DB01009,Ketoprofen
,1810148,steady-state clearances,The mean (+/- SEM) steady-state clearances of (R)-ibuprofen (15.5 +/- 1.1 ml/min/kg) and (S)-ibuprofen (13.6 +/- 1.9 ml/min/kg) were not significantly different from each other (p greater than 0.05) and exceeded the plasma clearance of indocyanine green (4.3 +/- 0.4 ml/min/kg) in a separate group of rabbits (n = 6).,Pharmacokinetics of the enantiomers of ibuprofen in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810148/),[ml] / [kg·min],13.6,14986,DB01009,Ketoprofen
,1810148,plasma clearance,The mean (+/- SEM) steady-state clearances of (R)-ibuprofen (15.5 +/- 1.1 ml/min/kg) and (S)-ibuprofen (13.6 +/- 1.9 ml/min/kg) were not significantly different from each other (p greater than 0.05) and exceeded the plasma clearance of indocyanine green (4.3 +/- 0.4 ml/min/kg) in a separate group of rabbits (n = 6).,Pharmacokinetics of the enantiomers of ibuprofen in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810148/),[ml] / [kg·min],4.3,14987,DB01009,Ketoprofen
,1810148,fi,There was enantiospecific chiral inversion of (R)-ibuprofen to (S)-ibuprofen (fi = 0.30 +/- 0.07) as has been observed in all species so far studied for this 2-arylpropionic acid.,Pharmacokinetics of the enantiomers of ibuprofen in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810148/),,0.30,14988,DB01009,Ketoprofen
,18167095,C(max),"Mean +/- SD C(max) was 5.09 +/- 1.41 microg/mL and 7.62 +/- 1.22 microg/mL after oral and IM doses of 3 mg/kg, respectively.","Evaluation of bioequivalence after oral, intramuscular, and intravenous administration of racemic ketoprofen in pigs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18167095/),[μg] / [ml],5.09,18031,DB01009,Ketoprofen
,18167095,C(max),"Mean +/- SD C(max) was 5.09 +/- 1.41 microg/mL and 7.62 +/- 1.22 microg/mL after oral and IM doses of 3 mg/kg, respectively.","Evaluation of bioequivalence after oral, intramuscular, and intravenous administration of racemic ketoprofen in pigs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18167095/),[μg] / [ml],7.62,18032,DB01009,Ketoprofen
,18167095,elimination half-life,Mean elimination half-life varied from 3.52 +/- 0.90 hours after oral administration of 3 mg/kg to 2.66 +/- 0.50 hours after IV administration.,"Evaluation of bioequivalence after oral, intramuscular, and intravenous administration of racemic ketoprofen in pigs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18167095/),h,3.52,18033,DB01009,Ketoprofen
,18167095,elimination half-life,Mean elimination half-life varied from 3.52 +/- 0.90 hours after oral administration of 3 mg/kg to 2.66 +/- 0.50 hours after IV administration.,"Evaluation of bioequivalence after oral, intramuscular, and intravenous administration of racemic ketoprofen in pigs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18167095/),h,2.66,18034,DB01009,Ketoprofen
,18167095,Time to peak C(max),Time to peak C(max) after administration of all treatments was approximately 1 hour.,"Evaluation of bioequivalence after oral, intramuscular, and intravenous administration of racemic ketoprofen in pigs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18167095/),h,1,18035,DB01009,Ketoprofen
,24648267,Cmax,"The pharmacokinetic and pharmacodynamic parameters expressed as mean ± s.e.m. following administration of 1, 3.2, and 10 mg/kg ketoprofen were: Cmax 1.27 ± 0.08, 3.44 ± 0.20 and 11.76 ± 0.81 μg/mL; AUClast 4.16 ± 0.17, 11.63 ± 0.65 and 28.15 ± 1.32 μg h/mL; and Emax observed (AUCE ): 65.41 ± 7.79, 92.06 ± 6.46 and 98.42 ± 7.53%.",Relationship between blood levels and the anti-hyperalgesic effect of ketoprofen in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24648267/),[μg] / [ml],1.27,20959,DB01009,Ketoprofen
,24648267,Cmax,"The pharmacokinetic and pharmacodynamic parameters expressed as mean ± s.e.m. following administration of 1, 3.2, and 10 mg/kg ketoprofen were: Cmax 1.27 ± 0.08, 3.44 ± 0.20 and 11.76 ± 0.81 μg/mL; AUClast 4.16 ± 0.17, 11.63 ± 0.65 and 28.15 ± 1.32 μg h/mL; and Emax observed (AUCE ): 65.41 ± 7.79, 92.06 ± 6.46 and 98.42 ± 7.53%.",Relationship between blood levels and the anti-hyperalgesic effect of ketoprofen in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24648267/),[μg] / [ml],3.44,20960,DB01009,Ketoprofen
,24648267,Cmax,"The pharmacokinetic and pharmacodynamic parameters expressed as mean ± s.e.m. following administration of 1, 3.2, and 10 mg/kg ketoprofen were: Cmax 1.27 ± 0.08, 3.44 ± 0.20 and 11.76 ± 0.81 μg/mL; AUClast 4.16 ± 0.17, 11.63 ± 0.65 and 28.15 ± 1.32 μg h/mL; and Emax observed (AUCE ): 65.41 ± 7.79, 92.06 ± 6.46 and 98.42 ± 7.53%.",Relationship between blood levels and the anti-hyperalgesic effect of ketoprofen in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24648267/),[μg] / [ml],11.76,20961,DB01009,Ketoprofen
,24648267,AUClast,"The pharmacokinetic and pharmacodynamic parameters expressed as mean ± s.e.m. following administration of 1, 3.2, and 10 mg/kg ketoprofen were: Cmax 1.27 ± 0.08, 3.44 ± 0.20 and 11.76 ± 0.81 μg/mL; AUClast 4.16 ± 0.17, 11.63 ± 0.65 and 28.15 ± 1.32 μg h/mL; and Emax observed (AUCE ): 65.41 ± 7.79, 92.06 ± 6.46 and 98.42 ± 7.53%.",Relationship between blood levels and the anti-hyperalgesic effect of ketoprofen in the rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24648267/),[h·μg] / [ml],4.16,20962,DB01009,Ketoprofen
,24648267,AUClast,"The pharmacokinetic and pharmacodynamic parameters expressed as mean ± s.e.m. following administration of 1, 3.2, and 10 mg/kg ketoprofen were: Cmax 1.27 ± 0.08, 3.44 ± 0.20 and 11.76 ± 0.81 μg/mL; AUClast 4.16 ± 0.17, 11.63 ± 0.65 and 28.15 ± 1.32 μg h/mL; and Emax observed (AUCE ): 65.41 ± 7.79, 92.06 ± 6.46 and 98.42 ± 7.53%.",Relationship between blood levels and the anti-hyperalgesic effect of ketoprofen in the rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24648267/),[h·μg] / [ml],11.63,20963,DB01009,Ketoprofen
,24648267,AUClast,"The pharmacokinetic and pharmacodynamic parameters expressed as mean ± s.e.m. following administration of 1, 3.2, and 10 mg/kg ketoprofen were: Cmax 1.27 ± 0.08, 3.44 ± 0.20 and 11.76 ± 0.81 μg/mL; AUClast 4.16 ± 0.17, 11.63 ± 0.65 and 28.15 ± 1.32 μg h/mL; and Emax observed (AUCE ): 65.41 ± 7.79, 92.06 ± 6.46 and 98.42 ± 7.53%.",Relationship between blood levels and the anti-hyperalgesic effect of ketoprofen in the rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24648267/),[h·μg] / [ml],28.15,20964,DB01009,Ketoprofen
,24648267,Emax observed (AUCE ),"The pharmacokinetic and pharmacodynamic parameters expressed as mean ± s.e.m. following administration of 1, 3.2, and 10 mg/kg ketoprofen were: Cmax 1.27 ± 0.08, 3.44 ± 0.20 and 11.76 ± 0.81 μg/mL; AUClast 4.16 ± 0.17, 11.63 ± 0.65 and 28.15 ± 1.32 μg h/mL; and Emax observed (AUCE ): 65.41 ± 7.79, 92.06 ± 6.46 and 98.42 ± 7.53%.",Relationship between blood levels and the anti-hyperalgesic effect of ketoprofen in the rat. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24648267/),%,65.41,20965,DB01009,Ketoprofen
,24648267,Emax observed (AUCE ),"The pharmacokinetic and pharmacodynamic parameters expressed as mean ± s.e.m. following administration of 1, 3.2, and 10 mg/kg ketoprofen were: Cmax 1.27 ± 0.08, 3.44 ± 0.20 and 11.76 ± 0.81 μg/mL; AUClast 4.16 ± 0.17, 11.63 ± 0.65 and 28.15 ± 1.32 μg h/mL; and Emax observed (AUCE ): 65.41 ± 7.79, 92.06 ± 6.46 and 98.42 ± 7.53%.",Relationship between blood levels and the anti-hyperalgesic effect of ketoprofen in the rat. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24648267/),%,92.06,20966,DB01009,Ketoprofen
,24648267,Emax observed (AUCE ),"The pharmacokinetic and pharmacodynamic parameters expressed as mean ± s.e.m. following administration of 1, 3.2, and 10 mg/kg ketoprofen were: Cmax 1.27 ± 0.08, 3.44 ± 0.20 and 11.76 ± 0.81 μg/mL; AUClast 4.16 ± 0.17, 11.63 ± 0.65 and 28.15 ± 1.32 μg h/mL; and Emax observed (AUCE ): 65.41 ± 7.79, 92.06 ± 6.46 and 98.42 ± 7.53%.",Relationship between blood levels and the anti-hyperalgesic effect of ketoprofen in the rat. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24648267/),%,98.42,20967,DB01009,Ketoprofen
,2903033,AUC S/R ratios,"The mean +/- SD AUC S/R ratios were 11.8 +/- 9.93 (N = 5), 11.0 +/- 2.64 (N = 4), and 33.7 +/- 11.2 (N = 5) after iv, ip, and po doses, respectively.",Stereoselective pharmacokinetics of ketoprofen in the rat. Influence of route of administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903033/),,11.8,23277,DB01009,Ketoprofen
,2903033,AUC S/R ratios,"The mean +/- SD AUC S/R ratios were 11.8 +/- 9.93 (N = 5), 11.0 +/- 2.64 (N = 4), and 33.7 +/- 11.2 (N = 5) after iv, ip, and po doses, respectively.",Stereoselective pharmacokinetics of ketoprofen in the rat. Influence of route of administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903033/),,11.0,23278,DB01009,Ketoprofen
,2903033,AUC S/R ratios,"The mean +/- SD AUC S/R ratios were 11.8 +/- 9.93 (N = 5), 11.0 +/- 2.64 (N = 4), and 33.7 +/- 11.2 (N = 5) after iv, ip, and po doses, respectively.",Stereoselective pharmacokinetics of ketoprofen in the rat. Influence of route of administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903033/),,33.7,23279,DB01009,Ketoprofen
,2903033,AUCs,"Bile duct-cannulated rats (N = 4) had AUCs of 85.4 +/- 58.6 and 22.8 +/- 18.4 (mg/liter) hr for (S)- and (R)-KT, respectively.",Stereoselective pharmacokinetics of ketoprofen in the rat. Influence of route of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903033/),h,85.4,23280,DB01009,Ketoprofen
,2903033,AUCs,"Bile duct-cannulated rats (N = 4) had AUCs of 85.4 +/- 58.6 and 22.8 +/- 18.4 (mg/liter) hr for (S)- and (R)-KT, respectively.",Stereoselective pharmacokinetics of ketoprofen in the rat. Influence of route of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903033/),h,22.8,23281,DB01009,Ketoprofen
,12618066,plasma AUC,"Absorption of both S(+) and R(-) enantiomers was rapid after oral dosing and enantioselective pharmacokinetics was demonstrated by the predominance of S(+) KTP, as indicated by plasma AUC of 20.25 (S(+)KTP) and 4.09 (R(-)KTP) microg h/mL after IV and 6.36 (S(+)KTP) and 1.83 (R(-)KTP) microg h/mL after oral dosing.",Ketoprofen in the cat: pharmacodynamics and chiral pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12618066/),[h·μg] / [ml],20.25,23943,DB01009,Ketoprofen
,12618066,plasma AUC,"Absorption of both S(+) and R(-) enantiomers was rapid after oral dosing and enantioselective pharmacokinetics was demonstrated by the predominance of S(+) KTP, as indicated by plasma AUC of 20.25 (S(+)KTP) and 4.09 (R(-)KTP) microg h/mL after IV and 6.36 (S(+)KTP) and 1.83 (R(-)KTP) microg h/mL after oral dosing.",Ketoprofen in the cat: pharmacodynamics and chiral pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12618066/),[h·μg] / [ml],4.09,23944,DB01009,Ketoprofen
,12618066,plasma AUC,"Absorption of both S(+) and R(-) enantiomers was rapid after oral dosing and enantioselective pharmacokinetics was demonstrated by the predominance of S(+) KTP, as indicated by plasma AUC of 20.25 (S(+)KTP) and 4.09 (R(-)KTP) microg h/mL after IV and 6.36 (S(+)KTP) and 1.83 (R(-)KTP) microg h/mL after oral dosing.",Ketoprofen in the cat: pharmacodynamics and chiral pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12618066/),[h·μg] / [ml],6.36,23945,DB01009,Ketoprofen
,12618066,plasma AUC,"Absorption of both S(+) and R(-) enantiomers was rapid after oral dosing and enantioselective pharmacokinetics was demonstrated by the predominance of S(+) KTP, as indicated by plasma AUC of 20.25 (S(+)KTP) and 4.09 (R(-)KTP) microg h/mL after IV and 6.36 (S(+)KTP) and 1.83 (R(-)KTP) microg h/mL after oral dosing.",Ketoprofen in the cat: pharmacodynamics and chiral pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12618066/),[h·μg] / [ml],1.83,23946,DB01009,Ketoprofen
,16595933,recovery rate,"The in vitro and in vivo recovery rate of the microdialysis probe was 30.42+/-0.74% (n=3) and 40.27+/-2.74% (n=3), respectively.",Pharmacokinetic study of ketoprofen isopropyl ester-loaded lipid microspheres in rat blood using microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16595933/),%,30.42,25908,DB01009,Ketoprofen
,16595933,recovery rate,"The in vitro and in vivo recovery rate of the microdialysis probe was 30.42+/-0.74% (n=3) and 40.27+/-2.74% (n=3), respectively.",Pharmacokinetic study of ketoprofen isopropyl ester-loaded lipid microspheres in rat blood using microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16595933/),%,40.27,25909,DB01009,Ketoprofen
,8593252,R:S ratio,"The R:S ratio in plasma was 33:1 5 min after administration, decreasing to 1:1 at 8 h.",Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),,33:1,28012,DB01009,Ketoprofen
,8593252,R:S ratio,"The R:S ratio in plasma was 33:1 5 min after administration, decreasing to 1:1 at 8 h.",Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),,1:1,28013,DB01009,Ketoprofen
,8593252,Elimination half-life,Elimination half-life was longer for the (S) (2.19 h) than the (R)-enantiomer (1.30 h) and volume of distribution was also somewhat higher for the (S)-enantiomer.,Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),h,2.19,28014,DB01009,Ketoprofen
,8593252,Elimination half-life,Elimination half-life was longer for the (S) (2.19 h) than the (R)-enantiomer (1.30 h) and volume of distribution was also somewhat higher for the (S)-enantiomer.,Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),h,1.30,28015,DB01009,Ketoprofen
,8593252,Body clearance,Body clearance values were 0.119 l/kg/h for (S)-KTP and 0.151 l/kg/h for the (R)-antipode.,Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),[l] / [h·kg],0.119,28016,DB01009,Ketoprofen
,8593252,Body clearance,Body clearance values were 0.119 l/kg/h for (S)-KTP and 0.151 l/kg/h for the (R)-antipode.,Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),[l] / [h·kg],0.151,28017,DB01009,Ketoprofen
,8593252,EC50,"EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.047, 0.042, 0.101, and 0.038 microgram/ml, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),[μg] / [ml],0.047,28018,DB01009,Ketoprofen
,8593252,EC50,"EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.047, 0.042, 0.101, and 0.038 microgram/ml, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),[μg] / [ml],0.042,28019,DB01009,Ketoprofen
,8593252,EC50,"EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.047, 0.042, 0.101, and 0.038 microgram/ml, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),[μg] / [ml],0.101,28020,DB01009,Ketoprofen
,8593252,EC50,"EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.047, 0.042, 0.101, and 0.038 microgram/ml, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),[μg] / [ml],0.038,28021,DB01009,Ketoprofen
,24628410,clearance,S(+) ketoprofen clearance scaled by bioavailability (CL/F) was 0.114 L/kg/h (elimination half-life = 1.62 h).,Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628410/),[l] / [h·kg],0.114,30009,DB01009,Ketoprofen
,24628410,bioavailability (CL/F),S(+) ketoprofen clearance scaled by bioavailability (CL/F) was 0.114 L/kg/h (elimination half-life = 1.62 h).,Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628410/),[l] / [h·kg],0.114,30010,DB01009,Ketoprofen
,24628410,elimination half-life,S(+) ketoprofen clearance scaled by bioavailability (CL/F) was 0.114 L/kg/h (elimination half-life = 1.62 h).,Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628410/),h,1.62,30011,DB01009,Ketoprofen
,24628410,blood CL/F,"For robenacoxib, blood CL/F was 0.684 L/kg/h (elimination half-life = 1.13 h).",Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628410/),[l] / [h·kg],0.684,30012,DB01009,Ketoprofen
,24628410,elimination half-life,"For robenacoxib, blood CL/F was 0.684 L/kg/h (elimination half-life = 1.13 h).",Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628410/),h,1.13,30013,DB01009,Ketoprofen
,24628410,elimination half-lives,"Exudate elimination half-lives were 25.9 and 41.5 h for S(+) ketoprofen and robenacoxib, respectively.",Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628410/),h,25.9,30014,DB01009,Ketoprofen
,24628410,elimination half-lives,"Exudate elimination half-lives were 25.9 and 41.5 h for S(+) ketoprofen and robenacoxib, respectively.",Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628410/),h,41.5,30015,DB01009,Ketoprofen
,24628410,IC50 COX-1/IC50 COX-2 ratios,In vivo IC50 COX-1/IC50 COX-2 ratios were 66.9:1 for robenacoxib and 1:107 for S(+) ketoprofen.,Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628410/),,66.9:1,30016,DB01009,Ketoprofen
,24628410,IC50 COX-1/IC50 COX-2 ratios,In vivo IC50 COX-1/IC50 COX-2 ratios were 66.9:1 for robenacoxib and 1:107 for S(+) ketoprofen.,Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628410/),,1:107,30017,DB01009,Ketoprofen
,6970498,detection limit,"As an example, the practical detection limit for naproxen in plasma was about 0.2 microgram ml-1.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[μg] / [ml],0.2,31759,DB01009,Ketoprofen
,6970498,Vc,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.038,31760,DB01009,Ketoprofen
,6970498,Vdss,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.138,31761,DB01009,Ketoprofen
,6970498,t 1/2 (beta,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,21.3,31762,DB01009,Ketoprofen
,6970498,t 1/2 (alpha),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.99,31763,DB01009,Ketoprofen
,6970498,t 1/2 (ka),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.67,31764,DB01009,Ketoprofen
,7986668,elimination half-life,"The pharmacokinetic parameters for (S)-KP after administration of (S)-KP and for (R)-KP after administration of (R)-KP were, respectively, elimination half-life 2.32 +/- 0.36 and 1.64 +/- 0.40 h; oral clearance 3.50 +/- 0.66 and 7.50 +/- 3.20 ml/min/kg; apparent volume of distribution 0.74 +/- 0.24 and 1.16 +/- 0.76 liter/kg; mean residence time 1.79 +/- 0.77 and 1.41 +/- 0.65 h; area under the concentration/time curve 14.16 +/- 2.93 and 7.31 +/- 2.98 micrograms.h/ml.",Pharmacokinetics of ketoprofen enantiomers in monkeys following single and multiple oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986668/),h,2.32,32314,DB01009,Ketoprofen
,7986668,elimination half-life,"The pharmacokinetic parameters for (S)-KP after administration of (S)-KP and for (R)-KP after administration of (R)-KP were, respectively, elimination half-life 2.32 +/- 0.36 and 1.64 +/- 0.40 h; oral clearance 3.50 +/- 0.66 and 7.50 +/- 3.20 ml/min/kg; apparent volume of distribution 0.74 +/- 0.24 and 1.16 +/- 0.76 liter/kg; mean residence time 1.79 +/- 0.77 and 1.41 +/- 0.65 h; area under the concentration/time curve 14.16 +/- 2.93 and 7.31 +/- 2.98 micrograms.h/ml.",Pharmacokinetics of ketoprofen enantiomers in monkeys following single and multiple oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986668/),h,1.64,32315,DB01009,Ketoprofen
,7986668,oral clearance,"The pharmacokinetic parameters for (S)-KP after administration of (S)-KP and for (R)-KP after administration of (R)-KP were, respectively, elimination half-life 2.32 +/- 0.36 and 1.64 +/- 0.40 h; oral clearance 3.50 +/- 0.66 and 7.50 +/- 3.20 ml/min/kg; apparent volume of distribution 0.74 +/- 0.24 and 1.16 +/- 0.76 liter/kg; mean residence time 1.79 +/- 0.77 and 1.41 +/- 0.65 h; area under the concentration/time curve 14.16 +/- 2.93 and 7.31 +/- 2.98 micrograms.h/ml.",Pharmacokinetics of ketoprofen enantiomers in monkeys following single and multiple oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986668/),[ml] / [kg·min],3.50,32316,DB01009,Ketoprofen
,7986668,oral clearance,"The pharmacokinetic parameters for (S)-KP after administration of (S)-KP and for (R)-KP after administration of (R)-KP were, respectively, elimination half-life 2.32 +/- 0.36 and 1.64 +/- 0.40 h; oral clearance 3.50 +/- 0.66 and 7.50 +/- 3.20 ml/min/kg; apparent volume of distribution 0.74 +/- 0.24 and 1.16 +/- 0.76 liter/kg; mean residence time 1.79 +/- 0.77 and 1.41 +/- 0.65 h; area under the concentration/time curve 14.16 +/- 2.93 and 7.31 +/- 2.98 micrograms.h/ml.",Pharmacokinetics of ketoprofen enantiomers in monkeys following single and multiple oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986668/),[ml] / [kg·min],7.50,32317,DB01009,Ketoprofen
,7986668,apparent volume of distribution,"The pharmacokinetic parameters for (S)-KP after administration of (S)-KP and for (R)-KP after administration of (R)-KP were, respectively, elimination half-life 2.32 +/- 0.36 and 1.64 +/- 0.40 h; oral clearance 3.50 +/- 0.66 and 7.50 +/- 3.20 ml/min/kg; apparent volume of distribution 0.74 +/- 0.24 and 1.16 +/- 0.76 liter/kg; mean residence time 1.79 +/- 0.77 and 1.41 +/- 0.65 h; area under the concentration/time curve 14.16 +/- 2.93 and 7.31 +/- 2.98 micrograms.h/ml.",Pharmacokinetics of ketoprofen enantiomers in monkeys following single and multiple oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986668/),[l] / [kg],0.74,32318,DB01009,Ketoprofen
,7986668,apparent volume of distribution,"The pharmacokinetic parameters for (S)-KP after administration of (S)-KP and for (R)-KP after administration of (R)-KP were, respectively, elimination half-life 2.32 +/- 0.36 and 1.64 +/- 0.40 h; oral clearance 3.50 +/- 0.66 and 7.50 +/- 3.20 ml/min/kg; apparent volume of distribution 0.74 +/- 0.24 and 1.16 +/- 0.76 liter/kg; mean residence time 1.79 +/- 0.77 and 1.41 +/- 0.65 h; area under the concentration/time curve 14.16 +/- 2.93 and 7.31 +/- 2.98 micrograms.h/ml.",Pharmacokinetics of ketoprofen enantiomers in monkeys following single and multiple oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986668/),[l] / [kg],1.16,32319,DB01009,Ketoprofen
,7986668,mean residence time,"The pharmacokinetic parameters for (S)-KP after administration of (S)-KP and for (R)-KP after administration of (R)-KP were, respectively, elimination half-life 2.32 +/- 0.36 and 1.64 +/- 0.40 h; oral clearance 3.50 +/- 0.66 and 7.50 +/- 3.20 ml/min/kg; apparent volume of distribution 0.74 +/- 0.24 and 1.16 +/- 0.76 liter/kg; mean residence time 1.79 +/- 0.77 and 1.41 +/- 0.65 h; area under the concentration/time curve 14.16 +/- 2.93 and 7.31 +/- 2.98 micrograms.h/ml.",Pharmacokinetics of ketoprofen enantiomers in monkeys following single and multiple oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986668/),h,1.79,32320,DB01009,Ketoprofen
,7986668,mean residence time,"The pharmacokinetic parameters for (S)-KP after administration of (S)-KP and for (R)-KP after administration of (R)-KP were, respectively, elimination half-life 2.32 +/- 0.36 and 1.64 +/- 0.40 h; oral clearance 3.50 +/- 0.66 and 7.50 +/- 3.20 ml/min/kg; apparent volume of distribution 0.74 +/- 0.24 and 1.16 +/- 0.76 liter/kg; mean residence time 1.79 +/- 0.77 and 1.41 +/- 0.65 h; area under the concentration/time curve 14.16 +/- 2.93 and 7.31 +/- 2.98 micrograms.h/ml.",Pharmacokinetics of ketoprofen enantiomers in monkeys following single and multiple oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986668/),h,1.41,32321,DB01009,Ketoprofen
,7986668,area under the concentration/time curve,"The pharmacokinetic parameters for (S)-KP after administration of (S)-KP and for (R)-KP after administration of (R)-KP were, respectively, elimination half-life 2.32 +/- 0.36 and 1.64 +/- 0.40 h; oral clearance 3.50 +/- 0.66 and 7.50 +/- 3.20 ml/min/kg; apparent volume of distribution 0.74 +/- 0.24 and 1.16 +/- 0.76 liter/kg; mean residence time 1.79 +/- 0.77 and 1.41 +/- 0.65 h; area under the concentration/time curve 14.16 +/- 2.93 and 7.31 +/- 2.98 micrograms.h/ml.",Pharmacokinetics of ketoprofen enantiomers in monkeys following single and multiple oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986668/),[h·μg] / [ml],14.16,32322,DB01009,Ketoprofen
,7986668,area under the concentration/time curve,"The pharmacokinetic parameters for (S)-KP after administration of (S)-KP and for (R)-KP after administration of (R)-KP were, respectively, elimination half-life 2.32 +/- 0.36 and 1.64 +/- 0.40 h; oral clearance 3.50 +/- 0.66 and 7.50 +/- 3.20 ml/min/kg; apparent volume of distribution 0.74 +/- 0.24 and 1.16 +/- 0.76 liter/kg; mean residence time 1.79 +/- 0.77 and 1.41 +/- 0.65 h; area under the concentration/time curve 14.16 +/- 2.93 and 7.31 +/- 2.98 micrograms.h/ml.",Pharmacokinetics of ketoprofen enantiomers in monkeys following single and multiple oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986668/),[h·μg] / [ml],7.31,32323,DB01009,Ketoprofen
,29433307,Michaelis-Menten constant ( Km),"Using stably transfected HEK293 cells, both enantiomers were found to be substrates of organic anion transporter (OAT)2 with a Michaelis-Menten constant ( Km) of ∼7-12 μM but did not show substrate affinity for other major hepatic uptake transporters.",Role of Hepatic Organic Anion Transporter 2 in the Pharmacokinetics of R- and S-Warfarin: In Vitro Studies and Mechanistic Evaluation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29433307/),μM,∼7-12,41110,DB01009,Ketoprofen
,29433307,Km,"Uptake of both enantiomers by primary human hepatocytes was saturable ( Km ≈ 7-10 μM) and inhibitable by OAT2 inhibitors (e.g., ketoprofen) but not by OATP1B1/1B3 inhibitors (e.g., cyclosporine).",Role of Hepatic Organic Anion Transporter 2 in the Pharmacokinetics of R- and S-Warfarin: In Vitro Studies and Mechanistic Evaluation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29433307/),μM,7-10,41111,DB01009,Ketoprofen
,8789698,t1/2 beta,"For S(+) and R(-)KTP, respectively, pharmacokinetic parameters were, t1/2 beta 0.99 +/- 0.14 h, 0.70 +/- 0.13 h; ClB 0.56 +/- 0.09, 0.92 +/- 0.20 L/h/kg; Vd(ss) 0.53 +/- 0.11, 0.61 +/- 0.10 L/kg.",Influence of formulation on the pharmacokinetics and bioavailability of racemic ketoprofen in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789698/),h,0.99,41731,DB01009,Ketoprofen
,8789698,t1/2 beta,"For S(+) and R(-)KTP, respectively, pharmacokinetic parameters were, t1/2 beta 0.99 +/- 0.14 h, 0.70 +/- 0.13 h; ClB 0.56 +/- 0.09, 0.92 +/- 0.20 L/h/kg; Vd(ss) 0.53 +/- 0.11, 0.61 +/- 0.10 L/kg.",Influence of formulation on the pharmacokinetics and bioavailability of racemic ketoprofen in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789698/),h,0.70,41732,DB01009,Ketoprofen
,8789698,ClB,"For S(+) and R(-)KTP, respectively, pharmacokinetic parameters were, t1/2 beta 0.99 +/- 0.14 h, 0.70 +/- 0.13 h; ClB 0.56 +/- 0.09, 0.92 +/- 0.20 L/h/kg; Vd(ss) 0.53 +/- 0.11, 0.61 +/- 0.10 L/kg.",Influence of formulation on the pharmacokinetics and bioavailability of racemic ketoprofen in horses. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789698/),[l] / [h·kg],0.56,41733,DB01009,Ketoprofen
,8789698,ClB,"For S(+) and R(-)KTP, respectively, pharmacokinetic parameters were, t1/2 beta 0.99 +/- 0.14 h, 0.70 +/- 0.13 h; ClB 0.56 +/- 0.09, 0.92 +/- 0.20 L/h/kg; Vd(ss) 0.53 +/- 0.11, 0.61 +/- 0.10 L/kg.",Influence of formulation on the pharmacokinetics and bioavailability of racemic ketoprofen in horses. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789698/),[l] / [h·kg],0.92,41734,DB01009,Ketoprofen
,8789698,Vd(ss),"For S(+) and R(-)KTP, respectively, pharmacokinetic parameters were, t1/2 beta 0.99 +/- 0.14 h, 0.70 +/- 0.13 h; ClB 0.56 +/- 0.09, 0.92 +/- 0.20 L/h/kg; Vd(ss) 0.53 +/- 0.11, 0.61 +/- 0.10 L/kg.",Influence of formulation on the pharmacokinetics and bioavailability of racemic ketoprofen in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789698/),[l] / [kg],0.53,41735,DB01009,Ketoprofen
,8789698,Vd(ss),"For S(+) and R(-)KTP, respectively, pharmacokinetic parameters were, t1/2 beta 0.99 +/- 0.14 h, 0.70 +/- 0.13 h; ClB 0.56 +/- 0.09, 0.92 +/- 0.20 L/h/kg; Vd(ss) 0.53 +/- 0.11, 0.61 +/- 0.10 L/kg.",Influence of formulation on the pharmacokinetics and bioavailability of racemic ketoprofen in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789698/),[l] / [kg],0.61,41736,DB01009,Ketoprofen
,8789698,bioavailability,"However, bioavailability was very low, 2.67 +/- 0.43 and 5.75 +/- 1.48% for R(-) and S(+)KTP, respectively.",Influence of formulation on the pharmacokinetics and bioavailability of racemic ketoprofen in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789698/),%,2.67,41737,DB01009,Ketoprofen
,8789698,bioavailability,"However, bioavailability was very low, 2.67 +/- 0.43 and 5.75 +/- 1.48% for R(-) and S(+)KTP, respectively.",Influence of formulation on the pharmacokinetics and bioavailability of racemic ketoprofen in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789698/),%,5.75,41738,DB01009,Ketoprofen
,8789698,Bioavailability,"Bioavailability was 50.55 +/- 10.95 and 54.17 +/- 9.9% for R(-) and S(+)KTP, respectively.",Influence of formulation on the pharmacokinetics and bioavailability of racemic ketoprofen in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789698/),%,50.55,41739,DB01009,Ketoprofen
,8789698,Bioavailability,"Bioavailability was 50.55 +/- 10.95 and 54.17 +/- 9.9% for R(-) and S(+)KTP, respectively.",Influence of formulation on the pharmacokinetics and bioavailability of racemic ketoprofen in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789698/),%,54.17,41740,DB01009,Ketoprofen
,24096820,n,n value of this formulation was also found approximately 0.5.,In vitro-in vivo evaluation of in situ gelling and thermosensitive ketoprofen liquid suppositories. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24096820/),,0.5,43112,DB01009,Ketoprofen
,3581635,distribution half-life,The mean (+/- SD) values of clinical parameters were as follows: distribution half-life = 0.34 +/- 0.19 h; elimination half-life = 2.05 +/- 0.58 h; kel = 0.968 +/- 0.282 h-1; k21 = 0.943 +/- 0.425 h-1; k12 = 1.004 +/- 0.708 h-1; volume of central compartment = 5.58 +/- 1.67L; volume of tissue compartment = 5.14 +/- 2.12L; plasma clearance = 5.10 +/- 1.14L/h.,Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581635/),h,0.34,46711,DB01009,Ketoprofen
,3581635,elimination half-life,The mean (+/- SD) values of clinical parameters were as follows: distribution half-life = 0.34 +/- 0.19 h; elimination half-life = 2.05 +/- 0.58 h; kel = 0.968 +/- 0.282 h-1; k21 = 0.943 +/- 0.425 h-1; k12 = 1.004 +/- 0.708 h-1; volume of central compartment = 5.58 +/- 1.67L; volume of tissue compartment = 5.14 +/- 2.12L; plasma clearance = 5.10 +/- 1.14L/h.,Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581635/),h,2.05,46712,DB01009,Ketoprofen
,3581635,kel,The mean (+/- SD) values of clinical parameters were as follows: distribution half-life = 0.34 +/- 0.19 h; elimination half-life = 2.05 +/- 0.58 h; kel = 0.968 +/- 0.282 h-1; k21 = 0.943 +/- 0.425 h-1; k12 = 1.004 +/- 0.708 h-1; volume of central compartment = 5.58 +/- 1.67L; volume of tissue compartment = 5.14 +/- 2.12L; plasma clearance = 5.10 +/- 1.14L/h.,Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581635/),1/[h],0.968,46713,DB01009,Ketoprofen
,3581635,k21,The mean (+/- SD) values of clinical parameters were as follows: distribution half-life = 0.34 +/- 0.19 h; elimination half-life = 2.05 +/- 0.58 h; kel = 0.968 +/- 0.282 h-1; k21 = 0.943 +/- 0.425 h-1; k12 = 1.004 +/- 0.708 h-1; volume of central compartment = 5.58 +/- 1.67L; volume of tissue compartment = 5.14 +/- 2.12L; plasma clearance = 5.10 +/- 1.14L/h.,Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581635/),1/[h],0.943,46714,DB01009,Ketoprofen
,3581635,k12,The mean (+/- SD) values of clinical parameters were as follows: distribution half-life = 0.34 +/- 0.19 h; elimination half-life = 2.05 +/- 0.58 h; kel = 0.968 +/- 0.282 h-1; k21 = 0.943 +/- 0.425 h-1; k12 = 1.004 +/- 0.708 h-1; volume of central compartment = 5.58 +/- 1.67L; volume of tissue compartment = 5.14 +/- 2.12L; plasma clearance = 5.10 +/- 1.14L/h.,Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581635/),1/[h],1.004,46715,DB01009,Ketoprofen
,3581635,volume of central compartment,The mean (+/- SD) values of clinical parameters were as follows: distribution half-life = 0.34 +/- 0.19 h; elimination half-life = 2.05 +/- 0.58 h; kel = 0.968 +/- 0.282 h-1; k21 = 0.943 +/- 0.425 h-1; k12 = 1.004 +/- 0.708 h-1; volume of central compartment = 5.58 +/- 1.67L; volume of tissue compartment = 5.14 +/- 2.12L; plasma clearance = 5.10 +/- 1.14L/h.,Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581635/),l,5.58,46716,DB01009,Ketoprofen
,3581635,volume of tissue compartment,The mean (+/- SD) values of clinical parameters were as follows: distribution half-life = 0.34 +/- 0.19 h; elimination half-life = 2.05 +/- 0.58 h; kel = 0.968 +/- 0.282 h-1; k21 = 0.943 +/- 0.425 h-1; k12 = 1.004 +/- 0.708 h-1; volume of central compartment = 5.58 +/- 1.67L; volume of tissue compartment = 5.14 +/- 2.12L; plasma clearance = 5.10 +/- 1.14L/h.,Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581635/),l,5.14,46717,DB01009,Ketoprofen
,3581635,plasma clearance,The mean (+/- SD) values of clinical parameters were as follows: distribution half-life = 0.34 +/- 0.19 h; elimination half-life = 2.05 +/- 0.58 h; kel = 0.968 +/- 0.282 h-1; k21 = 0.943 +/- 0.425 h-1; k12 = 1.004 +/- 0.708 h-1; volume of central compartment = 5.58 +/- 1.67L; volume of tissue compartment = 5.14 +/- 2.12L; plasma clearance = 5.10 +/- 1.14L/h.,Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581635/),[l] / [h],5.10,46718,DB01009,Ketoprofen
,10875543,AUC,The mean AUC value for diclofenac was increased from 2.29 to 5.04 microg mL(-1) h in the presence of AZT.,"Zidovudine, diclofenac and ketoprofen pharmacokinetic interactions in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10875543/),[h·μg] / [ml],2.29,46732,DB01009,Ketoprofen
,10875543,AUC,The mean AUC value for diclofenac was increased from 2.29 to 5.04 microg mL(-1) h in the presence of AZT.,"Zidovudine, diclofenac and ketoprofen pharmacokinetic interactions in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10875543/),[h·μg] / [ml],5.04,46733,DB01009,Ketoprofen
,2203580,terminal phase half-life,"Sustained release dosage forms are available, which may be beneficial due to the short terminal phase half-life of ketoprofen (1 to 3h).",Clinical pharmacokinetics of ketoprofen and its enantiomers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203580/),h,1 to 3,46734,DB01009,Ketoprofen
,11110100,areas under the curve to infinity (AUC),"The data collected (median and range) were as follows: the areas under the curve to infinity (AUC) (microg/mL per h) were 22.4 (13.5-29.7) and 19.8 (13.8-22.1) for R- and S-KP, respectively, in female camels while the corresponding values in male camels were 16.0 (12.9-22.4) and 14.4 (11.0-19.3).",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),[μg] / [h·ml],22.4,47963,DB01009,Ketoprofen
,11110100,areas under the curve to infinity (AUC),"The data collected (median and range) were as follows: the areas under the curve to infinity (AUC) (microg/mL per h) were 22.4 (13.5-29.7) and 19.8 (13.8-22.1) for R- and S-KP, respectively, in female camels while the corresponding values in male camels were 16.0 (12.9-22.4) and 14.4 (11.0-19.3).",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),[μg] / [h·ml],19.8,47964,DB01009,Ketoprofen
,11110100,areas under the curve to infinity (AUC),"The data collected (median and range) were as follows: the areas under the curve to infinity (AUC) (microg/mL per h) were 22.4 (13.5-29.7) and 19.8 (13.8-22.1) for R- and S-KP, respectively, in female camels while the corresponding values in male camels were 16.0 (12.9-22.4) and 14.4 (11.0-19.3).",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),[μg] / [h·ml],16.0,47965,DB01009,Ketoprofen
,11110100,areas under the curve to infinity (AUC),"The data collected (median and range) were as follows: the areas under the curve to infinity (AUC) (microg/mL per h) were 22.4 (13.5-29.7) and 19.8 (13.8-22.1) for R- and S-KP, respectively, in female camels while the corresponding values in male camels were 16.0 (12.9-22.4) and 14.4 (11.0-19.3).",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),[μg] / [h·ml],14.4,47966,DB01009,Ketoprofen
,11110100,Total body clearances (Cl(t)),"Total body clearances (Cl(t)) were 44.6 (33.7-74.1) and 50.6 (45.2-72.4) mL/kg per h for R- and S-KP, respectively, in female camels and were 62.8 (44.6-77.8) and 69.6 (51.8-91.1) mL/kg per h for R- and S-KP, respectively, in male camels.",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),[ml] / [h·kg],44.6,47967,DB01009,Ketoprofen
,11110100,Total body clearances (Cl(t)),"Total body clearances (Cl(t)) were 44.6 (33.7-74.1) and 50.6 (45.2-72.4) mL/kg per h for R- and S-KP, respectively, in female camels and were 62.8 (44.6-77.8) and 69.6 (51.8-91.1) mL/kg per h for R- and S-KP, respectively, in male camels.",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),[ml] / [h·kg],50.6,47968,DB01009,Ketoprofen
,11110100,Total body clearances (Cl(t)),"Total body clearances (Cl(t)) were 44.6 (33.7-74.1) and 50.6 (45.2-72.4) mL/kg per h for R- and S-KP, respectively, in female camels and were 62.8 (44.6-77.8) and 69.6 (51.8-91.1) mL/kg per h for R- and S-KP, respectively, in male camels.",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),[ml] / [h·kg],62.8,47969,DB01009,Ketoprofen
,11110100,Total body clearances (Cl(t)),"Total body clearances (Cl(t)) were 44.6 (33.7-74.1) and 50.6 (45.2-72.4) mL/kg per h for R- and S-KP, respectively, in female camels and were 62.8 (44.6-77.8) and 69.6 (51.8-91.1) mL/kg per h for R- and S-KP, respectively, in male camels.",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),[ml] / [h·kg],69.6,47970,DB01009,Ketoprofen
,11110100,steady-state volumes of distribution (Vss),"The steady-state volumes of distribution (Vss) were 97.9 (82.8-147.2) and 102.0 (90.1-169.0) mL/kg for R- and S-KP, respectively, in female camels and were significantly different from each other, while the respective values in male camels were 151.5 (105.3-222.3) and 154.0 (114.7-229.0) mL/kg but were not significantly different from each other.",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),[ml] / [kg],97.9,47971,DB01009,Ketoprofen
,11110100,steady-state volumes of distribution (Vss),"The steady-state volumes of distribution (Vss) were 97.9 (82.8-147.2) and 102.0 (90.1-169.0) mL/kg for R- and S-KP, respectively, in female camels and were significantly different from each other, while the respective values in male camels were 151.5 (105.3-222.3) and 154.0 (114.7-229.0) mL/kg but were not significantly different from each other.",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),[ml] / [kg],102.0,47972,DB01009,Ketoprofen
,11110100,steady-state volumes of distribution (Vss),"The steady-state volumes of distribution (Vss) were 97.9 (82.8-147.2) and 102.0 (90.1-169.0) mL/kg for R- and S-KP, respectively, in female camels and were significantly different from each other, while the respective values in male camels were 151.5 (105.3-222.3) and 154.0 (114.7-229.0) mL/kg but were not significantly different from each other.",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),[ml] / [kg],151.5,47973,DB01009,Ketoprofen
,11110100,steady-state volumes of distribution (Vss),"The steady-state volumes of distribution (Vss) were 97.9 (82.8-147.2) and 102.0 (90.1-169.0) mL/kg for R- and S-KP, respectively, in female camels and were significantly different from each other, while the respective values in male camels were 151.5 (105.3-222.3) and 154.0 (114.7-229.0) mL/kg but were not significantly different from each other.",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),[ml] / [kg],154.0,47974,DB01009,Ketoprofen
,11110100,volumes of distribution (area),"The volumes of distribution (area) followed a similar pattern, where the values for R- and S-KP in female camels were 118.5 (95.6-195.2) and 137.6 (115.8-236.2) mL/kg, respectively, and the respective values in male camels were 215.6 (119.1-270.1) and 229.1 (143.3-277.4) mL/kg.",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),[ml] / [kg],118.5,47975,DB01009,Ketoprofen
,11110100,volumes of distribution (area),"The volumes of distribution (area) followed a similar pattern, where the values for R- and S-KP in female camels were 118.5 (95.6-195.2) and 137.6 (115.8-236.2) mL/kg, respectively, and the respective values in male camels were 215.6 (119.1-270.1) and 229.1 (143.3-277.4) mL/kg.",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),[ml] / [kg],137.6,47976,DB01009,Ketoprofen
,11110100,volumes of distribution (area),"The volumes of distribution (area) followed a similar pattern, where the values for R- and S-KP in female camels were 118.5 (95.6-195.2) and 137.6 (115.8-236.2) mL/kg, respectively, and the respective values in male camels were 215.6 (119.1-270.1) and 229.1 (143.3-277.4) mL/kg.",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),[ml] / [kg],215.6,47977,DB01009,Ketoprofen
,11110100,volumes of distribution (area),"The volumes of distribution (area) followed a similar pattern, where the values for R- and S-KP in female camels were 118.5 (95.6-195.2) and 137.6 (115.8-236.2) mL/kg, respectively, and the respective values in male camels were 215.6 (119.1-270.1) and 229.1 (143.3-277.4) mL/kg.",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),[ml] / [kg],229.1,47978,DB01009,Ketoprofen
,11110100,elimination half-lives (t1/2beta),"The elimination half-lives (t1/2beta) were 1.88 (1.42-2.34) h and 1.83 (1.67-2.26) h for R- and S-KP, respectively, in female camels and were significantly different from each other, while the corresponding values in male camels were 2.11 (1.50-4.20) and 2.33 (1.52-3.83) h for R and S-KP, respectively, but were not significantly different from each other.",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),h,1.88,47979,DB01009,Ketoprofen
,11110100,elimination half-lives (t1/2beta),"The elimination half-lives (t1/2beta) were 1.88 (1.42-2.34) h and 1.83 (1.67-2.26) h for R- and S-KP, respectively, in female camels and were significantly different from each other, while the corresponding values in male camels were 2.11 (1.50-4.20) and 2.33 (1.52-3.83) h for R and S-KP, respectively, but were not significantly different from each other.",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),h,1.83,47980,DB01009,Ketoprofen
,11110100,elimination half-lives (t1/2beta),"The elimination half-lives (t1/2beta) were 1.88 (1.42-2.34) h and 1.83 (1.67-2.26) h for R- and S-KP, respectively, in female camels and were significantly different from each other, while the corresponding values in male camels were 2.11 (1.50-4.20) and 2.33 (1.52-3.83) h for R and S-KP, respectively, but were not significantly different from each other.",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),h,2.11,47981,DB01009,Ketoprofen
,11110100,elimination half-lives (t1/2beta),"The elimination half-lives (t1/2beta) were 1.88 (1.42-2.34) h and 1.83 (1.67-2.26) h for R- and S-KP, respectively, in female camels and were significantly different from each other, while the corresponding values in male camels were 2.11 (1.50-4.20) and 2.33 (1.52-3.83) h for R and S-KP, respectively, but were not significantly different from each other.",Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11110100/),h,2.33,47982,DB01009,Ketoprofen
,31564501,maximum blood concentration,"The maximum blood concentration were 0.153 mmol L-1 and 0.0243 mmol L-1, respectively for paracetamol and ketoprofen.",A new gastro-intestinal mathematical model to study drug bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564501/),[mM] / [l],0.153,48681,DB01009,Ketoprofen
,31564501,maximum blood concentration,"The maximum blood concentration were 0.153 mmol L-1 and 0.0243 mmol L-1, respectively for paracetamol and ketoprofen.",A new gastro-intestinal mathematical model to study drug bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564501/),[mM] / [l],0.0243,48682,DB01009,Ketoprofen
,31564501,time to reach the maximum concentration,The time to reach the maximum concentration for the paracetamol and ketoprofen was around 55 min.,A new gastro-intestinal mathematical model to study drug bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564501/),min,55,48683,DB01009,Ketoprofen
,31564501,maximum concentration,"In case of contemporary meal digestion, the maximum concentration of paracetamol in the blood was 0.100 mmol L-1 and 0.0135 mmol L-1 for ketoprofen; the time to reach the maximum concentration was 3 h and 45 min for paracetamol and 3 h and 35 min for ketoprofen.",A new gastro-intestinal mathematical model to study drug bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564501/),[mM] / [l],0.100,48684,DB01009,Ketoprofen
,31564501,maximum concentration,"In case of contemporary meal digestion, the maximum concentration of paracetamol in the blood was 0.100 mmol L-1 and 0.0135 mmol L-1 for ketoprofen; the time to reach the maximum concentration was 3 h and 45 min for paracetamol and 3 h and 35 min for ketoprofen.",A new gastro-intestinal mathematical model to study drug bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564501/),[mM] / [l],0.0135,48685,DB01009,Ketoprofen
,31564501,time to reach the maximum concentration,"In case of contemporary meal digestion, the maximum concentration of paracetamol in the blood was 0.100 mmol L-1 and 0.0135 mmol L-1 for ketoprofen; the time to reach the maximum concentration was 3 h and 45 min for paracetamol and 3 h and 35 min for ketoprofen.",A new gastro-intestinal mathematical model to study drug bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564501/),h,3,48686,DB01009,Ketoprofen
,31564501,time to reach the maximum concentration,"In case of contemporary meal digestion, the maximum concentration of paracetamol in the blood was 0.100 mmol L-1 and 0.0135 mmol L-1 for ketoprofen; the time to reach the maximum concentration was 3 h and 45 min for paracetamol and 3 h and 35 min for ketoprofen.",A new gastro-intestinal mathematical model to study drug bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564501/),min,45,48687,DB01009,Ketoprofen
,31564501,time to reach the maximum concentration,"In case of contemporary meal digestion, the maximum concentration of paracetamol in the blood was 0.100 mmol L-1 and 0.0135 mmol L-1 for ketoprofen; the time to reach the maximum concentration was 3 h and 45 min for paracetamol and 3 h and 35 min for ketoprofen.",A new gastro-intestinal mathematical model to study drug bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564501/),min,35,48688,DB01009,Ketoprofen
,24368338,recoveries,Enantiomer recoveries yielded 100.0 ± 15%.,HPLC method with solid-phase extraction for determination of (R)- and (S)-ketoprofen in plasma without caffeine interference: application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368338/),%,100.0,49544,DB01009,Ketoprofen
,28178590,maximum plasma concentration (Cmax),"The PK parameters in group TG and PG were as follows: maximum plasma concentration (Cmax), 3.42 [0.99] and 4.66 [0.81] mg/l (p=0.0220); area under the plasma concentration-time curve from zero to infinity (AUC0-∞), 9.12 [2.78] and 9.17 [2.87] mg×h/ml (p=0.9734); area under the first moment curve from zero to the time of infinity (AUMC0-∞), 25.95 [8.52] and 26.53 [11.43] mg×h2/l (p=0.9056); time to reach maximum concentration (tmax), 0.47 [0.25] and 0.55 [0.27] h (p=0.5327), respectively.",The pharmacokinetics of oral ketoprofen in patients after gastric resection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28178590/),[mg] / [l],3.42,50712,DB01009,Ketoprofen
,28178590,maximum plasma concentration (Cmax),"The PK parameters in group TG and PG were as follows: maximum plasma concentration (Cmax), 3.42 [0.99] and 4.66 [0.81] mg/l (p=0.0220); area under the plasma concentration-time curve from zero to infinity (AUC0-∞), 9.12 [2.78] and 9.17 [2.87] mg×h/ml (p=0.9734); area under the first moment curve from zero to the time of infinity (AUMC0-∞), 25.95 [8.52] and 26.53 [11.43] mg×h2/l (p=0.9056); time to reach maximum concentration (tmax), 0.47 [0.25] and 0.55 [0.27] h (p=0.5327), respectively.",The pharmacokinetics of oral ketoprofen in patients after gastric resection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28178590/),[mg] / [l],4.66,50713,DB01009,Ketoprofen
,28178590,area under the plasma concentration-time curve from zero to infinity (AUC0-∞),"The PK parameters in group TG and PG were as follows: maximum plasma concentration (Cmax), 3.42 [0.99] and 4.66 [0.81] mg/l (p=0.0220); area under the plasma concentration-time curve from zero to infinity (AUC0-∞), 9.12 [2.78] and 9.17 [2.87] mg×h/ml (p=0.9734); area under the first moment curve from zero to the time of infinity (AUMC0-∞), 25.95 [8.52] and 26.53 [11.43] mg×h2/l (p=0.9056); time to reach maximum concentration (tmax), 0.47 [0.25] and 0.55 [0.27] h (p=0.5327), respectively.",The pharmacokinetics of oral ketoprofen in patients after gastric resection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28178590/),[h·mg] / [ml],9.12,50714,DB01009,Ketoprofen
,28178590,area under the plasma concentration-time curve from zero to infinity (AUC0-∞),"The PK parameters in group TG and PG were as follows: maximum plasma concentration (Cmax), 3.42 [0.99] and 4.66 [0.81] mg/l (p=0.0220); area under the plasma concentration-time curve from zero to infinity (AUC0-∞), 9.12 [2.78] and 9.17 [2.87] mg×h/ml (p=0.9734); area under the first moment curve from zero to the time of infinity (AUMC0-∞), 25.95 [8.52] and 26.53 [11.43] mg×h2/l (p=0.9056); time to reach maximum concentration (tmax), 0.47 [0.25] and 0.55 [0.27] h (p=0.5327), respectively.",The pharmacokinetics of oral ketoprofen in patients after gastric resection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28178590/),[h·mg] / [ml],9.17,50715,DB01009,Ketoprofen
,28178590,area under the first moment curve from zero to the time of infinity (AUMC0-∞),"The PK parameters in group TG and PG were as follows: maximum plasma concentration (Cmax), 3.42 [0.99] and 4.66 [0.81] mg/l (p=0.0220); area under the plasma concentration-time curve from zero to infinity (AUC0-∞), 9.12 [2.78] and 9.17 [2.87] mg×h/ml (p=0.9734); area under the first moment curve from zero to the time of infinity (AUMC0-∞), 25.95 [8.52] and 26.53 [11.43] mg×h2/l (p=0.9056); time to reach maximum concentration (tmax), 0.47 [0.25] and 0.55 [0.27] h (p=0.5327), respectively.",The pharmacokinetics of oral ketoprofen in patients after gastric resection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28178590/),[h2·mg] / [l],25.95,50716,DB01009,Ketoprofen
,28178590,area under the first moment curve from zero to the time of infinity (AUMC0-∞),"The PK parameters in group TG and PG were as follows: maximum plasma concentration (Cmax), 3.42 [0.99] and 4.66 [0.81] mg/l (p=0.0220); area under the plasma concentration-time curve from zero to infinity (AUC0-∞), 9.12 [2.78] and 9.17 [2.87] mg×h/ml (p=0.9734); area under the first moment curve from zero to the time of infinity (AUMC0-∞), 25.95 [8.52] and 26.53 [11.43] mg×h2/l (p=0.9056); time to reach maximum concentration (tmax), 0.47 [0.25] and 0.55 [0.27] h (p=0.5327), respectively.",The pharmacokinetics of oral ketoprofen in patients after gastric resection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28178590/),[h2·mg] / [l],26.53,50717,DB01009,Ketoprofen
,28178590,time to reach maximum concentration (tmax),"The PK parameters in group TG and PG were as follows: maximum plasma concentration (Cmax), 3.42 [0.99] and 4.66 [0.81] mg/l (p=0.0220); area under the plasma concentration-time curve from zero to infinity (AUC0-∞), 9.12 [2.78] and 9.17 [2.87] mg×h/ml (p=0.9734); area under the first moment curve from zero to the time of infinity (AUMC0-∞), 25.95 [8.52] and 26.53 [11.43] mg×h2/l (p=0.9056); time to reach maximum concentration (tmax), 0.47 [0.25] and 0.55 [0.27] h (p=0.5327), respectively.",The pharmacokinetics of oral ketoprofen in patients after gastric resection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28178590/),h,0.47,50718,DB01009,Ketoprofen
,28178590,time to reach maximum concentration (tmax),"The PK parameters in group TG and PG were as follows: maximum plasma concentration (Cmax), 3.42 [0.99] and 4.66 [0.81] mg/l (p=0.0220); area under the plasma concentration-time curve from zero to infinity (AUC0-∞), 9.12 [2.78] and 9.17 [2.87] mg×h/ml (p=0.9734); area under the first moment curve from zero to the time of infinity (AUMC0-∞), 25.95 [8.52] and 26.53 [11.43] mg×h2/l (p=0.9056); time to reach maximum concentration (tmax), 0.47 [0.25] and 0.55 [0.27] h (p=0.5327), respectively.",The pharmacokinetics of oral ketoprofen in patients after gastric resection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28178590/),h,0.55,50719,DB01009,Ketoprofen
,32877823,recoveries,"The mean recoveries of R-(-)- and S-(+)-AMF at three spiked levels of 2.00, 1000.0 and 16000.0 ng mL-1 ranged from 92.0 %-96.1 %, and the intra-day and inter-day relative standard deviations (RSDs) were within 8.9 %.",Enantioseparation and determination of alminoprofen in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32877823/),%,92.0,51408,DB01009,Ketoprofen
,32877823,recoveries,"The mean recoveries of R-(-)- and S-(+)-AMF at three spiked levels of 2.00, 1000.0 and 16000.0 ng mL-1 ranged from 92.0 %-96.1 %, and the intra-day and inter-day relative standard deviations (RSDs) were within 8.9 %.",Enantioseparation and determination of alminoprofen in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32877823/),%,96.1,51409,DB01009,Ketoprofen
,10372597,elimination half-life (t(1/2beta)),"The data obtained (median and range) following i.v. administration was as follows: the elimination half-life (t(1/2beta)) was 4.16 (2.65-4.29) h, the steady state volume of distribution (Vss) was 130.2 (103.4-165.3) mL/kg, volume of distribution (area method) (Vd(area)) was 321.5 (211.4-371.0) mL/kg, total body clearance (Cl) was 1.00 (0.88-1.08) mL/min x kg and renal clearance was 0.01 (0.003-0.033) mL/min x kg.",Pharmacokinetics and metabolism of ketoprofen after intravenous and intramuscular administration in camels. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372597/),h,4.16,53256,DB01009,Ketoprofen
,10372597,steady state volume of distribution (Vss),"The data obtained (median and range) following i.v. administration was as follows: the elimination half-life (t(1/2beta)) was 4.16 (2.65-4.29) h, the steady state volume of distribution (Vss) was 130.2 (103.4-165.3) mL/kg, volume of distribution (area method) (Vd(area)) was 321.5 (211.4-371.0) mL/kg, total body clearance (Cl) was 1.00 (0.88-1.08) mL/min x kg and renal clearance was 0.01 (0.003-0.033) mL/min x kg.",Pharmacokinetics and metabolism of ketoprofen after intravenous and intramuscular administration in camels. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372597/),[ml] / [kg],130.2,53257,DB01009,Ketoprofen
,10372597,volume of distribution (area method) (Vd(area)),"The data obtained (median and range) following i.v. administration was as follows: the elimination half-life (t(1/2beta)) was 4.16 (2.65-4.29) h, the steady state volume of distribution (Vss) was 130.2 (103.4-165.3) mL/kg, volume of distribution (area method) (Vd(area)) was 321.5 (211.4-371.0) mL/kg, total body clearance (Cl) was 1.00 (0.88-1.08) mL/min x kg and renal clearance was 0.01 (0.003-0.033) mL/min x kg.",Pharmacokinetics and metabolism of ketoprofen after intravenous and intramuscular administration in camels. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372597/),[ml] / [kg],321.5,53258,DB01009,Ketoprofen
,10372597,total body clearance (Cl),"The data obtained (median and range) following i.v. administration was as follows: the elimination half-life (t(1/2beta)) was 4.16 (2.65-4.29) h, the steady state volume of distribution (Vss) was 130.2 (103.4-165.3) mL/kg, volume of distribution (area method) (Vd(area)) was 321.5 (211.4-371.0) mL/kg, total body clearance (Cl) was 1.00 (0.88-1.08) mL/min x kg and renal clearance was 0.01 (0.003-0.033) mL/min x kg.",Pharmacokinetics and metabolism of ketoprofen after intravenous and intramuscular administration in camels. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372597/),[ml] / [kg·min],1.00,53259,DB01009,Ketoprofen
,10372597,renal clearance,"The data obtained (median and range) following i.v. administration was as follows: the elimination half-life (t(1/2beta)) was 4.16 (2.65-4.29) h, the steady state volume of distribution (Vss) was 130.2 (103.4-165.3) mL/kg, volume of distribution (area method) (Vd(area)) was 321.5 (211.4-371.0) mL/kg, total body clearance (Cl) was 1.00 (0.88-1.08) mL/min x kg and renal clearance was 0.01 (0.003-0.033) mL/min x kg.",Pharmacokinetics and metabolism of ketoprofen after intravenous and intramuscular administration in camels. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372597/),[ml] / [kg·min],0.01,53260,DB01009,Ketoprofen
,10372597,peak serum concentration,"Following i.m. administration, the drug was rapidly absorbed with peak serum concentration of 12.2 (4.80-14.4) microg/mL at 1.50 (1.00-2.00) h.",Pharmacokinetics and metabolism of ketoprofen after intravenous and intramuscular administration in camels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372597/),[μg] / [ml],12.2,53261,DB01009,Ketoprofen
,10372597,apparent half-life,The apparent half-life was 3.28 (2.56-4.14) h.,Pharmacokinetics and metabolism of ketoprofen after intravenous and intramuscular administration in camels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372597/),h,3.28,53262,DB01009,Ketoprofen
,10372597,detection times,"The detection times for ketoprofen and hydroxy ketoprofen in urine after an intravenous (i.v.) dose of 3.0 mg/kg body weight was 24.00 and 70.00 h, respectively.",Pharmacokinetics and metabolism of ketoprofen after intravenous and intramuscular administration in camels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372597/),h,24.00,53263,DB01009,Ketoprofen
,10372597,detection times,"The detection times for ketoprofen and hydroxy ketoprofen in urine after an intravenous (i.v.) dose of 3.0 mg/kg body weight was 24.00 and 70.00 h, respectively.",Pharmacokinetics and metabolism of ketoprofen after intravenous and intramuscular administration in camels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372597/),h,70.00,53264,DB01009,Ketoprofen
,10372597,Serum protein binding,Serum protein binding of ketoprofen at 20 microg/mL was extensive; (99.1+/-0.15%).,Pharmacokinetics and metabolism of ketoprofen after intravenous and intramuscular administration in camels. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372597/),%,99.1,53265,DB01009,Ketoprofen
,21970858,F(a)F(g),"F(a)F(g) was calculated from pharmacokinetic parameters after intravenous and oral administration or using the portal-systemic concentration difference method, with values ranging from 0.027 (ezetimibe) to 1 (tolcapone).",Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970858/),,0.027,53866,DB01009,Ketoprofen
,21970858,F(a)F(g),"F(a)F(g) was calculated from pharmacokinetic parameters after intravenous and oral administration or using the portal-systemic concentration difference method, with values ranging from 0.027 (ezetimibe) to 1 (tolcapone).",Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970858/),,1,53867,DB01009,Ketoprofen
,21970858,"CL(int, UGT)","Glucuronides of model compounds were observed in the portal plasma after oral administration, with CL(int, UGT) values ranging from 57.8 (tolcapone) to 19,200 µL/min/mg (resveratrol).",Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970858/),[μl] / [mg·min],57.8,53868,DB01009,Ketoprofen
,21970858,"CL(int, UGT)","Glucuronides of model compounds were observed in the portal plasma after oral administration, with CL(int, UGT) values ranging from 57.8 (tolcapone) to 19,200 µL/min/mg (resveratrol).",Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970858/),[μl] / [mg·min],"19,200",53869,DB01009,Ketoprofen
,7506156,maximum nimesulide concentration,"In a pharmacokinetic study of healthy volunteers who received oral nimesulide 100mg as a single dose, the mean maximum nimesulide concentration (0.58 +/- 0.13 mg/L) in seminal fluid was achieved after 2 hours while the maximum seminal fluid: blood plasma ratio 0.32 +/- 0.02 was observed after 4 hours.",Treatment of abacterial prostato-vesiculitis with nimesulide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506156/),[mg] / [l],0.58,55703,DB01009,Ketoprofen
,7506156,maximum seminal fluid: blood plasma ratio,"In a pharmacokinetic study of healthy volunteers who received oral nimesulide 100mg as a single dose, the mean maximum nimesulide concentration (0.58 +/- 0.13 mg/L) in seminal fluid was achieved after 2 hours while the maximum seminal fluid: blood plasma ratio 0.32 +/- 0.02 was observed after 4 hours.",Treatment of abacterial prostato-vesiculitis with nimesulide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506156/),,0.32,55704,DB01009,Ketoprofen
,3242582,time-averaged plasma ketoprofen concentrations,The mean (+/- s.e. mean) time-averaged plasma ketoprofen concentrations over the dosage interval were 0.76 (+/- 0.06) mg l-1 for R-ketoprofen and 0.78 (+/- 0.06) mg l-1 for S-ketoprofen.,The disposition of ketoprofen enantiomers in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3242582/),[mg] / [l],0.76,60022,DB01009,Ketoprofen
,3242582,time-averaged plasma ketoprofen concentrations,The mean (+/- s.e. mean) time-averaged plasma ketoprofen concentrations over the dosage interval were 0.76 (+/- 0.06) mg l-1 for R-ketoprofen and 0.78 (+/- 0.06) mg l-1 for S-ketoprofen.,The disposition of ketoprofen enantiomers in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3242582/),[mg] / [l],0.78,60023,DB01009,Ketoprofen
,16111170,oral bioavailability,"Firocoxib had moderate to high oral bioavailability (54% to 70%), low plasma clearance (4.7 to 5.8 mL/min/kg), and an elimination half-life of 8.7 to 12.2 hours.",In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111170/),%,54,61081,DB01009,Ketoprofen
,16111170,plasma clearance,"Firocoxib had moderate to high oral bioavailability (54% to 70%), low plasma clearance (4.7 to 5.8 mL/min/kg), and an elimination half-life of 8.7 to 12.2 hours.",In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111170/),[ml] / [kg·min],4.7 to 5.8,61082,DB01009,Ketoprofen
,16111170,elimination half-life,"Firocoxib had moderate to high oral bioavailability (54% to 70%), low plasma clearance (4.7 to 5.8 mL/min/kg), and an elimination half-life of 8.7 to 12.2 hours.",In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111170/),h,8.7 to 12.2,61083,DB01009,Ketoprofen
,7291952,minimum level of detection,Ketoprofen concentrations were determined by mass-fragmentography with a minimum level of detection of 0.02 mg/l.,Pharmacokinetics of ketoprofen in patients with chronic renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7291952/),[mg] / [l],0.02,61681,DB01009,Ketoprofen
,32815194,terminal elimination half-life (t1/2ʎz ),"The mean terminal elimination half-life (t1/2ʎz ), area under the concentration-time curve (AUC0-24 ), peak concentration (Cmax ), apparent volume of distribution (Vdarea /F), and total body clearance (CL/F) of cefquinome after the administration alone were 4.85 hr, 11.06 hr*µg/ml, 2.37 µg/mL, 1.23 L/kg, and 0.17 L/h/kg after the first dose, and 5.88 hr, 17.01 hr*µg/mL, 3.04 µg/mL, 0.95 L/kg, and 0.11 L/h/kg after the last dose.",Effect of ketoprofen co-administration on pharmacokinetics of cefquinome following repeated administration in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32815194/),h,4.85,63459,DB01009,Ketoprofen
,32815194,area under the concentration-time curve (AUC0-24 ),"The mean terminal elimination half-life (t1/2ʎz ), area under the concentration-time curve (AUC0-24 ), peak concentration (Cmax ), apparent volume of distribution (Vdarea /F), and total body clearance (CL/F) of cefquinome after the administration alone were 4.85 hr, 11.06 hr*µg/ml, 2.37 µg/mL, 1.23 L/kg, and 0.17 L/h/kg after the first dose, and 5.88 hr, 17.01 hr*µg/mL, 3.04 µg/mL, 0.95 L/kg, and 0.11 L/h/kg after the last dose.",Effect of ketoprofen co-administration on pharmacokinetics of cefquinome following repeated administration in goats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32815194/),[h·μg] / [ml],11.06,63460,DB01009,Ketoprofen
,32815194,area under the concentration-time curve (AUC0-24 ),"The mean terminal elimination half-life (t1/2ʎz ), area under the concentration-time curve (AUC0-24 ), peak concentration (Cmax ), apparent volume of distribution (Vdarea /F), and total body clearance (CL/F) of cefquinome after the administration alone were 4.85 hr, 11.06 hr*µg/ml, 2.37 µg/mL, 1.23 L/kg, and 0.17 L/h/kg after the first dose, and 5.88 hr, 17.01 hr*µg/mL, 3.04 µg/mL, 0.95 L/kg, and 0.11 L/h/kg after the last dose.",Effect of ketoprofen co-administration on pharmacokinetics of cefquinome following repeated administration in goats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32815194/),[μg] / [ml],2.37,63461,DB01009,Ketoprofen
,32815194,peak concentration (Cmax ),"The mean terminal elimination half-life (t1/2ʎz ), area under the concentration-time curve (AUC0-24 ), peak concentration (Cmax ), apparent volume of distribution (Vdarea /F), and total body clearance (CL/F) of cefquinome after the administration alone were 4.85 hr, 11.06 hr*µg/ml, 2.37 µg/mL, 1.23 L/kg, and 0.17 L/h/kg after the first dose, and 5.88 hr, 17.01 hr*µg/mL, 3.04 µg/mL, 0.95 L/kg, and 0.11 L/h/kg after the last dose.",Effect of ketoprofen co-administration on pharmacokinetics of cefquinome following repeated administration in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32815194/),[h·μg] / [ml],11.06,63462,DB01009,Ketoprofen
,32815194,peak concentration (Cmax ),"The mean terminal elimination half-life (t1/2ʎz ), area under the concentration-time curve (AUC0-24 ), peak concentration (Cmax ), apparent volume of distribution (Vdarea /F), and total body clearance (CL/F) of cefquinome after the administration alone were 4.85 hr, 11.06 hr*µg/ml, 2.37 µg/mL, 1.23 L/kg, and 0.17 L/h/kg after the first dose, and 5.88 hr, 17.01 hr*µg/mL, 3.04 µg/mL, 0.95 L/kg, and 0.11 L/h/kg after the last dose.",Effect of ketoprofen co-administration on pharmacokinetics of cefquinome following repeated administration in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32815194/),[μg] / [ml],2.37,63463,DB01009,Ketoprofen
,32815194,apparent volume of distribution (Vdarea /F),"The mean terminal elimination half-life (t1/2ʎz ), area under the concentration-time curve (AUC0-24 ), peak concentration (Cmax ), apparent volume of distribution (Vdarea /F), and total body clearance (CL/F) of cefquinome after the administration alone were 4.85 hr, 11.06 hr*µg/ml, 2.37 µg/mL, 1.23 L/kg, and 0.17 L/h/kg after the first dose, and 5.88 hr, 17.01 hr*µg/mL, 3.04 µg/mL, 0.95 L/kg, and 0.11 L/h/kg after the last dose.",Effect of ketoprofen co-administration on pharmacokinetics of cefquinome following repeated administration in goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32815194/),[h·μg] / [ml],11.06,63464,DB01009,Ketoprofen
,32815194,apparent volume of distribution (Vdarea /F),"The mean terminal elimination half-life (t1/2ʎz ), area under the concentration-time curve (AUC0-24 ), peak concentration (Cmax ), apparent volume of distribution (Vdarea /F), and total body clearance (CL/F) of cefquinome after the administration alone were 4.85 hr, 11.06 hr*µg/ml, 2.37 µg/mL, 1.23 L/kg, and 0.17 L/h/kg after the first dose, and 5.88 hr, 17.01 hr*µg/mL, 3.04 µg/mL, 0.95 L/kg, and 0.11 L/h/kg after the last dose.",Effect of ketoprofen co-administration on pharmacokinetics of cefquinome following repeated administration in goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32815194/),[μg] / [ml],2.37,63465,DB01009,Ketoprofen
,32815194,total body clearance (CL/F),"The mean terminal elimination half-life (t1/2ʎz ), area under the concentration-time curve (AUC0-24 ), peak concentration (Cmax ), apparent volume of distribution (Vdarea /F), and total body clearance (CL/F) of cefquinome after the administration alone were 4.85 hr, 11.06 hr*µg/ml, 2.37 µg/mL, 1.23 L/kg, and 0.17 L/h/kg after the first dose, and 5.88 hr, 17.01 hr*µg/mL, 3.04 µg/mL, 0.95 L/kg, and 0.11 L/h/kg after the last dose.",Effect of ketoprofen co-administration on pharmacokinetics of cefquinome following repeated administration in goats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32815194/),[l] / [h·kg],0.17,63466,DB01009,Ketoprofen
,32815194,total body clearance (CL/F),"The mean terminal elimination half-life (t1/2ʎz ), area under the concentration-time curve (AUC0-24 ), peak concentration (Cmax ), apparent volume of distribution (Vdarea /F), and total body clearance (CL/F) of cefquinome after the administration alone were 4.85 hr, 11.06 hr*µg/ml, 2.37 µg/mL, 1.23 L/kg, and 0.17 L/h/kg after the first dose, and 5.88 hr, 17.01 hr*µg/mL, 3.04 µg/mL, 0.95 L/kg, and 0.11 L/h/kg after the last dose.",Effect of ketoprofen co-administration on pharmacokinetics of cefquinome following repeated administration in goats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32815194/),[l] / [h·kg],0.11,63467,DB01009,Ketoprofen
above,32815194,T> minimum inhibitory concentration (MIC),"The 24-hr dosing intervals at 2 mg/kg dose of cefquinome, which co-administered with ketoprofen, may maintain T> minimum inhibitory concentration (MIC) values above 40% in the treatment of infections caused by susceptible pathogens with the MIC value of ≤0.75 μg/ml in goats with an inflammatory condition.",Effect of ketoprofen co-administration on pharmacokinetics of cefquinome following repeated administration in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32815194/),%,40,63468,DB01009,Ketoprofen
≤,32815194,MIC,"The 24-hr dosing intervals at 2 mg/kg dose of cefquinome, which co-administered with ketoprofen, may maintain T> minimum inhibitory concentration (MIC) values above 40% in the treatment of infections caused by susceptible pathogens with the MIC value of ≤0.75 μg/ml in goats with an inflammatory condition.",Effect of ketoprofen co-administration on pharmacokinetics of cefquinome following repeated administration in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32815194/),[μg] / [ml],0.75,63469,DB01009,Ketoprofen
,9811435,half-life of elimination (t1/2beta),"Pharmacokinetic parameters from each goat were combined to obtain mean estimates (mean +/- SD) of half-life of elimination (t1/2beta) of 0.32 +/- 0.14 h, systemic clearance (Cl) of 0.74 +/- 0.12 L/kg x h, and volume of distribution at steady state (V(ss)) of 0.23 +/- 0.051 L/kg.",Pharmacokinetic parameters and milk concentrations of ketoprofen after administration as a single intravenous bolus dose to lactating goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811435/),h,0.32,65706,DB01009,Ketoprofen
,9811435,systemic clearance (Cl),"Pharmacokinetic parameters from each goat were combined to obtain mean estimates (mean +/- SD) of half-life of elimination (t1/2beta) of 0.32 +/- 0.14 h, systemic clearance (Cl) of 0.74 +/- 0.12 L/kg x h, and volume of distribution at steady state (V(ss)) of 0.23 +/- 0.051 L/kg.",Pharmacokinetic parameters and milk concentrations of ketoprofen after administration as a single intravenous bolus dose to lactating goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811435/),[l] / [h·kg],0.74,65707,DB01009,Ketoprofen
,9811435,volume of distribution at steady state (V(ss)),"Pharmacokinetic parameters from each goat were combined to obtain mean estimates (mean +/- SD) of half-life of elimination (t1/2beta) of 0.32 +/- 0.14 h, systemic clearance (Cl) of 0.74 +/- 0.12 L/kg x h, and volume of distribution at steady state (V(ss)) of 0.23 +/- 0.051 L/kg.",Pharmacokinetic parameters and milk concentrations of ketoprofen after administration as a single intravenous bolus dose to lactating goats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811435/),[l] / [kg],0.23,65708,DB01009,Ketoprofen
,9811435,level of detection,"In milk, ketoprofen was unmeasurable by the method employed (level of detection 25 ng/mL) for all samples.",Pharmacokinetic parameters and milk concentrations of ketoprofen after administration as a single intravenous bolus dose to lactating goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811435/),[ng] / [ml],25,65709,DB01009,Ketoprofen
,22401710,feed rate,The optimal parameters of spray drying were 100°C for inlet air temperature and 1.5 mL/min for feed rate.,Preparation and in vitro/in vivo evaluation of a ketoprofen orally disintegrating/sustained release tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22401710/),[ml] / [min],1.5,69455,DB01009,Ketoprofen
,10583018,S:R ratios,"In contrast with the R-isomers, S-ketoprofen and S-ketoprofen glucuronide exhibited an unexpected accumulation (2.7-3. 8 fold) after repeated dosing achieving S:R ratios of 3.3+/-1.7 and 11.2+/-5.3, respectively.",Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583018/),,3.3,69596,DB01009,Ketoprofen
,10583018,S:R ratios,"In contrast with the R-isomers, S-ketoprofen and S-ketoprofen glucuronide exhibited an unexpected accumulation (2.7-3. 8 fold) after repeated dosing achieving S:R ratios of 3.3+/-1.7 and 11.2+/-5.3, respectively.",Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583018/),,11.2,69597,DB01009,Ketoprofen
,10583018,plasma dialysis clearances,"The plasma dialysis clearances for R- and S-ketoprofen glucuronides were 49.4+/-19.8 and 39.0+/-15.9 ml min-1, respectively, and 10.8+/-17.6 and 13.3+/-23.5 ml min-1 for unconjugated R- and S-ketoprofen.",Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583018/),[ml] / [min],49.4,69598,DB01009,Ketoprofen
,10583018,plasma dialysis clearances,"The plasma dialysis clearances for R- and S-ketoprofen glucuronides were 49.4+/-19.8 and 39.0+/-15.9 ml min-1, respectively, and 10.8+/-17.6 and 13.3+/-23.5 ml min-1 for unconjugated R- and S-ketoprofen.",Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583018/),[ml] / [min],39.0,69599,DB01009,Ketoprofen
,10583018,plasma dialysis clearances,"The plasma dialysis clearances for R- and S-ketoprofen glucuronides were 49.4+/-19.8 and 39.0+/-15.9 ml min-1, respectively, and 10.8+/-17.6 and 13.3+/-23.5 ml min-1 for unconjugated R- and S-ketoprofen.",Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583018/),[ml] / [min],10.8,69600,DB01009,Ketoprofen
,10583018,plasma dialysis clearances,"The plasma dialysis clearances for R- and S-ketoprofen glucuronides were 49.4+/-19.8 and 39.0+/-15.9 ml min-1, respectively, and 10.8+/-17.6 and 13.3+/-23.5 ml min-1 for unconjugated R- and S-ketoprofen.",Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583018/),[ml] / [min],13.3,69601,DB01009,Ketoprofen
,8587147,elimination half-life (t1/2 beta),"S(+)- and R(-)- KTP each had a short elimination half-life (t1/2 beta) of 0.42 +/- 0.08 h and 0.42 +/- 0.09 h, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),h,0.42,73070,DB01009,Ketoprofen
,8587147,elimination half-life (t1/2 beta),"S(+)- and R(-)- KTP each had a short elimination half-life (t1/2 beta) of 0.42 +/- 0.08 h and 0.42 +/- 0.09 h, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),h,0.42,73071,DB01009,Ketoprofen
,8587147,volume of distribution (Vd),"The volume of distribution (Vd) was low, values of 0.20 +/- 0.06 L/kg and 0.22 +/- 0.06 L/kg being obtained for R(-) and S(+)KTP, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),[l] / [kg],0.20,73072,DB01009,Ketoprofen
,8587147,volume of distribution (Vd),"The volume of distribution (Vd) was low, values of 0.20 +/- 0.06 L/kg and 0.22 +/- 0.06 L/kg being obtained for R(-) and S(+)KTP, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),[l] / [kg],0.22,73073,DB01009,Ketoprofen
,8587147,elimination half-life,"Body clearance (ClB) was high, correlating with the short elimination half-life, 0.33 +/- 0.03 L/kg/h [R(-)KTP] and 0.32 +/- 0.04 L/kg/h [S(+)-KTP].",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),[l] / [h·kg],0.33,73074,DB01009,Ketoprofen
,8587147,elimination half-life,"Body clearance (ClB) was high, correlating with the short elimination half-life, 0.33 +/- 0.03 L/kg/h [R(-)KTP] and 0.32 +/- 0.04 L/kg/h [S(+)-KTP].",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),[l] / [h·kg],0.32,73075,DB01009,Ketoprofen
,8587147,EC50,"The mean EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.118, 0.086, 0.06 and 0.00029 microgram/mL, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),[μg] / [ml],0.118,73076,DB01009,Ketoprofen
,8587147,EC50,"The mean EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.118, 0.086, 0.06 and 0.00029 microgram/mL, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),[μg] / [ml],0.086,73077,DB01009,Ketoprofen
,8587147,EC50,"The mean EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.118, 0.086, 0.06 and 0.00029 microgram/mL, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),[μg] / [ml],0.06,73078,DB01009,Ketoprofen
,8587147,EC50,"The mean EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.118, 0.086, 0.06 and 0.00029 microgram/mL, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),[μg] / [ml],0.00029,73079,DB01009,Ketoprofen
,27163498,T0,"A significant difference (P < .01) was found between lag-time medians (T0 ), with a longer T0 after food intake (5.5 vs 2.5 hours).",Sex and Food Influence on Intestinal Absorption of Ketoprofen Gastroresistant Formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163498/),h,5.5,73807,DB01009,Ketoprofen
,27163498,T0,"A significant difference (P < .01) was found between lag-time medians (T0 ), with a longer T0 after food intake (5.5 vs 2.5 hours).",Sex and Food Influence on Intestinal Absorption of Ketoprofen Gastroresistant Formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163498/),h,2.5,73808,DB01009,Ketoprofen
,27163498,Tmax,"Also, a significant difference between the medians of Tmax was found (P < .01), being 7.0 hours after food coadministration and 4.0 hours under fasting administration, but this difference disappeared once T0 was subtracted from Tmax .",Sex and Food Influence on Intestinal Absorption of Ketoprofen Gastroresistant Formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163498/),h,7.0,73809,DB01009,Ketoprofen
,27163498,Tmax,"Also, a significant difference between the medians of Tmax was found (P < .01), being 7.0 hours after food coadministration and 4.0 hours under fasting administration, but this difference disappeared once T0 was subtracted from Tmax .",Sex and Food Influence on Intestinal Absorption of Ketoprofen Gastroresistant Formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163498/),h,4.0,73810,DB01009,Ketoprofen
,27163498,Cmax /AUC,Men showed higher (P =.006) Cmax /AUC means (0.468 ± 0.094 vs 0.361 ± 0.087 h(-1) .,Sex and Food Influence on Intestinal Absorption of Ketoprofen Gastroresistant Formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163498/),1/[h],0.468,73811,DB01009,Ketoprofen
,27163498,Cmax /AUC,Men showed higher (P =.006) Cmax /AUC means (0.468 ± 0.094 vs 0.361 ± 0.087 h(-1) .,Sex and Food Influence on Intestinal Absorption of Ketoprofen Gastroresistant Formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163498/),1/[h],0.361,73812,DB01009,Ketoprofen
,27163498,Tmax,"Tmax was also significantly different (P < .05), being 4.0 (3.0-5.0) hours for men and 8.0 (5.0-10.0) hours for women.",Sex and Food Influence on Intestinal Absorption of Ketoprofen Gastroresistant Formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163498/),h,4.0,73813,DB01009,Ketoprofen
,27163498,Tmax,"Tmax was also significantly different (P < .05), being 4.0 (3.0-5.0) hours for men and 8.0 (5.0-10.0) hours for women.",Sex and Food Influence on Intestinal Absorption of Ketoprofen Gastroresistant Formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163498/),h,8.0,73814,DB01009,Ketoprofen
,29057479,Cmax,"S-isomer pharmacokinetic parameters determined in this study were Cmax of 10.1 μg/ml by IM injection, C0 of 13.4 μg/ml by IV injection, AUC of 44.7 or 69.4 μg*hr/ml by IM or IV injection, respectively, and T½ of 2.8 or 3.6 hr by IM or IV injection, respectively.",Ketoprofen pharmacokinetics of R- and S-isomers in juvenile loggerhead sea turtles (Caretta caretta) after single intravenous and single- and multidose intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29057479/),[μg] / [ml],10.1,74987,DB01009,Ketoprofen
,29057479,C0,"S-isomer pharmacokinetic parameters determined in this study were Cmax of 10.1 μg/ml by IM injection, C0 of 13.4 μg/ml by IV injection, AUC of 44.7 or 69.4 μg*hr/ml by IM or IV injection, respectively, and T½ of 2.8 or 3.6 hr by IM or IV injection, respectively.",Ketoprofen pharmacokinetics of R- and S-isomers in juvenile loggerhead sea turtles (Caretta caretta) after single intravenous and single- and multidose intramuscular administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29057479/),[μg] / [ml],13.4,74988,DB01009,Ketoprofen
,29057479,AUC,"S-isomer pharmacokinetic parameters determined in this study were Cmax of 10.1 μg/ml by IM injection, C0 of 13.4 μg/ml by IV injection, AUC of 44.7 or 69.4 μg*hr/ml by IM or IV injection, respectively, and T½ of 2.8 or 3.6 hr by IM or IV injection, respectively.",Ketoprofen pharmacokinetics of R- and S-isomers in juvenile loggerhead sea turtles (Caretta caretta) after single intravenous and single- and multidose intramuscular administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29057479/),[h·μg] / [ml],44.7,74989,DB01009,Ketoprofen
,29057479,AUC,"S-isomer pharmacokinetic parameters determined in this study were Cmax of 10.1 μg/ml by IM injection, C0 of 13.4 μg/ml by IV injection, AUC of 44.7 or 69.4 μg*hr/ml by IM or IV injection, respectively, and T½ of 2.8 or 3.6 hr by IM or IV injection, respectively.",Ketoprofen pharmacokinetics of R- and S-isomers in juvenile loggerhead sea turtles (Caretta caretta) after single intravenous and single- and multidose intramuscular administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29057479/),[h·μg] / [ml],69.4,74990,DB01009,Ketoprofen
,29057479,T½,"S-isomer pharmacokinetic parameters determined in this study were Cmax of 10.1 μg/ml by IM injection, C0 of 13.4 μg/ml by IV injection, AUC of 44.7 or 69.4 μg*hr/ml by IM or IV injection, respectively, and T½ of 2.8 or 3.6 hr by IM or IV injection, respectively.",Ketoprofen pharmacokinetics of R- and S-isomers in juvenile loggerhead sea turtles (Caretta caretta) after single intravenous and single- and multidose intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29057479/),h,2.8,74991,DB01009,Ketoprofen
,29057479,T½,"S-isomer pharmacokinetic parameters determined in this study were Cmax of 10.1 μg/ml by IM injection, C0 of 13.4 μg/ml by IV injection, AUC of 44.7 or 69.4 μg*hr/ml by IM or IV injection, respectively, and T½ of 2.8 or 3.6 hr by IM or IV injection, respectively.",Ketoprofen pharmacokinetics of R- and S-isomers in juvenile loggerhead sea turtles (Caretta caretta) after single intravenous and single- and multidose intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29057479/),h,3.6,74992,DB01009,Ketoprofen
,11942870,steady state plasma concentration,The steady state plasma concentration of ketoprofen was 2.0 microg/mL (range 1.3-2.7 microg/mL).,Pharmacokinetics of a 24-hour intravenous ketoprofen infusion in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11942870/),[μg] / [ml],2.0,80847,DB01009,Ketoprofen
,11942870,clearance,The clearance of ketoprofen was 0.09 L x h(-1) x kg(-1) (range 0.06-0.13 L x h(-1) x kg(-1)).,Pharmacokinetics of a 24-hour intravenous ketoprofen infusion in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11942870/),[l] / [h·kg],0.09,80848,DB01009,Ketoprofen
,11942870,distribution volume,The distribution volume was 0.16 L/kg (range 0.12-0.21 L/kg).,Pharmacokinetics of a 24-hour intravenous ketoprofen infusion in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11942870/),[l] / [kg],0.16,80849,DB01009,Ketoprofen
,11942870,terminal half-life,The terminal half-life was 1.3 h (range 0.8-1.7 h).,Pharmacokinetics of a 24-hour intravenous ketoprofen infusion in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11942870/),h,1.3,80850,DB01009,Ketoprofen
,20961590,absolute bioavailability,"The absolute bioavailability of R(-) and S(+) ketoprofen in chickens, turkeys, dogs and pigs was 31.5% and 52.6%, 42.6% and 32.5%, 33.6% and 89.1%, and 85.9% and 83.5% respectively.",Species comparison of enantioselective oral bioavailability and pharmacokinetics of ketoprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20961590/),%,31.5,81205,DB01009,Ketoprofen
,20961590,absolute bioavailability,"The absolute bioavailability of R(-) and S(+) ketoprofen in chickens, turkeys, dogs and pigs was 31.5% and 52.6%, 42.6% and 32.5%, 33.6% and 89.1%, and 85.9% and 83.5% respectively.",Species comparison of enantioselective oral bioavailability and pharmacokinetics of ketoprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20961590/),%,52.6,81206,DB01009,Ketoprofen
,20961590,absolute bioavailability,"The absolute bioavailability of R(-) and S(+) ketoprofen in chickens, turkeys, dogs and pigs was 31.5% and 52.6%, 42.6% and 32.5%, 33.6% and 89.1%, and 85.9% and 83.5% respectively.",Species comparison of enantioselective oral bioavailability and pharmacokinetics of ketoprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20961590/),%,42.6,81207,DB01009,Ketoprofen
,20961590,absolute bioavailability,"The absolute bioavailability of R(-) and S(+) ketoprofen in chickens, turkeys, dogs and pigs was 31.5% and 52.6%, 42.6% and 32.5%, 33.6% and 89.1%, and 85.9% and 83.5% respectively.",Species comparison of enantioselective oral bioavailability and pharmacokinetics of ketoprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20961590/),%,32.5,81208,DB01009,Ketoprofen
,20961590,absolute bioavailability,"The absolute bioavailability of R(-) and S(+) ketoprofen in chickens, turkeys, dogs and pigs was 31.5% and 52.6%, 42.6% and 32.5%, 33.6% and 89.1%, and 85.9% and 83.5% respectively.",Species comparison of enantioselective oral bioavailability and pharmacokinetics of ketoprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20961590/),%,33.6,81209,DB01009,Ketoprofen
,20961590,absolute bioavailability,"The absolute bioavailability of R(-) and S(+) ketoprofen in chickens, turkeys, dogs and pigs was 31.5% and 52.6%, 42.6% and 32.5%, 33.6% and 89.1%, and 85.9% and 83.5% respectively.",Species comparison of enantioselective oral bioavailability and pharmacokinetics of ketoprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20961590/),%,89.1,81210,DB01009,Ketoprofen
,20961590,absolute bioavailability,"The absolute bioavailability of R(-) and S(+) ketoprofen in chickens, turkeys, dogs and pigs was 31.5% and 52.6%, 42.6% and 32.5%, 33.6% and 89.1%, and 85.9% and 83.5% respectively.",Species comparison of enantioselective oral bioavailability and pharmacokinetics of ketoprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20961590/),%,85.9,81211,DB01009,Ketoprofen
,20961590,absolute bioavailability,"The absolute bioavailability of R(-) and S(+) ketoprofen in chickens, turkeys, dogs and pigs was 31.5% and 52.6%, 42.6% and 32.5%, 33.6% and 89.1%, and 85.9% and 83.5% respectively.",Species comparison of enantioselective oral bioavailability and pharmacokinetics of ketoprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20961590/),%,83.5,81212,DB01009,Ketoprofen
,2084127,limit of detection,"The limit of detection was 0.1 micrograms/ml for the enantiomers of ketoprofen and ibuprofen, and 0.25 micrograms/ml for the enantiomers of fenoprofen.","Stereoselective high-performance liquid chromatographic determination of ketoprofen, ibuprofen and fenoprofen in plasma using a chiral alpha 1-acid glycoprotein column. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2084127/),[μg] / [ml],0.1,81250,DB01009,Ketoprofen
,2084127,limit of detection,"The limit of detection was 0.1 micrograms/ml for the enantiomers of ketoprofen and ibuprofen, and 0.25 micrograms/ml for the enantiomers of fenoprofen.","Stereoselective high-performance liquid chromatographic determination of ketoprofen, ibuprofen and fenoprofen in plasma using a chiral alpha 1-acid glycoprotein column. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2084127/),[μg] / [ml],0.25,81251,DB01009,Ketoprofen
,25893979,Recovery from,Recovery from muscle soreness was longer with oral ketoprofen plus TDT 064 (mean 91.0 ± 19.5 h) versus IDEA-033 plus placebo (mean 81.4 ± 22.9 h; P = 0.5964) or TDT 064 plus placebo (mean 78.9 ± 22.8 h; P = 0.0262).,A randomised trial comparing the efficacy and safety of topical ketoprofen in Transfersome(®) gel (IDEA-033) with oral ketoprofen and drug-free ultra-deformable Sequessome™ vesicles (TDT 064) for the treatment of muscle soreness following exercise. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25893979/),h,91.0,83045,DB01009,Ketoprofen
,25893979,Recovery from,Recovery from muscle soreness was longer with oral ketoprofen plus TDT 064 (mean 91.0 ± 19.5 h) versus IDEA-033 plus placebo (mean 81.4 ± 22.9 h; P = 0.5964) or TDT 064 plus placebo (mean 78.9 ± 22.8 h; P = 0.0262).,A randomised trial comparing the efficacy and safety of topical ketoprofen in Transfersome(®) gel (IDEA-033) with oral ketoprofen and drug-free ultra-deformable Sequessome™ vesicles (TDT 064) for the treatment of muscle soreness following exercise. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25893979/),h,81.4,83046,DB01009,Ketoprofen
,25893979,Recovery from,Recovery from muscle soreness was longer with oral ketoprofen plus TDT 064 (mean 91.0 ± 19.5 h) versus IDEA-033 plus placebo (mean 81.4 ± 22.9 h; P = 0.5964) or TDT 064 plus placebo (mean 78.9 ± 22.8 h; P = 0.0262).,A randomised trial comparing the efficacy and safety of topical ketoprofen in Transfersome(®) gel (IDEA-033) with oral ketoprofen and drug-free ultra-deformable Sequessome™ vesicles (TDT 064) for the treatment of muscle soreness following exercise. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25893979/),h,78.9,83047,DB01009,Ketoprofen
,16801988,AUC,"After the repeated dose, AUC, t1/2,z and CL/F averaged 5067.8 +/- 1373.4 vs. 3194.4 +/- 694.3 ng.h/ml (p < 0.001); 1.65 +/- 0.44 vs. 1.11 +/- 0.29 h (p < 0.005); and 1.12 +/- 0.23 vs. 1.87 +/- 0.42 ml/min/kg (p < 0.001).",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in young and elderly subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801988/),[h·ng] / [ml],5067.8,84074,DB01009,Ketoprofen
,16801988,"t1/2,z","After the repeated dose, AUC, t1/2,z and CL/F averaged 5067.8 +/- 1373.4 vs. 3194.4 +/- 694.3 ng.h/ml (p < 0.001); 1.65 +/- 0.44 vs. 1.11 +/- 0.29 h (p < 0.005); and 1.12 +/- 0.23 vs. 1.87 +/- 0.42 ml/min/kg (p < 0.001).",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in young and elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801988/),[h·ng] / [ml],3194.4,84075,DB01009,Ketoprofen
,16801988,"t1/2,z","After the repeated dose, AUC, t1/2,z and CL/F averaged 5067.8 +/- 1373.4 vs. 3194.4 +/- 694.3 ng.h/ml (p < 0.001); 1.65 +/- 0.44 vs. 1.11 +/- 0.29 h (p < 0.005); and 1.12 +/- 0.23 vs. 1.87 +/- 0.42 ml/min/kg (p < 0.001).",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in young and elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801988/),h,1.65,84076,DB01009,Ketoprofen
,16801988,CL/F,"After the repeated dose, AUC, t1/2,z and CL/F averaged 5067.8 +/- 1373.4 vs. 3194.4 +/- 694.3 ng.h/ml (p < 0.001); 1.65 +/- 0.44 vs. 1.11 +/- 0.29 h (p < 0.005); and 1.12 +/- 0.23 vs. 1.87 +/- 0.42 ml/min/kg (p < 0.001).",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in young and elderly subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801988/),h,1.11,84077,DB01009,Ketoprofen
,16801988,CL/F,"After the repeated dose, AUC, t1/2,z and CL/F averaged 5067.8 +/- 1373.4 vs. 3194.4 +/- 694.3 ng.h/ml (p < 0.001); 1.65 +/- 0.44 vs. 1.11 +/- 0.29 h (p < 0.005); and 1.12 +/- 0.23 vs. 1.87 +/- 0.42 ml/min/kg (p < 0.001).",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in young and elderly subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801988/),[ml] / [kg·min],1.12,84078,DB01009,Ketoprofen
,16801988,CL/F,"After the repeated dose, AUC, t1/2,z and CL/F averaged 5067.8 +/- 1373.4 vs. 3194.4 +/- 694.3 ng.h/ml (p < 0.001); 1.65 +/- 0.44 vs. 1.11 +/- 0.29 h (p < 0.005); and 1.12 +/- 0.23 vs. 1.87 +/- 0.42 ml/min/kg (p < 0.001).",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in young and elderly subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801988/),[ml] / [kg·min],1.87,84079,DB01009,Ketoprofen
,16801988,tmax,Median tmax was 0.5 h.,Single and repeated dose pharmacokinetics of dexketoprofen trometamol in young and elderly subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801988/),h,0.5,84080,DB01009,Ketoprofen
,7674454,half-life,The plasma harmonic mean half-life in healthy horses (0.88 h) was longer than in horses with synovitis (0.55 h).,Pharmacokinetics of ketoprofen in healthy horses and horses with acute synovitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7674454/),h,0.88,87473,DB01009,Ketoprofen
,7674454,half-life,The plasma harmonic mean half-life in healthy horses (0.88 h) was longer than in horses with synovitis (0.55 h).,Pharmacokinetics of ketoprofen in healthy horses and horses with acute synovitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7674454/),h,0.55,87474,DB01009,Ketoprofen
,1279651,Plasma steady-state concentrations,Plasma steady-state concentrations of ketoprofen following the prodrug administration were between 2 and 4 micrograms/ml.,Multiple oral administration of a ketoprofen-dextran ester prodrug in pigs: assessment of gastrointestinal bioavailability by deconvolution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1279651/),[μg] / [ml],2 and 4,88019,DB01009,Ketoprofen
,1279651,dissolution/release times (MDT),"The mean in vivo dissolution/release times (MDT) were calculated to be 5.4, 6.1, and 5.7 hr, respectively.",Multiple oral administration of a ketoprofen-dextran ester prodrug in pigs: assessment of gastrointestinal bioavailability by deconvolution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1279651/),h,5.4,88020,DB01009,Ketoprofen
,1279651,dissolution/release times (MDT),"The mean in vivo dissolution/release times (MDT) were calculated to be 5.4, 6.1, and 5.7 hr, respectively.",Multiple oral administration of a ketoprofen-dextran ester prodrug in pigs: assessment of gastrointestinal bioavailability by deconvolution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1279651/),h,6.1,88021,DB01009,Ketoprofen
,1279651,dissolution/release times (MDT),"The mean in vivo dissolution/release times (MDT) were calculated to be 5.4, 6.1, and 5.7 hr, respectively.",Multiple oral administration of a ketoprofen-dextran ester prodrug in pigs: assessment of gastrointestinal bioavailability by deconvolution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1279651/),h,5.7,88022,DB01009,Ketoprofen
,22214588,C(max),"The predicted plasma concentration profile of each product reflected its release profile, and estimated C(max) ranged from 61.70 to 290.30 ng/mL (0.46- to 2.15-fold vs. brand-name product).",[Prediction of systemic exposure of ketoprofen tapes by in vitro release test and pharmacokinetic model analysis: comparison between brand-name and generic formulations]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22214588/),[ng] / [ml],61.70 to 290.30,89810,DB01009,Ketoprofen
,11791893,maximal plasma concentration,"The maximal plasma concentration of ketoprofen ranged between 3.6 microg ml(-1) and 7.4 microg ml(-1) in the intramuscular group and, following a dose normalisation, between 2.8 microg ml(-1) and 8.2 microg ml(-1) in the tablet group (dose normalised for 1 mg kg(-1)).",Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791893/),[μg] / [ml],3.6,91711,DB01009,Ketoprofen
,11791893,maximal plasma concentration,"The maximal plasma concentration of ketoprofen ranged between 3.6 microg ml(-1) and 7.4 microg ml(-1) in the intramuscular group and, following a dose normalisation, between 2.8 microg ml(-1) and 8.2 microg ml(-1) in the tablet group (dose normalised for 1 mg kg(-1)).",Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791893/),[μg] / [ml],7.4,91712,DB01009,Ketoprofen
,11791893,maximal plasma concentration,"The maximal plasma concentration of ketoprofen ranged between 3.6 microg ml(-1) and 7.4 microg ml(-1) in the intramuscular group and, following a dose normalisation, between 2.8 microg ml(-1) and 8.2 microg ml(-1) in the tablet group (dose normalised for 1 mg kg(-1)).",Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791893/),[μg] / [ml],2.8,91713,DB01009,Ketoprofen
,11791893,maximal plasma concentration,"The maximal plasma concentration of ketoprofen ranged between 3.6 microg ml(-1) and 7.4 microg ml(-1) in the intramuscular group and, following a dose normalisation, between 2.8 microg ml(-1) and 8.2 microg ml(-1) in the tablet group (dose normalised for 1 mg kg(-1)).",Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791893/),[μg] / [ml],8.2,91714,DB01009,Ketoprofen
,11791893,relative bioavailability,The relative bioavailability of oral ketoprofen was about 100% of the intramuscular administration.,Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791893/),%,100,91715,DB01009,Ketoprofen
,11791893,area under the plasma concentration-time curve (AUC0-infinity),The extrapolated area under the plasma concentration-time curve (AUC0-infinity) ranged between 8.8 microg ml(-1) h and 14.6 microg ml(-1) h in the intramuscular group and between 8.7 microg ml(-1) h and 14.1 microg ml(-1) h in the tablet group (dose-normalised AUC0-infinity).,Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791893/),[h·μg] / [ml],8.8,91716,DB01009,Ketoprofen
,11791893,area under the plasma concentration-time curve (AUC0-infinity),The extrapolated area under the plasma concentration-time curve (AUC0-infinity) ranged between 8.8 microg ml(-1) h and 14.6 microg ml(-1) h in the intramuscular group and between 8.7 microg ml(-1) h and 14.1 microg ml(-1) h in the tablet group (dose-normalised AUC0-infinity).,Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791893/),[h·μg] / [ml],14.6,91717,DB01009,Ketoprofen
,11791893,area under the plasma concentration-time curve (AUC0-infinity),The extrapolated area under the plasma concentration-time curve (AUC0-infinity) ranged between 8.8 microg ml(-1) h and 14.6 microg ml(-1) h in the intramuscular group and between 8.7 microg ml(-1) h and 14.1 microg ml(-1) h in the tablet group (dose-normalised AUC0-infinity).,Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791893/),[h·μg] / [ml],8.7,91718,DB01009,Ketoprofen
,11791893,area under the plasma concentration-time curve (AUC0-infinity),The extrapolated area under the plasma concentration-time curve (AUC0-infinity) ranged between 8.8 microg ml(-1) h and 14.6 microg ml(-1) h in the intramuscular group and between 8.7 microg ml(-1) h and 14.1 microg ml(-1) h in the tablet group (dose-normalised AUC0-infinity).,Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791893/),[h·μg] / [ml],14.1,91719,DB01009,Ketoprofen
,11791893,terminal half-life,"The terminal half-life was comparable in both study groups, ranging between 0.8 h and 2.2 h in the intramuscular group and between 0.9 h and 2.1 h in the tablet group.",Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791893/),h,0.8,91720,DB01009,Ketoprofen
,11791893,terminal half-life,"The terminal half-life was comparable in both study groups, ranging between 0.8 h and 2.2 h in the intramuscular group and between 0.9 h and 2.1 h in the tablet group.",Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791893/),h,2.2,91721,DB01009,Ketoprofen
,11791893,terminal half-life,"The terminal half-life was comparable in both study groups, ranging between 0.8 h and 2.2 h in the intramuscular group and between 0.9 h and 2.1 h in the tablet group.",Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791893/),h,0.9,91722,DB01009,Ketoprofen
,11791893,terminal half-life,"The terminal half-life was comparable in both study groups, ranging between 0.8 h and 2.2 h in the intramuscular group and between 0.9 h and 2.1 h in the tablet group.",Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791893/),h,2.1,91723,DB01009,Ketoprofen
,21536505,absolute recovery,"The principal advantage of this LC-MS/MS method is the simultaneous achievement of high absolute recovery (90.0±3.6%), acceptable sensitivity (lower limit of quantitation of 0.100 μg/mL), high inter-day precision (CV≤9.4%), high analytical recovery (between 94.4 and 103.1%), and excellent linearity over the concentration range 0.100-50.0 μg/mL (r(2)≥0.998) combined with a short run time of only 2 min.","An LC-MS/MS procedure for the quantification of naproxen in human plasma: development, validation, comparison with other methods, and application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21536505/),%,90.0,91732,DB01009,Ketoprofen
,3791708,Tmax,"Pharmacokinetic parameters following the first dose including Tmax which was 6.92 h (s.e.m. = 0.80), Cmax 3.87 micrograms/ml (s.e.m. = 0.54), apparent half-life 8.8 h (s.e.m. = 1.0) and AUC 41.92 micrograms.h/ml (s.e.m. = 4.02) were not significantly different from those following the last dose after 3 months of chronic treatment, when these were Tmax 6.38 h (s.e.m. = 0.84) Cmax 3.57 micrograms/ml (s.e.m. = 0.33) apparent half-life 8.8 h (s.e.m. = 1.1) and AUC 43.18 micrograms.h/ml (s.e.m. = 5.34) respectively.",Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791708/),h,6.92,92136,DB01009,Ketoprofen
,3791708,Cmax,"Pharmacokinetic parameters following the first dose including Tmax which was 6.92 h (s.e.m. = 0.80), Cmax 3.87 micrograms/ml (s.e.m. = 0.54), apparent half-life 8.8 h (s.e.m. = 1.0) and AUC 41.92 micrograms.h/ml (s.e.m. = 4.02) were not significantly different from those following the last dose after 3 months of chronic treatment, when these were Tmax 6.38 h (s.e.m. = 0.84) Cmax 3.57 micrograms/ml (s.e.m. = 0.33) apparent half-life 8.8 h (s.e.m. = 1.1) and AUC 43.18 micrograms.h/ml (s.e.m. = 5.34) respectively.",Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791708/),[μg] / [ml],3.87,92137,DB01009,Ketoprofen
,3791708,apparent half-life,"Pharmacokinetic parameters following the first dose including Tmax which was 6.92 h (s.e.m. = 0.80), Cmax 3.87 micrograms/ml (s.e.m. = 0.54), apparent half-life 8.8 h (s.e.m. = 1.0) and AUC 41.92 micrograms.h/ml (s.e.m. = 4.02) were not significantly different from those following the last dose after 3 months of chronic treatment, when these were Tmax 6.38 h (s.e.m. = 0.84) Cmax 3.57 micrograms/ml (s.e.m. = 0.33) apparent half-life 8.8 h (s.e.m. = 1.1) and AUC 43.18 micrograms.h/ml (s.e.m. = 5.34) respectively.",Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791708/),h,8.8,92138,DB01009,Ketoprofen
,3791708,AUC,"Pharmacokinetic parameters following the first dose including Tmax which was 6.92 h (s.e.m. = 0.80), Cmax 3.87 micrograms/ml (s.e.m. = 0.54), apparent half-life 8.8 h (s.e.m. = 1.0) and AUC 41.92 micrograms.h/ml (s.e.m. = 4.02) were not significantly different from those following the last dose after 3 months of chronic treatment, when these were Tmax 6.38 h (s.e.m. = 0.84) Cmax 3.57 micrograms/ml (s.e.m. = 0.33) apparent half-life 8.8 h (s.e.m. = 1.1) and AUC 43.18 micrograms.h/ml (s.e.m. = 5.34) respectively.",Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791708/),[h·μg] / [ml],41.92,92139,DB01009,Ketoprofen
,3791708,Tmax,"Pharmacokinetic parameters following the first dose including Tmax which was 6.92 h (s.e.m. = 0.80), Cmax 3.87 micrograms/ml (s.e.m. = 0.54), apparent half-life 8.8 h (s.e.m. = 1.0) and AUC 41.92 micrograms.h/ml (s.e.m. = 4.02) were not significantly different from those following the last dose after 3 months of chronic treatment, when these were Tmax 6.38 h (s.e.m. = 0.84) Cmax 3.57 micrograms/ml (s.e.m. = 0.33) apparent half-life 8.8 h (s.e.m. = 1.1) and AUC 43.18 micrograms.h/ml (s.e.m. = 5.34) respectively.",Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791708/),h,6.38,92140,DB01009,Ketoprofen
,3791708,Cmax,"Pharmacokinetic parameters following the first dose including Tmax which was 6.92 h (s.e.m. = 0.80), Cmax 3.87 micrograms/ml (s.e.m. = 0.54), apparent half-life 8.8 h (s.e.m. = 1.0) and AUC 41.92 micrograms.h/ml (s.e.m. = 4.02) were not significantly different from those following the last dose after 3 months of chronic treatment, when these were Tmax 6.38 h (s.e.m. = 0.84) Cmax 3.57 micrograms/ml (s.e.m. = 0.33) apparent half-life 8.8 h (s.e.m. = 1.1) and AUC 43.18 micrograms.h/ml (s.e.m. = 5.34) respectively.",Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791708/),[μg] / [ml],3.57,92141,DB01009,Ketoprofen
,3791708,apparent half-life,"Pharmacokinetic parameters following the first dose including Tmax which was 6.92 h (s.e.m. = 0.80), Cmax 3.87 micrograms/ml (s.e.m. = 0.54), apparent half-life 8.8 h (s.e.m. = 1.0) and AUC 41.92 micrograms.h/ml (s.e.m. = 4.02) were not significantly different from those following the last dose after 3 months of chronic treatment, when these were Tmax 6.38 h (s.e.m. = 0.84) Cmax 3.57 micrograms/ml (s.e.m. = 0.33) apparent half-life 8.8 h (s.e.m. = 1.1) and AUC 43.18 micrograms.h/ml (s.e.m. = 5.34) respectively.",Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791708/),h,8.8,92142,DB01009,Ketoprofen
,3791708,AUC,"Pharmacokinetic parameters following the first dose including Tmax which was 6.92 h (s.e.m. = 0.80), Cmax 3.87 micrograms/ml (s.e.m. = 0.54), apparent half-life 8.8 h (s.e.m. = 1.0) and AUC 41.92 micrograms.h/ml (s.e.m. = 4.02) were not significantly different from those following the last dose after 3 months of chronic treatment, when these were Tmax 6.38 h (s.e.m. = 0.84) Cmax 3.57 micrograms/ml (s.e.m. = 0.33) apparent half-life 8.8 h (s.e.m. = 1.1) and AUC 43.18 micrograms.h/ml (s.e.m. = 5.34) respectively.",Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791708/),[h·μg] / [ml],43.18,92143,DB01009,Ketoprofen
,16389642,flow rate,"Mobile phase consisting of 0.05 m formic acid and acetonitrile (55:45, v/v) was used at a flow rate of 1.0 mL/min for the effective separation of RST and IS.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),[ml] / [min],1.0,94723,DB01009,Ketoprofen
,16389642,Nominal retention times,"Nominal retention times of RST and IS were 8.6 and 12.5 min, respectively.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),min,8.6,94724,DB01009,Ketoprofen
,16389642,Nominal retention times,"Nominal retention times of RST and IS were 8.6 and 12.5 min, respectively.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),min,12.5,94725,DB01009,Ketoprofen
,16389642,Absolute recoveries,"Absolute recoveries of RST and IS were 85-110 and >100%, respectively, from rat plasma.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),%,85-110,94726,DB01009,Ketoprofen
,16389642,Absolute recoveries,"Absolute recoveries of RST and IS were 85-110 and >100%, respectively, from rat plasma.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),%,>,94727,DB01009,Ketoprofen
,16389642,Absolute recoveries,"Absolute recoveries of RST and IS were 85-110 and >100%, respectively, from rat plasma.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),%,100,94728,DB01009,Ketoprofen
,6519121,apparent elimination half-life,"The mean (+/- standard deviation) apparent elimination half-life of ketoprofen after this sustained-release formulation was 7.4 +/- 3.1 h, compared with 4.1 +/- 0.85 h after ketoprofen capsules.",Urinary pharmacokinetics of orally administered ketoprofen in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519121/),h,7.4,94941,DB01009,Ketoprofen
,6519121,apparent elimination half-life,"The mean (+/- standard deviation) apparent elimination half-life of ketoprofen after this sustained-release formulation was 7.4 +/- 3.1 h, compared with 4.1 +/- 0.85 h after ketoprofen capsules.",Urinary pharmacokinetics of orally administered ketoprofen in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519121/),h,4.1,94942,DB01009,Ketoprofen
,11368291,Relative bioavailability,"Relative bioavailability of oral dexketoprofen (12.5 and 25mg, respectively) is similar to that of oral racemic ketoprofen (25 and 50mg, respectively), as measured in all cases by the area under the concentration-time curve values for (S)-(+)-ketoprofen.",Clinical pharmacokinetics of dexketoprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368291/),mg,12.5,96438,DB01009,Ketoprofen
,11368291,Relative bioavailability,"Relative bioavailability of oral dexketoprofen (12.5 and 25mg, respectively) is similar to that of oral racemic ketoprofen (25 and 50mg, respectively), as measured in all cases by the area under the concentration-time curve values for (S)-(+)-ketoprofen.",Clinical pharmacokinetics of dexketoprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368291/),mg,25,96439,DB01009,Ketoprofen
,11368291,Relative bioavailability,"Relative bioavailability of oral dexketoprofen (12.5 and 25mg, respectively) is similar to that of oral racemic ketoprofen (25 and 50mg, respectively), as measured in all cases by the area under the concentration-time curve values for (S)-(+)-ketoprofen.",Clinical pharmacokinetics of dexketoprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368291/),mg,50,96440,DB01009,Ketoprofen
,11368291,time to maximum plasma concentration (tmax),"Dexketoprofen trometamol, given as a tablet, is rapidly absorbed, with a time to maximum plasma concentration (tmax) of between 0.25 and 0.75 hours, whereas the tmax for the (S)-(+)-enantiomer after the racemic drug, administered as tablets or capsules prepared with the free acid, is between 0.5 and 3 hours.",Clinical pharmacokinetics of dexketoprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368291/),h,0.25 and 0.75,96441,DB01009,Ketoprofen
,11368291,tmax,"Dexketoprofen trometamol, given as a tablet, is rapidly absorbed, with a time to maximum plasma concentration (tmax) of between 0.25 and 0.75 hours, whereas the tmax for the (S)-(+)-enantiomer after the racemic drug, administered as tablets or capsules prepared with the free acid, is between 0.5 and 3 hours.",Clinical pharmacokinetics of dexketoprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368291/),h,0.5 and 3,96442,DB01009,Ketoprofen
,476288,Detection limits,Detection limits range from 10 ng ml-1 for urine and serum samples to 50 ng ml-1 for maternal milk specimens.,A quantitative selected ion monitoring assay for ketoprofen determination in human biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/476288/),[ng] / [ml],10,98183,DB01009,Ketoprofen
,476288,Detection limits,Detection limits range from 10 ng ml-1 for urine and serum samples to 50 ng ml-1 for maternal milk specimens.,A quantitative selected ion monitoring assay for ketoprofen determination in human biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/476288/),[ng] / [ml],50,98184,DB01009,Ketoprofen
,9876518,maximal plasma concentration of ketoprofen (Cmax),The maximal plasma concentration of ketoprofen (Cmax) and the area under the concentration-time curve from zero to 8 hr (AUC0-8 hr) after the oral administration of dry elixir increased about 3.2- (24.6 versus 7.6 micrograms/ml) and 2.2-(38.4 versus 17.3 micrograms hr/ml) fold compared with powder alone.,Enhancement of bioavailability of ketoprofen using dry elixir as a novel dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876518/),[μg] / [ml],24.6,102301,DB01009,Ketoprofen
,9876518,maximal plasma concentration of ketoprofen (Cmax),The maximal plasma concentration of ketoprofen (Cmax) and the area under the concentration-time curve from zero to 8 hr (AUC0-8 hr) after the oral administration of dry elixir increased about 3.2- (24.6 versus 7.6 micrograms/ml) and 2.2-(38.4 versus 17.3 micrograms hr/ml) fold compared with powder alone.,Enhancement of bioavailability of ketoprofen using dry elixir as a novel dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876518/),[μg] / [ml],7.6,102302,DB01009,Ketoprofen
,9876518,area under the concentration-time curve from zero to 8 hr (AUC0-8 hr),The maximal plasma concentration of ketoprofen (Cmax) and the area under the concentration-time curve from zero to 8 hr (AUC0-8 hr) after the oral administration of dry elixir increased about 3.2- (24.6 versus 7.6 micrograms/ml) and 2.2-(38.4 versus 17.3 micrograms hr/ml) fold compared with powder alone.,Enhancement of bioavailability of ketoprofen using dry elixir as a novel dosage form. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876518/),[μg] / [ml],7.6,102303,DB01009,Ketoprofen
,9876518,area under the concentration-time curve from zero to 8 hr (AUC0-8 hr),The maximal plasma concentration of ketoprofen (Cmax) and the area under the concentration-time curve from zero to 8 hr (AUC0-8 hr) after the oral administration of dry elixir increased about 3.2- (24.6 versus 7.6 micrograms/ml) and 2.2-(38.4 versus 17.3 micrograms hr/ml) fold compared with powder alone.,Enhancement of bioavailability of ketoprofen using dry elixir as a novel dosage form. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876518/),[h·μg] / [ml],38.4,102304,DB01009,Ketoprofen
,9876518,area under the concentration-time curve from zero to 8 hr (AUC0-8 hr),The maximal plasma concentration of ketoprofen (Cmax) and the area under the concentration-time curve from zero to 8 hr (AUC0-8 hr) after the oral administration of dry elixir increased about 3.2- (24.6 versus 7.6 micrograms/ml) and 2.2-(38.4 versus 17.3 micrograms hr/ml) fold compared with powder alone.,Enhancement of bioavailability of ketoprofen using dry elixir as a novel dosage form. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876518/),[h·μg] / [ml],17.3,102305,DB01009,Ketoprofen
,19402344,flow,The flow was set at 5 ml x min(-1) and the wavelength at 254 nm.,Fast HPLC method for the determination of ketoprofen in human plasma using a monolithic column and its application to a comparative bioavailability study in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19402344/),[ml] / [min],5,104740,DB01009,Ketoprofen
less,19402344,total analysis time,The total analysis time was less than 5 min.,Fast HPLC method for the determination of ketoprofen in human plasma using a monolithic column and its application to a comparative bioavailability study in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19402344/),min,5,104741,DB01009,Ketoprofen
greater,19402344,signal-to noise ratio,The limit of detection was defined as the ketoprofen concentration that produced a signal-to noise ratio greater than 3.,Fast HPLC method for the determination of ketoprofen in human plasma using a monolithic column and its application to a comparative bioavailability study in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19402344/),,3,104742,DB01009,Ketoprofen
,19402344,minimum detectable limit,The calibration curve was linear over the concentration range 1-500 ng x ml(-1) with a minimum detectable limit of 10 ng x ml(-1).,Fast HPLC method for the determination of ketoprofen in human plasma using a monolithic column and its application to a comparative bioavailability study in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19402344/),[ng] / [ml],10,104743,DB01009,Ketoprofen
,16474960,half-lives,"At 24 h after the final dosing, KP concentrations in the skin with R-KP and S-KP treatment were 187.4 and 254.7 microg/g, respectively, and their half-lives were 80.5 and 84.4 h, respectively.",Study on the mechanism of photosensitive dermatitis caused by ketoprofen in the guinea pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16474960/),h,80.5,105102,DB01009,Ketoprofen
,16474960,half-lives,"At 24 h after the final dosing, KP concentrations in the skin with R-KP and S-KP treatment were 187.4 and 254.7 microg/g, respectively, and their half-lives were 80.5 and 84.4 h, respectively.",Study on the mechanism of photosensitive dermatitis caused by ketoprofen in the guinea pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16474960/),h,84.4,105103,DB01009,Ketoprofen
,16474960,concentrations,KP concentrations at 336 h after final dosing were 11.3 microg/g for R-KP and 15.7 microg/g for S-KP treatment.,Study on the mechanism of photosensitive dermatitis caused by ketoprofen in the guinea pig. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16474960/),[μg] / [g],11.3,105104,DB01009,Ketoprofen
,16474960,concentrations,KP concentrations at 336 h after final dosing were 11.3 microg/g for R-KP and 15.7 microg/g for S-KP treatment.,Study on the mechanism of photosensitive dermatitis caused by ketoprofen in the guinea pig. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16474960/),[μg] / [g],15.7,105105,DB01009,Ketoprofen
,16013036,flow rate,The chromatographic separation was achieved by gradient elution consisting of 0.05 M formic acid (pH 3)-acetonitrile-methanol-water at a flow rate of 1.0 mL/min.,"Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),[ml] / [min],1.0,105998,DB01009,Ketoprofen
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,15.63,105999,DB01009,Ketoprofen
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,17.20,106000,DB01009,Ketoprofen
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,21.66,106001,DB01009,Ketoprofen
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,24.95,106002,DB01009,Ketoprofen
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,26.27,106003,DB01009,Ketoprofen
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,30.24,106004,DB01009,Ketoprofen
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,32.22,106005,DB01009,Ketoprofen
>,16013036,Absolute recovery,Absolute recovery was >83% from human plasma for all the analytes and IS.,"Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),%,83,106006,DB01009,Ketoprofen
,9522947,plasma half-life,Mean (harmonic) plasma half-life for healthy foals < 24 hours old was 4.3 hours.,Pharmacokinetics of ketoprofen in healthy foals less than twenty-four hours old. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9522947/),h,4.3,108478,DB01009,Ketoprofen
,2716941,distribution half-life,The mean (+/- SD) values of pharmacokinetic parameters measured with a 2 open compartment model were as follows: distribution half-life: 0.34 +/- 0.19 h; elimination half-life: 2.05 +/- 0.58 h; kel: 0.96 +/- 0.28 h-1; k21: 0.94 +/- 0.42 h-1; k12: 1.00 +/- 0.70 h-1; volume of central compartment: 5.58 +/- 1.67 l; volume of tissue compartment: 5.14 +/- 2.12 l; plasma clearance: 5.10 +/- 1.14 l.,[Pharmacokinetics of intravenous ketoprofen. Therapeutic value in renal colic]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2716941/),h,0.34,109459,DB01009,Ketoprofen
,2716941,elimination half-life,The mean (+/- SD) values of pharmacokinetic parameters measured with a 2 open compartment model were as follows: distribution half-life: 0.34 +/- 0.19 h; elimination half-life: 2.05 +/- 0.58 h; kel: 0.96 +/- 0.28 h-1; k21: 0.94 +/- 0.42 h-1; k12: 1.00 +/- 0.70 h-1; volume of central compartment: 5.58 +/- 1.67 l; volume of tissue compartment: 5.14 +/- 2.12 l; plasma clearance: 5.10 +/- 1.14 l.,[Pharmacokinetics of intravenous ketoprofen. Therapeutic value in renal colic]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2716941/),h,2.05,109460,DB01009,Ketoprofen
,2716941,kel,The mean (+/- SD) values of pharmacokinetic parameters measured with a 2 open compartment model were as follows: distribution half-life: 0.34 +/- 0.19 h; elimination half-life: 2.05 +/- 0.58 h; kel: 0.96 +/- 0.28 h-1; k21: 0.94 +/- 0.42 h-1; k12: 1.00 +/- 0.70 h-1; volume of central compartment: 5.58 +/- 1.67 l; volume of tissue compartment: 5.14 +/- 2.12 l; plasma clearance: 5.10 +/- 1.14 l.,[Pharmacokinetics of intravenous ketoprofen. Therapeutic value in renal colic]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2716941/),1/[h],0.96,109461,DB01009,Ketoprofen
,2716941,k21,The mean (+/- SD) values of pharmacokinetic parameters measured with a 2 open compartment model were as follows: distribution half-life: 0.34 +/- 0.19 h; elimination half-life: 2.05 +/- 0.58 h; kel: 0.96 +/- 0.28 h-1; k21: 0.94 +/- 0.42 h-1; k12: 1.00 +/- 0.70 h-1; volume of central compartment: 5.58 +/- 1.67 l; volume of tissue compartment: 5.14 +/- 2.12 l; plasma clearance: 5.10 +/- 1.14 l.,[Pharmacokinetics of intravenous ketoprofen. Therapeutic value in renal colic]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2716941/),1/[h],0.94,109462,DB01009,Ketoprofen
,2716941,k12,The mean (+/- SD) values of pharmacokinetic parameters measured with a 2 open compartment model were as follows: distribution half-life: 0.34 +/- 0.19 h; elimination half-life: 2.05 +/- 0.58 h; kel: 0.96 +/- 0.28 h-1; k21: 0.94 +/- 0.42 h-1; k12: 1.00 +/- 0.70 h-1; volume of central compartment: 5.58 +/- 1.67 l; volume of tissue compartment: 5.14 +/- 2.12 l; plasma clearance: 5.10 +/- 1.14 l.,[Pharmacokinetics of intravenous ketoprofen. Therapeutic value in renal colic]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2716941/),1/[h],1.00,109463,DB01009,Ketoprofen
,2716941,volume of central compartment,The mean (+/- SD) values of pharmacokinetic parameters measured with a 2 open compartment model were as follows: distribution half-life: 0.34 +/- 0.19 h; elimination half-life: 2.05 +/- 0.58 h; kel: 0.96 +/- 0.28 h-1; k21: 0.94 +/- 0.42 h-1; k12: 1.00 +/- 0.70 h-1; volume of central compartment: 5.58 +/- 1.67 l; volume of tissue compartment: 5.14 +/- 2.12 l; plasma clearance: 5.10 +/- 1.14 l.,[Pharmacokinetics of intravenous ketoprofen. Therapeutic value in renal colic]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2716941/),l,5.58,109464,DB01009,Ketoprofen
,2716941,volume of tissue compartment,The mean (+/- SD) values of pharmacokinetic parameters measured with a 2 open compartment model were as follows: distribution half-life: 0.34 +/- 0.19 h; elimination half-life: 2.05 +/- 0.58 h; kel: 0.96 +/- 0.28 h-1; k21: 0.94 +/- 0.42 h-1; k12: 1.00 +/- 0.70 h-1; volume of central compartment: 5.58 +/- 1.67 l; volume of tissue compartment: 5.14 +/- 2.12 l; plasma clearance: 5.10 +/- 1.14 l.,[Pharmacokinetics of intravenous ketoprofen. Therapeutic value in renal colic]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2716941/),l,5.14,109465,DB01009,Ketoprofen
,2716941,plasma clearance,The mean (+/- SD) values of pharmacokinetic parameters measured with a 2 open compartment model were as follows: distribution half-life: 0.34 +/- 0.19 h; elimination half-life: 2.05 +/- 0.58 h; kel: 0.96 +/- 0.28 h-1; k21: 0.94 +/- 0.42 h-1; k12: 1.00 +/- 0.70 h-1; volume of central compartment: 5.58 +/- 1.67 l; volume of tissue compartment: 5.14 +/- 2.12 l; plasma clearance: 5.10 +/- 1.14 l.,[Pharmacokinetics of intravenous ketoprofen. Therapeutic value in renal colic]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2716941/),l,5.10,109466,DB01009,Ketoprofen
,10761162,C0.5 hours,"Ketoprofen syrup was absorbed rapidly, the plasma level reaching its maximum at 0.5 hours, with C0.5 hours = 3 micrograms/ml.",Pharmacokinetics of ketoprofen syrup in small children. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761162/),[μg] / [ml],3,110016,DB01009,Ketoprofen
,10761162,elimination half-life,"The elimination half-life, 2.0 hours in Group 1 or 1.9 hours in Group 2, was similar to that reported in adults.",Pharmacokinetics of ketoprofen syrup in small children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761162/),h,2.0,110017,DB01009,Ketoprofen
,10761162,elimination half-life,"The elimination half-life, 2.0 hours in Group 1 or 1.9 hours in Group 2, was similar to that reported in adults.",Pharmacokinetics of ketoprofen syrup in small children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761162/),h,1.9,110018,DB01009,Ketoprofen
,28633956,lag-time,"The in vivo release behavior of the tablets was evaluated in Beagle dogs after a parallel oral administration of KF TAPS tablets and commercial KF capsules, when it was found that the KF TAPS tablets released the drug after a lag-time of 3.458h and the Tmax was 5.833h.",A time-adjustable pulsatile release system for ketoprofen: In vitro and in vivo investigation in a pharmacokinetic study and an IVIVC evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28633956/),h,3.458,113716,DB01009,Ketoprofen
,28633956,Tmax,"The in vivo release behavior of the tablets was evaluated in Beagle dogs after a parallel oral administration of KF TAPS tablets and commercial KF capsules, when it was found that the KF TAPS tablets released the drug after a lag-time of 3.458h and the Tmax was 5.833h.",A time-adjustable pulsatile release system for ketoprofen: In vitro and in vivo investigation in a pharmacokinetic study and an IVIVC evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28633956/),h,5.833,113717,DB01009,Ketoprofen
,28633956,relative bioavailability,"The relative bioavailability was 85.01%, and the two formulations were bioequivalent in terms of Cmax and AUC0-t and the in vitro- in vivo correlations indicated that test formulation had a good in vivo-in vitro correlation (r=0.9703).",A time-adjustable pulsatile release system for ketoprofen: In vitro and in vivo investigation in a pharmacokinetic study and an IVIVC evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28633956/),%,85.01,113718,DB01009,Ketoprofen
,9356198,maximal effect,"The maximal effect lasted 12 and 36 h following 10 and 20 mg kg-1 doses, respectively.",Toxicokinetics of indomethacin-induced intestinal permeability in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356198/),h,12,116211,DB01009,Ketoprofen
,9356198,maximal effect,"The maximal effect lasted 12 and 36 h following 10 and 20 mg kg-1 doses, respectively.",Toxicokinetics of indomethacin-induced intestinal permeability in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356198/),h,36,116212,DB01009,Ketoprofen
,12408894,Recovery,Recovery of both enantiomers was in the range of 85-91%.,Determination of ketoprofen enantiomers in human serum by capillary zone electrophoresis: man pharmacokinetic studies after administration of rac-ketoprofen tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408894/),%,85-91,116320,DB01009,Ketoprofen
>,12408894,signal-to-noise baseline ratio (S/N),"The linear range of calibration curves was between 0.25 and 50 mg l(-1), with detection limit of 0.1 mg l(-1) (signal-to-noise baseline ratio (S/N) >4).",Determination of ketoprofen enantiomers in human serum by capillary zone electrophoresis: man pharmacokinetic studies after administration of rac-ketoprofen tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408894/),,4,116321,DB01009,Ketoprofen
,2735334,maximal plasma concentration,"In the presence of food, maximal plasma concentration decreased from 10.7 to 6.3 micrograms/ml after single-dose administration and 12.1 to 8.0 micrograms/ml after multiple-dose administration.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),[μg] / [ml],10.7 to 6.3,121101,DB01009,Ketoprofen
,2735334,maximal plasma concentration,"In the presence of food, maximal plasma concentration decreased from 10.7 to 6.3 micrograms/ml after single-dose administration and 12.1 to 8.0 micrograms/ml after multiple-dose administration.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),[μg] / [ml],12.1 to 8.0,121102,DB01009,Ketoprofen
,2735334,time to reach maximal plasma concentration,"The time to reach maximal plasma concentration was also modified by food, increasing from 2.8 to 7.1 hours after single-dose and 2.8 to 7.6 hours after multiple-dose administration.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),h,2.8,121103,DB01009,Ketoprofen
,2735334,time to reach maximal plasma concentration,"The time to reach maximal plasma concentration was also modified by food, increasing from 2.8 to 7.1 hours after single-dose and 2.8 to 7.6 hours after multiple-dose administration.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),h,7,121104,DB01009,Ketoprofen
,2735334,time to reach maximal plasma concentration,"The time to reach maximal plasma concentration was also modified by food, increasing from 2.8 to 7.1 hours after single-dose and 2.8 to 7.6 hours after multiple-dose administration.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),h,2.8 to 7.6,121105,DB01009,Ketoprofen
over,2735334,bioavailability,Food caused a significant decrease in the bioavailability of ketoprofen (over 40 percent) following both single-dose (23.8 versus 13.1 micrograms.hour/ml) and multiple-dose (29.3 versus 16.8 micrograms.hour/ml) administration.,Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),%,40,121106,DB01009,Ketoprofen
,2735334,bioavailability,Food caused a significant decrease in the bioavailability of ketoprofen (over 40 percent) following both single-dose (23.8 versus 13.1 micrograms.hour/ml) and multiple-dose (29.3 versus 16.8 micrograms.hour/ml) administration.,Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),μ,23.8,121107,DB01009,Ketoprofen
,2735334,bioavailability,Food caused a significant decrease in the bioavailability of ketoprofen (over 40 percent) following both single-dose (23.8 versus 13.1 micrograms.hour/ml) and multiple-dose (29.3 versus 16.8 micrograms.hour/ml) administration.,Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),μ,13.1,121108,DB01009,Ketoprofen
,2735334,bioavailability,Food caused a significant decrease in the bioavailability of ketoprofen (over 40 percent) following both single-dose (23.8 versus 13.1 micrograms.hour/ml) and multiple-dose (29.3 versus 16.8 micrograms.hour/ml) administration.,Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),μ,29.3,121109,DB01009,Ketoprofen
,2735334,bioavailability,Food caused a significant decrease in the bioavailability of ketoprofen (over 40 percent) following both single-dose (23.8 versus 13.1 micrograms.hour/ml) and multiple-dose (29.3 versus 16.8 micrograms.hour/ml) administration.,Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),μ,16.8,121110,DB01009,Ketoprofen
,2735334,absorption rate constant,"Results obtained in group 3 showed that sucralfate reduced the absorption rate constant of naproxen, from 1.7 to 1.2 hours-1 and from 1.5 to 0.7 hour-1 following single- and multiple-dose administration, respectively.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),1/[h],1.7 to 1.2,121111,DB01009,Ketoprofen
,2735334,absorption rate constant,"Results obtained in group 3 showed that sucralfate reduced the absorption rate constant of naproxen, from 1.7 to 1.2 hours-1 and from 1.5 to 0.7 hour-1 following single- and multiple-dose administration, respectively.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),1/[h],1.5 to 0.7,121112,DB01009,Ketoprofen
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],527.00,122561,DB01009,Ketoprofen
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],269. 45,122562,DB01009,Ketoprofen
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],258.65,122563,DB01009,Ketoprofen
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],243.22,122564,DB01009,Ketoprofen
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],88.09,122565,DB01009,Ketoprofen
,18295555,flow rate,"Chromatographic separation was achieved on a 5 microm Shiseido C8 column (150 mm x 2.0 mm i.d., particle size 5 microm) with a mobile phase consisting of methanol/ 6 mM ammonium acetate (60/40, v/v) at a flow rate of 0.3 ml/min.","Simultaneous determination of ginkgolides A, B, C and bilobalide in plasma by LC-MS/MS and its application to the pharmacokinetic study of Ginkgo biloba extract in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18295555/),[ml] / [min],0.3,128201,DB01009,Ketoprofen
,8864313,S/R,"4. Following both 50 and 100 mg doses, there was significant stereoselectivity in the AUC of KT (mean S/R, 0.87 and 0.83, respectively), the AUC of KTconj (mean S/R, 3.4 and 5.2, respectively) and the cumulative urinary excretion of KTconj (mean S/R, 2.1 and 2.2, respectively).",The influence of renal function on the pharmacokinetics of unchanged and acyl-glucuroconjugated ketoprofen enantiomers after 50 and 100 mg racemic ketoprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864313/),,0.87,128909,DB01009,Ketoprofen
,8864313,S/R,"4. Following both 50 and 100 mg doses, there was significant stereoselectivity in the AUC of KT (mean S/R, 0.87 and 0.83, respectively), the AUC of KTconj (mean S/R, 3.4 and 5.2, respectively) and the cumulative urinary excretion of KTconj (mean S/R, 2.1 and 2.2, respectively).",The influence of renal function on the pharmacokinetics of unchanged and acyl-glucuroconjugated ketoprofen enantiomers after 50 and 100 mg racemic ketoprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864313/),,0.83,128910,DB01009,Ketoprofen
,8864313,S/R,"4. Following both 50 and 100 mg doses, there was significant stereoselectivity in the AUC of KT (mean S/R, 0.87 and 0.83, respectively), the AUC of KTconj (mean S/R, 3.4 and 5.2, respectively) and the cumulative urinary excretion of KTconj (mean S/R, 2.1 and 2.2, respectively).",The influence of renal function on the pharmacokinetics of unchanged and acyl-glucuroconjugated ketoprofen enantiomers after 50 and 100 mg racemic ketoprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864313/),,3.4,128911,DB01009,Ketoprofen
,8864313,S/R,"4. Following both 50 and 100 mg doses, there was significant stereoselectivity in the AUC of KT (mean S/R, 0.87 and 0.83, respectively), the AUC of KTconj (mean S/R, 3.4 and 5.2, respectively) and the cumulative urinary excretion of KTconj (mean S/R, 2.1 and 2.2, respectively).",The influence of renal function on the pharmacokinetics of unchanged and acyl-glucuroconjugated ketoprofen enantiomers after 50 and 100 mg racemic ketoprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864313/),,5.2,128912,DB01009,Ketoprofen
,8864313,S/R,"4. Following both 50 and 100 mg doses, there was significant stereoselectivity in the AUC of KT (mean S/R, 0.87 and 0.83, respectively), the AUC of KTconj (mean S/R, 3.4 and 5.2, respectively) and the cumulative urinary excretion of KTconj (mean S/R, 2.1 and 2.2, respectively).",The influence of renal function on the pharmacokinetics of unchanged and acyl-glucuroconjugated ketoprofen enantiomers after 50 and 100 mg racemic ketoprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864313/),,2.1,128913,DB01009,Ketoprofen
,8864313,S/R,"4. Following both 50 and 100 mg doses, there was significant stereoselectivity in the AUC of KT (mean S/R, 0.87 and 0.83, respectively), the AUC of KTconj (mean S/R, 3.4 and 5.2, respectively) and the cumulative urinary excretion of KTconj (mean S/R, 2.1 and 2.2, respectively).",The influence of renal function on the pharmacokinetics of unchanged and acyl-glucuroconjugated ketoprofen enantiomers after 50 and 100 mg racemic ketoprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864313/),,2.2,128914,DB01009,Ketoprofen
,9823729,area under the plasma concentration vs. time curve (AUC(0-infinity)),"Significant differences in mean area under the plasma concentration vs. time curve (AUC(0-infinity)) among the groups were detected (p < 0.001), with the 25 mg p.o. capsule exhibiting the largest value (5054 ng-hr/mL), the 2.0% gel exhibiting an intermediate value (2244 ng-hr/mL), the 1.0% gels exhibiting lower but comparable values (1516 for the alternate formulation vs. 1461 ng-hr/mL), and the 0.5% gel showing the lowest value (736 ng-hr/mL).",Pharmacokinetic and safety evaluations of ketoprofen gels in subjects with adult periodontitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9823729/),[ng-hr] / [ml],5054,129779,DB01009,Ketoprofen
,9823729,area under the plasma concentration vs. time curve (AUC(0-infinity)),"Significant differences in mean area under the plasma concentration vs. time curve (AUC(0-infinity)) among the groups were detected (p < 0.001), with the 25 mg p.o. capsule exhibiting the largest value (5054 ng-hr/mL), the 2.0% gel exhibiting an intermediate value (2244 ng-hr/mL), the 1.0% gels exhibiting lower but comparable values (1516 for the alternate formulation vs. 1461 ng-hr/mL), and the 0.5% gel showing the lowest value (736 ng-hr/mL).",Pharmacokinetic and safety evaluations of ketoprofen gels in subjects with adult periodontitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9823729/),[ng-hr] / [ml],2244,129780,DB01009,Ketoprofen
,9823729,area under the plasma concentration vs. time curve (AUC(0-infinity)),"Significant differences in mean area under the plasma concentration vs. time curve (AUC(0-infinity)) among the groups were detected (p < 0.001), with the 25 mg p.o. capsule exhibiting the largest value (5054 ng-hr/mL), the 2.0% gel exhibiting an intermediate value (2244 ng-hr/mL), the 1.0% gels exhibiting lower but comparable values (1516 for the alternate formulation vs. 1461 ng-hr/mL), and the 0.5% gel showing the lowest value (736 ng-hr/mL).",Pharmacokinetic and safety evaluations of ketoprofen gels in subjects with adult periodontitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9823729/),[ng-hr] / [ml],1516,129781,DB01009,Ketoprofen
,9823729,area under the plasma concentration vs. time curve (AUC(0-infinity)),"Significant differences in mean area under the plasma concentration vs. time curve (AUC(0-infinity)) among the groups were detected (p < 0.001), with the 25 mg p.o. capsule exhibiting the largest value (5054 ng-hr/mL), the 2.0% gel exhibiting an intermediate value (2244 ng-hr/mL), the 1.0% gels exhibiting lower but comparable values (1516 for the alternate formulation vs. 1461 ng-hr/mL), and the 0.5% gel showing the lowest value (736 ng-hr/mL).",Pharmacokinetic and safety evaluations of ketoprofen gels in subjects with adult periodontitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9823729/),[ng-hr] / [ml],1461,129782,DB01009,Ketoprofen
,9823729,area under the plasma concentration vs. time curve (AUC(0-infinity)),"Significant differences in mean area under the plasma concentration vs. time curve (AUC(0-infinity)) among the groups were detected (p < 0.001), with the 25 mg p.o. capsule exhibiting the largest value (5054 ng-hr/mL), the 2.0% gel exhibiting an intermediate value (2244 ng-hr/mL), the 1.0% gels exhibiting lower but comparable values (1516 for the alternate formulation vs. 1461 ng-hr/mL), and the 0.5% gel showing the lowest value (736 ng-hr/mL).",Pharmacokinetic and safety evaluations of ketoprofen gels in subjects with adult periodontitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9823729/),[ng-hr] / [ml],736,129783,DB01009,Ketoprofen
,9823729,times of maximum plasma concentration (tmax),The 5 treatments exhibited similar mean times of maximum plasma concentration (tmax) values ranging from 0.6 to 1 hr.,Pharmacokinetic and safety evaluations of ketoprofen gels in subjects with adult periodontitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9823729/),h,0.6 to 1,129784,DB01009,Ketoprofen
,9823729,relative systemic bioavailability,The relative systemic bioavailability of the gels compared with peroral administration ranged from 54% to 69%.,Pharmacokinetic and safety evaluations of ketoprofen gels in subjects with adult periodontitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9823729/),%,54,129785,DB01009,Ketoprofen
,9823729,relative systemic bioavailability,The relative systemic bioavailability of the gels compared with peroral administration ranged from 54% to 69%.,Pharmacokinetic and safety evaluations of ketoprofen gels in subjects with adult periodontitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9823729/),%,69,129786,DB01009,Ketoprofen
,15454293,rate of penetration,The rate of penetration of ketoprofen through isolated skin was approximately 0.2 microg/cm2 h for both formulations.,Bioequivalence determination of topical ketoprofen using a dermatopharmacokinetic approach and excised skin penetration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454293/),[μg] / [cm2·h],0.2,131209,DB01009,Ketoprofen
,1013581,early plasma half-life,The mean early plasma half-life of ketoprofen in both volunteers and patients with rheumatoid arthritis was 1.5 to 2 hours.,Synovial-fluid pharmacokinetics of ketoprofen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1013581/),h,1.5 to 2,131930,DB01009,Ketoprofen
,27237337,half-life,"However, due to its short half-life of 1-2 h, a multiple dose regimen is required for oral administration.",Natural polysaccharides platforms for oral controlled release of ketoprofen lysine salt. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27237337/),h,1-2,132166,DB01009,Ketoprofen
,27237337,lag time,Hosting F8 in an acid-resistant capsule (DR®caps) a delivery platform has been developed to control KL release in a delayed (90 min lag time) and prolonged way (270 min complete release).,Natural polysaccharides platforms for oral controlled release of ketoprofen lysine salt. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27237337/),min,90,132167,DB01009,Ketoprofen
,8905569,elimination half-life,An average elimination half-life of 1.3 h (+/-1.2) was found.,Bioavailability of ketoprofen in horses after rectal administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8905569/),h,1.3,133100,DB01009,Ketoprofen
,8905569,total plasma clearance (ClT),The average value for the total plasma clearance (ClT) was 131.9mL/ min.kg (range 95-183.5).,Bioavailability of ketoprofen in horses after rectal administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8905569/),[ml] / [kg·min],131.9,133101,DB01009,Ketoprofen
,8905569,volume of distribution Vd(area),The volume of distribution Vd(area) was 255 mL/kg and the mean residence time (MRT) value was 0.47 h.,Bioavailability of ketoprofen in horses after rectal administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8905569/),[ml] / [kg],255,133102,DB01009,Ketoprofen
,8905569,mean residence time (MRT),The volume of distribution Vd(area) was 255 mL/kg and the mean residence time (MRT) value was 0.47 h.,Bioavailability of ketoprofen in horses after rectal administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8905569/),h,0.47,133103,DB01009,Ketoprofen
,8905569,maximal plasma ketoprofen concentrations,"After rectal administration, the mean maximal plasma ketoprofen concentrations were 1.6(+/-0.8), 1.1(+/-0.7) and 1.6(+/-0.2) micrograms/mL for the fatty suppository, the hydrophilic suppository and the liquid suspension respectively.",Bioavailability of ketoprofen in horses after rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8905569/),[μg] / [ml],1.6,133104,DB01009,Ketoprofen
,8905569,maximal plasma ketoprofen concentrations,"After rectal administration, the mean maximal plasma ketoprofen concentrations were 1.6(+/-0.8), 1.1(+/-0.7) and 1.6(+/-0.2) micrograms/mL for the fatty suppository, the hydrophilic suppository and the liquid suspension respectively.",Bioavailability of ketoprofen in horses after rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8905569/),[μg] / [ml],1.1,133105,DB01009,Ketoprofen
,8905569,maximal plasma ketoprofen concentrations,"After rectal administration, the mean maximal plasma ketoprofen concentrations were 1.6(+/-0.8), 1.1(+/-0.7) and 1.6(+/-0.2) micrograms/mL for the fatty suppository, the hydrophilic suppository and the liquid suspension respectively.",Bioavailability of ketoprofen in horses after rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8905569/),[μg] / [ml],1.6,133106,DB01009,Ketoprofen
,8905569,absolute bioavailability,"The absolute bioavailability of ketoprofen in horses after rectal administration of the three formulations was relatively low, with a large interindividual variability (24.5 +/- 9.5%, 28.7 +/- 18% and 31.3 +/- 6.8% for the fatty suppository, the hydrophilic suppository and the liquid suspension respectively).",Bioavailability of ketoprofen in horses after rectal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8905569/),%,24.5,133107,DB01009,Ketoprofen
,8905569,absolute bioavailability,"The absolute bioavailability of ketoprofen in horses after rectal administration of the three formulations was relatively low, with a large interindividual variability (24.5 +/- 9.5%, 28.7 +/- 18% and 31.3 +/- 6.8% for the fatty suppository, the hydrophilic suppository and the liquid suspension respectively).",Bioavailability of ketoprofen in horses after rectal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8905569/),%,28.7,133108,DB01009,Ketoprofen
,8905569,absolute bioavailability,"The absolute bioavailability of ketoprofen in horses after rectal administration of the three formulations was relatively low, with a large interindividual variability (24.5 +/- 9.5%, 28.7 +/- 18% and 31.3 +/- 6.8% for the fatty suppository, the hydrophilic suppository and the liquid suspension respectively).",Bioavailability of ketoprofen in horses after rectal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8905569/),%,31.3,133109,DB01009,Ketoprofen
,6882624,"t1/2,z","However, compared with younger subjects elderly patients showed a significant increase in t1/2,z (2.72 +/- 0.22 vs 1.77 +/- 0.16 h; P less than 0.01) and AUC (70.4 +/- 6.4 vs 29.13 +/- 2.02 mg l-1 h; P less than 0.001), a non-significant reduction of Vd/F per kg bodyweight (0.145 +/- 0.016 vs 0.213 +/- 0.028 l kg-1) and a decrease in total clearance CLT/F (0.037 +/- 0.002 vs 0.071 +/- 0.004 l h-1 kg-1, P less than 0.05).",Pharmacokinetics of ketoprofen in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882624/),h,2.72,135387,DB01009,Ketoprofen
,6882624,"t1/2,z","However, compared with younger subjects elderly patients showed a significant increase in t1/2,z (2.72 +/- 0.22 vs 1.77 +/- 0.16 h; P less than 0.01) and AUC (70.4 +/- 6.4 vs 29.13 +/- 2.02 mg l-1 h; P less than 0.001), a non-significant reduction of Vd/F per kg bodyweight (0.145 +/- 0.016 vs 0.213 +/- 0.028 l kg-1) and a decrease in total clearance CLT/F (0.037 +/- 0.002 vs 0.071 +/- 0.004 l h-1 kg-1, P less than 0.05).",Pharmacokinetics of ketoprofen in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882624/),h,1.77,135388,DB01009,Ketoprofen
,6882624,AUC,"However, compared with younger subjects elderly patients showed a significant increase in t1/2,z (2.72 +/- 0.22 vs 1.77 +/- 0.16 h; P less than 0.01) and AUC (70.4 +/- 6.4 vs 29.13 +/- 2.02 mg l-1 h; P less than 0.001), a non-significant reduction of Vd/F per kg bodyweight (0.145 +/- 0.016 vs 0.213 +/- 0.028 l kg-1) and a decrease in total clearance CLT/F (0.037 +/- 0.002 vs 0.071 +/- 0.004 l h-1 kg-1, P less than 0.05).",Pharmacokinetics of ketoprofen in the elderly. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882624/),[h·mg] / [l],70.4,135389,DB01009,Ketoprofen
,6882624,AUC,"However, compared with younger subjects elderly patients showed a significant increase in t1/2,z (2.72 +/- 0.22 vs 1.77 +/- 0.16 h; P less than 0.01) and AUC (70.4 +/- 6.4 vs 29.13 +/- 2.02 mg l-1 h; P less than 0.001), a non-significant reduction of Vd/F per kg bodyweight (0.145 +/- 0.016 vs 0.213 +/- 0.028 l kg-1) and a decrease in total clearance CLT/F (0.037 +/- 0.002 vs 0.071 +/- 0.004 l h-1 kg-1, P less than 0.05).",Pharmacokinetics of ketoprofen in the elderly. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882624/),[h·mg] / [l],29.13,135390,DB01009,Ketoprofen
,6882624,Vd/F,"However, compared with younger subjects elderly patients showed a significant increase in t1/2,z (2.72 +/- 0.22 vs 1.77 +/- 0.16 h; P less than 0.01) and AUC (70.4 +/- 6.4 vs 29.13 +/- 2.02 mg l-1 h; P less than 0.001), a non-significant reduction of Vd/F per kg bodyweight (0.145 +/- 0.016 vs 0.213 +/- 0.028 l kg-1) and a decrease in total clearance CLT/F (0.037 +/- 0.002 vs 0.071 +/- 0.004 l h-1 kg-1, P less than 0.05).",Pharmacokinetics of ketoprofen in the elderly. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882624/),[l] / [kg],0.145,135391,DB01009,Ketoprofen
,6882624,Vd/F,"However, compared with younger subjects elderly patients showed a significant increase in t1/2,z (2.72 +/- 0.22 vs 1.77 +/- 0.16 h; P less than 0.01) and AUC (70.4 +/- 6.4 vs 29.13 +/- 2.02 mg l-1 h; P less than 0.001), a non-significant reduction of Vd/F per kg bodyweight (0.145 +/- 0.016 vs 0.213 +/- 0.028 l kg-1) and a decrease in total clearance CLT/F (0.037 +/- 0.002 vs 0.071 +/- 0.004 l h-1 kg-1, P less than 0.05).",Pharmacokinetics of ketoprofen in the elderly. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882624/),[l] / [kg],0.213,135392,DB01009,Ketoprofen
,6882624,total clearance CLT/F,"However, compared with younger subjects elderly patients showed a significant increase in t1/2,z (2.72 +/- 0.22 vs 1.77 +/- 0.16 h; P less than 0.01) and AUC (70.4 +/- 6.4 vs 29.13 +/- 2.02 mg l-1 h; P less than 0.001), a non-significant reduction of Vd/F per kg bodyweight (0.145 +/- 0.016 vs 0.213 +/- 0.028 l kg-1) and a decrease in total clearance CLT/F (0.037 +/- 0.002 vs 0.071 +/- 0.004 l h-1 kg-1, P less than 0.05).",Pharmacokinetics of ketoprofen in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882624/),[l] / [h·kg],0.037,135393,DB01009,Ketoprofen
,6882624,total clearance CLT/F,"However, compared with younger subjects elderly patients showed a significant increase in t1/2,z (2.72 +/- 0.22 vs 1.77 +/- 0.16 h; P less than 0.01) and AUC (70.4 +/- 6.4 vs 29.13 +/- 2.02 mg l-1 h; P less than 0.001), a non-significant reduction of Vd/F per kg bodyweight (0.145 +/- 0.016 vs 0.213 +/- 0.028 l kg-1) and a decrease in total clearance CLT/F (0.037 +/- 0.002 vs 0.071 +/- 0.004 l h-1 kg-1, P less than 0.05).",Pharmacokinetics of ketoprofen in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882624/),[l] / [h·kg],0.071,135394,DB01009,Ketoprofen
,8536660,elimination half-life (T1/2 beta),FXN elimination half-life (T1/2 beta) in plasma was 3.37 +/- 1.09 h.,Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),h,3.37,136237,DB01009,Ketoprofen
,8536660,T1/2 beta,"However, in exudate a much longer T1/2 beta was obtained (15.99 +/- 3.80 h).",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),h,15.99,136238,DB01009,Ketoprofen
,8536660,Apparent volume of distribution (Vdarea),Apparent volume of distribution (Vdarea) for FXN was 0.317 +/- 0.126 l/kg and body clearance (ClB) was 0.058 +/- 0.004 l/kg/h.,Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),[l] / [kg],0.317,136239,DB01009,Ketoprofen
,8536660,body clearance (ClB),Apparent volume of distribution (Vdarea) for FXN was 0.317 +/- 0.126 l/kg and body clearance (ClB) was 0.058 +/- 0.004 l/kg/h.,Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),[l] / [h·kg],0.058,136240,DB01009,Ketoprofen
,8536660,T1/2 beta,"T1/2 beta values for R(-) and S(+)KTP were, respectively, 1.09 +/- 0.19 h and 1.51 +/- 0.45 h (plasma) and 19.73 +/- 2.72 h and 22.64 +/- 4.34 h (exudate), respectively.",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),h,1.09,136241,DB01009,Ketoprofen
,8536660,T1/2 beta,"T1/2 beta values for R(-) and S(+)KTP were, respectively, 1.09 +/- 0.19 h and 1.51 +/- 0.45 h (plasma) and 19.73 +/- 2.72 h and 22.64 +/- 4.34 h (exudate), respectively.",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),h,1.51,136242,DB01009,Ketoprofen
,8536660,T1/2 beta,"T1/2 beta values for R(-) and S(+)KTP were, respectively, 1.09 +/- 0.19 h and 1.51 +/- 0.45 h (plasma) and 19.73 +/- 2.72 h and 22.64 +/- 4.34 h (exudate), respectively.",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),h,19.73,136243,DB01009,Ketoprofen
,8536660,T1/2 beta,"T1/2 beta values for R(-) and S(+)KTP were, respectively, 1.09 +/- 0.19 h and 1.51 +/- 0.45 h (plasma) and 19.73 +/- 2.72 h and 22.64 +/- 4.34 h (exudate), respectively.",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),h,22.64,136244,DB01009,Ketoprofen
,8536660,ClB,"ClB values were 0.277 +/- 0.035 l/kg/h and 0.202 +/- 0.022 l/kg/h, respectively.",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),[l] / [h·kg],0.277,136245,DB01009,Ketoprofen
,8536660,ClB,"ClB values were 0.277 +/- 0.035 l/kg/h and 0.202 +/- 0.022 l/kg/h, respectively.",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),[l] / [h·kg],0.202,136246,DB01009,Ketoprofen
,8536660,EC50,"FXN was a more potent inhibitor of exudate PGE2, the EC50 for FXN being lower (P < 0.01) than that for KTP (0.019 +/- 0.010 microgram/ml and 0.057 +/- 0.009 microgram/ml, respectively).",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),[μg] / [ml],0.019,136247,DB01009,Ketoprofen
,8536660,EC50,"FXN was a more potent inhibitor of exudate PGE2, the EC50 for FXN being lower (P < 0.01) than that for KTP (0.019 +/- 0.010 microgram/ml and 0.057 +/- 0.009 microgram/ml, respectively).",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),[μg] / [ml],0.057,136248,DB01009,Ketoprofen
,28635050,Transplacental transfer,"Transplacental transfer value at the steady state of ketoprofen was 4.82%, which was approximately half that of antipyrine (passive marker).",Prediction of sustained fetal toxicity induced by ketoprofen based on PK/PD analysis using human placental perfusion and rat toxicity data. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28635050/),%,4.82,140833,DB01009,Ketoprofen
,12175753,lag time,"The conjugate showed a typical delayed-release pattern after oral administration to rats, i.e., plasma levels of KP increased after a lag time of about 3 h and reached a maximum concentration at about 7 h.",Cyclodextrin conjugate-based controlled release system: repeated- and prolonged-releases of ketoprofen after oral administration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12175753/),h,3,141587,DB01009,Ketoprofen
,31115034,Cmax (maximum plasma concentration),"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[mg] / [l],3.41,141678,DB01009,Ketoprofen
,31115034,AUC0-inf (area under the plasma concentration-time curve from time zero to infinity),"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[h·mg] / [l],10.45,141679,DB01009,Ketoprofen
,31115034,tmax (time to first occurrence of Cmax,"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),h,1.94,141680,DB01009,Ketoprofen
,31115034,Cl (clearance),"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[l] / [h·kg],0.199,141681,DB01009,Ketoprofen
,31115034,Vd/kg,"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[l] / [kg],0.71,141682,DB01009,Ketoprofen
,31115034,volume of distribution per kilo,"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[l] / [kg],0.71,141683,DB01009,Ketoprofen
,31115034,Cmax,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[ng] / [ml],226.4,141684,DB01009,Ketoprofen
,31115034,Cmax,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[ng] / [ml],55.6,141685,DB01009,Ketoprofen
,31115034,AUC0-inf,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[h·ng] / [ml],1903.3,141686,DB01009,Ketoprofen
,31115034,AUC0-inf,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[h·ng] / [ml],790.4,141687,DB01009,Ketoprofen
,31115034,tmax,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),h,1.78,141688,DB01009,Ketoprofen
,31115034,tmax,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),h,2.67,141689,DB01009,Ketoprofen
,9622744,S-to-R,"Mean +/- SD S-to-R serum concentration ratios after i.v. and i.m. administration were 1.36 +/- 0.214 and 1.34 +/- 0.245, respectively.",Stereospecific pharmacokinetics of free and protein-bound ketoprofen in serum and synovial fluid of horses after intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9622744/),,1.36,141805,DB01009,Ketoprofen
,9622744,serum concentration ratios,"Mean +/- SD S-to-R serum concentration ratios after i.v. and i.m. administration were 1.36 +/- 0.214 and 1.34 +/- 0.245, respectively.",Stereospecific pharmacokinetics of free and protein-bound ketoprofen in serum and synovial fluid of horses after intravenous and intramuscular administration. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9622744/),,1.36,141806,DB01009,Ketoprofen
,9622744,serum concentration ratios,"Mean +/- SD S-to-R serum concentration ratios after i.v. and i.m. administration were 1.36 +/- 0.214 and 1.34 +/- 0.245, respectively.",Stereospecific pharmacokinetics of free and protein-bound ketoprofen in serum and synovial fluid of horses after intravenous and intramuscular administration. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9622744/),,1.34,141807,DB01009,Ketoprofen
,8998561,minimum quantifiable concentration,"The minimum quantifiable concentration of the assay was found to be 0.025 or 0.25 microgram/ml based on 1 ml of human or 0.1 ml of rat plasma samples, respectively.","Rapid, sensitive and direct chiral high-performance liquid chromatographic method for ketoprofen enantiomers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8998561/),[μg] / [ml],0.025,142501,DB01009,Ketoprofen
,8998561,minimum quantifiable concentration,"The minimum quantifiable concentration of the assay was found to be 0.025 or 0.25 microgram/ml based on 1 ml of human or 0.1 ml of rat plasma samples, respectively.","Rapid, sensitive and direct chiral high-performance liquid chromatographic method for ketoprofen enantiomers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8998561/),[μg] / [ml],0.25,142502,DB01009,Ketoprofen
,7736918,AUC0-8,"In AA, the AUC0-8 of R- and S-PR were not significantly different in MILDKT rats (R, 15.8 +/- 9.5; S, 1.72 +/- 9.1 mg.hr/liter) as compared with MILDcontrol rats (R, 16.2 +/- 12; S, 1.76 +/- 1.2 mg.hr/liter).",Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736918/),[h·mg] / [l],15.8,142779,DB01009,Ketoprofen
,7736918,AUC0-8,"In AA, the AUC0-8 of R- and S-PR were not significantly different in MILDKT rats (R, 15.8 +/- 9.5; S, 1.72 +/- 9.1 mg.hr/liter) as compared with MILDcontrol rats (R, 16.2 +/- 12; S, 1.76 +/- 1.2 mg.hr/liter).",Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736918/),[h·mg] / [l],1.72,142780,DB01009,Ketoprofen
,7736918,AUC0-8,"In AA, the AUC0-8 of R- and S-PR were not significantly different in MILDKT rats (R, 15.8 +/- 9.5; S, 1.72 +/- 9.1 mg.hr/liter) as compared with MILDcontrol rats (R, 16.2 +/- 12; S, 1.76 +/- 1.2 mg.hr/liter).",Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736918/),[h·mg] / [l],16.2,142781,DB01009,Ketoprofen
,7736918,AUC0-8,"In AA, the AUC0-8 of R- and S-PR were not significantly different in MILDKT rats (R, 15.8 +/- 9.5; S, 1.72 +/- 9.1 mg.hr/liter) as compared with MILDcontrol rats (R, 16.2 +/- 12; S, 1.76 +/- 1.2 mg.hr/liter).",Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736918/),[h·mg] / [l],1.76,142782,DB01009,Ketoprofen
,7736918,AUC0-8,"On the other hand, the AUC0-8 of both enantiomers were significantly lower in SEVEREKT (R, 39.2 +/- 13.2; S, 2.92 +/- 1.2 mg.hr/liter) as compared with SEVEREcontrol (R, 79.9 +/- 17; S, 6.88 +/- 2.1 mg.hr/liter).",Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736918/),[h·mg] / [l],39.2,142783,DB01009,Ketoprofen
,7736918,AUC0-8,"On the other hand, the AUC0-8 of both enantiomers were significantly lower in SEVEREKT (R, 39.2 +/- 13.2; S, 2.92 +/- 1.2 mg.hr/liter) as compared with SEVEREcontrol (R, 79.9 +/- 17; S, 6.88 +/- 2.1 mg.hr/liter).",Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736918/),[h·mg] / [l],2.92,142784,DB01009,Ketoprofen
,7736918,AUC0-8,"On the other hand, the AUC0-8 of both enantiomers were significantly lower in SEVEREKT (R, 39.2 +/- 13.2; S, 2.92 +/- 1.2 mg.hr/liter) as compared with SEVEREcontrol (R, 79.9 +/- 17; S, 6.88 +/- 2.1 mg.hr/liter).",Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736918/),[h·mg] / [l],79.9,142785,DB01009,Ketoprofen
,7736918,AUC0-8,"On the other hand, the AUC0-8 of both enantiomers were significantly lower in SEVEREKT (R, 39.2 +/- 13.2; S, 2.92 +/- 1.2 mg.hr/liter) as compared with SEVEREcontrol (R, 79.9 +/- 17; S, 6.88 +/- 2.1 mg.hr/liter).",Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736918/),[h·mg] / [l],6.88,142786,DB01009,Ketoprofen
,15193725,R,"The calculated electrophoretic parameters of the analytes were as follows: electrophoretic mobility, micorep(-)-R = -0.75 x 10(-4) to -0.30 x 10(-4) cm2/Vs; micorep(+)-S = -0.83 -(-0.38) cm2/Vs and electroosmotic mobility, microEOF = 2.35 x 10(-4) cm2/Vs, migration times, tmigr R = 12.55 - 16.07 min; tmigr s = 13.08 - 16.9 min, resolution factors, RS = 1.88 - 3.70 and chiral selectivity, alpha = 1.16 - 1.34.",High performance capillary electrophoresis for determination of the enantiomers of 2-arylpropionic acid derivatives in human serum. Pharmacokinetic studies of ketoprofen enantiomers following administration of standard and sustained release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15193725/),min,12.55 - 16.07,145171,DB01009,Ketoprofen
,15193725,tmigr s,"The calculated electrophoretic parameters of the analytes were as follows: electrophoretic mobility, micorep(-)-R = -0.75 x 10(-4) to -0.30 x 10(-4) cm2/Vs; micorep(+)-S = -0.83 -(-0.38) cm2/Vs and electroosmotic mobility, microEOF = 2.35 x 10(-4) cm2/Vs, migration times, tmigr R = 12.55 - 16.07 min; tmigr s = 13.08 - 16.9 min, resolution factors, RS = 1.88 - 3.70 and chiral selectivity, alpha = 1.16 - 1.34.",High performance capillary electrophoresis for determination of the enantiomers of 2-arylpropionic acid derivatives in human serum. Pharmacokinetic studies of ketoprofen enantiomers following administration of standard and sustained release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15193725/),min,13.08 - 16.9,145172,DB01009,Ketoprofen
,15193725,Recovery,Recovery of the enantiomers from serum was about 90%.,High performance capillary electrophoresis for determination of the enantiomers of 2-arylpropionic acid derivatives in human serum. Pharmacokinetic studies of ketoprofen enantiomers following administration of standard and sustained release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15193725/),%,90,145173,DB01009,Ketoprofen
,8054251,oral clearance (CLo),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),[l] / [h],11.0,145184,DB01009,Ketoprofen
,8054251,renal clearance (CLR),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),[l] / [h],7.9,145185,DB01009,Ketoprofen
,8054251,percent excreted unchanged,"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),%,72,145186,DB01009,Ketoprofen
,8054251,fraction unbound (fu),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),,0.54,145187,DB01009,Ketoprofen
,12016948,distribution phase T1/2 alpha,"The distribution phase T1/2 alpha of the complexated KP was 0.4 h, while that of the KP entity was 0.56 h, KP in beta-CD inclusion complex could be absorbed more rapidly.",[Studies on the pharmacokinetic-pharmacodynamic model of ketoprofen beta-CD inclusion complex in rabbits]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016948/),h,0.4,147144,DB01009,Ketoprofen
,12016948,distribution phase T1/2 alpha,"The distribution phase T1/2 alpha of the complexated KP was 0.4 h, while that of the KP entity was 0.56 h, KP in beta-CD inclusion complex could be absorbed more rapidly.",[Studies on the pharmacokinetic-pharmacodynamic model of ketoprofen beta-CD inclusion complex in rabbits]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016948/),h,0.56,147145,DB01009,Ketoprofen
,8922555,time to maximum plasma concentration (tmax),"Dexketoprofen trometamol, given as a tablet, is rapidly absorbed, with a time to maximum plasma concentration (tmax) of between 0.25 and 0.75 hours, whereas the tmax for the S-enantiomer after the racemic drug, administered as tablets or capsules prepared with the free acid, is between 0.5 and 3 hours.",Preclinical and clinical development of dexketoprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922555/),h,0.25 and 0.75,147498,DB01009,Ketoprofen
,8922555,tmax,"Dexketoprofen trometamol, given as a tablet, is rapidly absorbed, with a time to maximum plasma concentration (tmax) of between 0.25 and 0.75 hours, whereas the tmax for the S-enantiomer after the racemic drug, administered as tablets or capsules prepared with the free acid, is between 0.5 and 3 hours.",Preclinical and clinical development of dexketoprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922555/),h,0.5 and 3,147499,DB01009,Ketoprofen
,8922555,Peak plasma concentrations,"Peak plasma concentrations of 1.4 and 3.1 mg/L are reached after administration of dexketoprofen trometamol 12.5 and 25 mg, respectively.",Preclinical and clinical development of dexketoprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922555/),[mg] / [l],1.4,147500,DB01009,Ketoprofen
,8922555,Peak plasma concentrations,"Peak plasma concentrations of 1.4 and 3.1 mg/L are reached after administration of dexketoprofen trometamol 12.5 and 25 mg, respectively.",Preclinical and clinical development of dexketoprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922555/),[mg] / [l],3.1,147501,DB01009,Ketoprofen
,2783185,peak plasma concentration,"The peak plasma concentration was 144 +/- 91 ng/ml after the first administration with apparent absorption and elimination half-lives of 3.2 +/- 2.4 h and 27.7 +/- 18.0 h, respectively.",Pharmacokinetics of ketoprofen in man after repeated percutaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783185/),[ng] / [ml],144,147578,DB01009,Ketoprofen
,2783185,apparent absorption,"The peak plasma concentration was 144 +/- 91 ng/ml after the first administration with apparent absorption and elimination half-lives of 3.2 +/- 2.4 h and 27.7 +/- 18.0 h, respectively.",Pharmacokinetics of ketoprofen in man after repeated percutaneous administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783185/),h,3.2,147579,DB01009,Ketoprofen
,2783185,elimination half-lives,"The peak plasma concentration was 144 +/- 91 ng/ml after the first administration with apparent absorption and elimination half-lives of 3.2 +/- 2.4 h and 27.7 +/- 18.0 h, respectively.",Pharmacokinetics of ketoprofen in man after repeated percutaneous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783185/),h,27.7,147580,DB01009,Ketoprofen
,2783185,apparent half-life,"At the end of the study, the apparent half-life of unchanged ketoprofen was 17.1 +/- 9.1 h, and there was no accumulation.",Pharmacokinetics of ketoprofen in man after repeated percutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783185/),h,17.1,147581,DB01009,Ketoprofen
,20950352,IC(50),Pharmacokinetic/pharmacodynamic modelling of the results from the mechanical nociceptive threshold testing gave a median IC(50) for S-ketoprofen of 26.7 μg/mL and an IC(50) for R-ketoprofen of 1.6 μg/mL.,"Ketoprofen in piglets: enantioselective pharmacokinetics, pharmacodynamics and PK/PD modelling. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950352/),[μg] / [ml],26.7,148414,DB01009,Ketoprofen
,20950352,IC(50),Pharmacokinetic/pharmacodynamic modelling of the results from the mechanical nociceptive threshold testing gave a median IC(50) for S-ketoprofen of 26.7 μg/mL and an IC(50) for R-ketoprofen of 1.6 μg/mL.,"Ketoprofen in piglets: enantioselective pharmacokinetics, pharmacodynamics and PK/PD modelling. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950352/),[μg] / [ml],1.6,148415,DB01009,Ketoprofen
,20950352,ED(50),Estimated ED(50) for racemic ketoprofen was 2.5 mg/kg.,"Ketoprofen in piglets: enantioselective pharmacokinetics, pharmacodynamics and PK/PD modelling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950352/),[mg] / [kg],2.5,148416,DB01009,Ketoprofen
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,128.8,153272,DB01009,Ketoprofen
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,48.5,153273,DB01009,Ketoprofen
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,29.2,153274,DB01009,Ketoprofen
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,17.,153275,DB01009,Ketoprofen
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,7,153276,DB01009,Ketoprofen
,34312894,elimination half-life (t1/2ʎz ),"Following the administration of ceftriaxone alone, the elimination half-life (t1/2ʎz ), area under the plasma concentration-time curve from zero (0) hours to infinity (∞) (AUC0-∞ ), total clearance (ClT ), and volume of distribution at steady state were 1.42 h, 182.41 h*µg/ml, 0.22 L/h/kg, and 0.17 L/kg, respectively.",Effect of ketoprofen and tolfenamic acid on intravenous pharmacokinetics of ceftriaxone in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34312894/),h,1.42,154586,DB01009,Ketoprofen
,34312894,area under the plasma concentration-time curve from zero (0) hours to infinity (∞) (AUC0-∞ ),"Following the administration of ceftriaxone alone, the elimination half-life (t1/2ʎz ), area under the plasma concentration-time curve from zero (0) hours to infinity (∞) (AUC0-∞ ), total clearance (ClT ), and volume of distribution at steady state were 1.42 h, 182.41 h*µg/ml, 0.22 L/h/kg, and 0.17 L/kg, respectively.",Effect of ketoprofen and tolfenamic acid on intravenous pharmacokinetics of ceftriaxone in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34312894/),[h·μg] / [ml],182.41,154587,DB01009,Ketoprofen
,34312894,area under the plasma concentration-time curve from zero (0) hours to infinity (∞) (AUC0-∞ ),"Following the administration of ceftriaxone alone, the elimination half-life (t1/2ʎz ), area under the plasma concentration-time curve from zero (0) hours to infinity (∞) (AUC0-∞ ), total clearance (ClT ), and volume of distribution at steady state were 1.42 h, 182.41 h*µg/ml, 0.22 L/h/kg, and 0.17 L/kg, respectively.",Effect of ketoprofen and tolfenamic acid on intravenous pharmacokinetics of ceftriaxone in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34312894/),[l] / [h·kg],0.22,154588,DB01009,Ketoprofen
,34312894,total clearance (ClT ),"Following the administration of ceftriaxone alone, the elimination half-life (t1/2ʎz ), area under the plasma concentration-time curve from zero (0) hours to infinity (∞) (AUC0-∞ ), total clearance (ClT ), and volume of distribution at steady state were 1.42 h, 182.41 h*µg/ml, 0.22 L/h/kg, and 0.17 L/kg, respectively.",Effect of ketoprofen and tolfenamic acid on intravenous pharmacokinetics of ceftriaxone in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34312894/),[h·μg] / [ml],182.41,154589,DB01009,Ketoprofen
,34312894,total clearance (ClT ),"Following the administration of ceftriaxone alone, the elimination half-life (t1/2ʎz ), area under the plasma concentration-time curve from zero (0) hours to infinity (∞) (AUC0-∞ ), total clearance (ClT ), and volume of distribution at steady state were 1.42 h, 182.41 h*µg/ml, 0.22 L/h/kg, and 0.17 L/kg, respectively.",Effect of ketoprofen and tolfenamic acid on intravenous pharmacokinetics of ceftriaxone in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34312894/),[l] / [h·kg],0.22,154590,DB01009,Ketoprofen
,34312894,volume of distribution at steady state,"Following the administration of ceftriaxone alone, the elimination half-life (t1/2ʎz ), area under the plasma concentration-time curve from zero (0) hours to infinity (∞) (AUC0-∞ ), total clearance (ClT ), and volume of distribution at steady state were 1.42 h, 182.41 h*µg/ml, 0.22 L/h/kg, and 0.17 L/kg, respectively.",Effect of ketoprofen and tolfenamic acid on intravenous pharmacokinetics of ceftriaxone in sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34312894/),[l] / [kg],0.17,154591,DB01009,Ketoprofen
≤,34312894,MIC,"While ketoprofen and tolfenamic acid significantly increased the t1/2ʎz and AUC0-∞ of ceftriaxone, they significantly reduced the ClT . Ceftriaxone (40 mg/kg, IV) in concurrent use with ketoprofen and tolfenamic acid can be administrated at the 12 h dosing intervals to maintain T> minimum inhibitory concentration (MIC) values above 60% in the treatment of infections caused by susceptible pathogens with the MIC value of ≤0.75 and ≤1 μg/mL, respectively, in sheep with an inflammatory condition.",Effect of ketoprofen and tolfenamic acid on intravenous pharmacokinetics of ceftriaxone in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34312894/),[μg] / [ml],0.75,154592,DB01009,Ketoprofen
≤,34312894,MIC,"While ketoprofen and tolfenamic acid significantly increased the t1/2ʎz and AUC0-∞ of ceftriaxone, they significantly reduced the ClT . Ceftriaxone (40 mg/kg, IV) in concurrent use with ketoprofen and tolfenamic acid can be administrated at the 12 h dosing intervals to maintain T> minimum inhibitory concentration (MIC) values above 60% in the treatment of infections caused by susceptible pathogens with the MIC value of ≤0.75 and ≤1 μg/mL, respectively, in sheep with an inflammatory condition.",Effect of ketoprofen and tolfenamic acid on intravenous pharmacokinetics of ceftriaxone in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34312894/),[μg] / [ml],1,154593,DB01009,Ketoprofen
,8527271,absolute bioavailability,"The absolute bioavailability of the 50 mg oral dose was 84.5 (s.d. 20.6) % and 81.4 (18.0) % for R-ketoprofen and S-ketoprofen, respectively.",Pharmacokinetics of ketoprofen enantiomers after different doses of the racemate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527271/),%,84.5,155774,DB01009,Ketoprofen
,8527271,absolute bioavailability,"The absolute bioavailability of the 50 mg oral dose was 84.5 (s.d. 20.6) % and 81.4 (18.0) % for R-ketoprofen and S-ketoprofen, respectively.",Pharmacokinetics of ketoprofen enantiomers after different doses of the racemate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527271/),%,81.4,155775,DB01009,Ketoprofen
,27152386,systemic clearance,"Mean ± standard error values for systemic clearance, steady state volume of distribution and terminal elimination half-life were 0.345 ± 0.033 [R(−) KTP] and 0.167 ± 0.016 [S(+) KTP] L/kg/h, 0.344 ± 0.044 [R(−) KTP] and 0.298 ± 0.025 [S(+) KTP] L/kg, and 2.49 ± 0.077 [R(−) KTP] and 2.86 ± 0.102 [S(+) KTP] h, respectively.",Pharmacokinetics of ketoprofen enantiomers following intravenous and oral administration to exercised Thoroughbred horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27152386/),[l] / [h·kg],0.345,158302,DB01009,Ketoprofen
,27152386,steady state volume of distribution,"Mean ± standard error values for systemic clearance, steady state volume of distribution and terminal elimination half-life were 0.345 ± 0.033 [R(−) KTP] and 0.167 ± 0.016 [S(+) KTP] L/kg/h, 0.344 ± 0.044 [R(−) KTP] and 0.298 ± 0.025 [S(+) KTP] L/kg, and 2.49 ± 0.077 [R(−) KTP] and 2.86 ± 0.102 [S(+) KTP] h, respectively.",Pharmacokinetics of ketoprofen enantiomers following intravenous and oral administration to exercised Thoroughbred horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27152386/),[l] / [h·kg],0.167,158303,DB01009,Ketoprofen
,27152386,steady state volume of distribution,"Mean ± standard error values for systemic clearance, steady state volume of distribution and terminal elimination half-life were 0.345 ± 0.033 [R(−) KTP] and 0.167 ± 0.016 [S(+) KTP] L/kg/h, 0.344 ± 0.044 [R(−) KTP] and 0.298 ± 0.025 [S(+) KTP] L/kg, and 2.49 ± 0.077 [R(−) KTP] and 2.86 ± 0.102 [S(+) KTP] h, respectively.",Pharmacokinetics of ketoprofen enantiomers following intravenous and oral administration to exercised Thoroughbred horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27152386/),[l] / [kg],0.344,158304,DB01009,Ketoprofen
,27152386,terminal elimination half-life,"Mean ± standard error values for systemic clearance, steady state volume of distribution and terminal elimination half-life were 0.345 ± 0.033 [R(−) KTP] and 0.167 ± 0.016 [S(+) KTP] L/kg/h, 0.344 ± 0.044 [R(−) KTP] and 0.298 ± 0.025 [S(+) KTP] L/kg, and 2.49 ± 0.077 [R(−) KTP] and 2.86 ± 0.102 [S(+) KTP] h, respectively.",Pharmacokinetics of ketoprofen enantiomers following intravenous and oral administration to exercised Thoroughbred horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27152386/),[l] / [kg],0.298,158305,DB01009,Ketoprofen
,27152386,terminal elimination half-life,"Mean ± standard error values for systemic clearance, steady state volume of distribution and terminal elimination half-life were 0.345 ± 0.033 [R(−) KTP] and 0.167 ± 0.016 [S(+) KTP] L/kg/h, 0.344 ± 0.044 [R(−) KTP] and 0.298 ± 0.025 [S(+) KTP] L/kg, and 2.49 ± 0.077 [R(−) KTP] and 2.86 ± 0.102 [S(+) KTP] h, respectively.",Pharmacokinetics of ketoprofen enantiomers following intravenous and oral administration to exercised Thoroughbred horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27152386/),h,2.49,158306,DB01009,Ketoprofen
,27152386,terminal elimination half-life,"Mean ± standard error values for systemic clearance, steady state volume of distribution and terminal elimination half-life were 0.345 ± 0.033 [R(−) KTP] and 0.167 ± 0.016 [S(+) KTP] L/kg/h, 0.344 ± 0.044 [R(−) KTP] and 0.298 ± 0.025 [S(+) KTP] L/kg, and 2.49 ± 0.077 [R(−) KTP] and 2.86 ± 0.102 [S(+) KTP] h, respectively.",Pharmacokinetics of ketoprofen enantiomers following intravenous and oral administration to exercised Thoroughbred horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27152386/),h,2.86,158307,DB01009,Ketoprofen
,27152386,Oral bioavailability,"Oral bioavailability was calculated as 69.5 ± 10.3% and 88.2 ± 15.9% for R(−) KTP and S(+) KTP, respectively, following administration of the injectable formulation and 53.0 ± 6.0 and 53.0 ± 16.0% for the R(−) KTP and S(+) KTP, respectively, following administration of KTP paste.",Pharmacokinetics of ketoprofen enantiomers following intravenous and oral administration to exercised Thoroughbred horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27152386/),%,69.5,158308,DB01009,Ketoprofen
,27152386,Oral bioavailability,"Oral bioavailability was calculated as 69.5 ± 10.3% and 88.2 ± 15.9% for R(−) KTP and S(+) KTP, respectively, following administration of the injectable formulation and 53.0 ± 6.0 and 53.0 ± 16.0% for the R(−) KTP and S(+) KTP, respectively, following administration of KTP paste.",Pharmacokinetics of ketoprofen enantiomers following intravenous and oral administration to exercised Thoroughbred horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27152386/),%,88.2,158309,DB01009,Ketoprofen
,27152386,Oral bioavailability,"Oral bioavailability was calculated as 69.5 ± 10.3% and 88.2 ± 15.9% for R(−) KTP and S(+) KTP, respectively, following administration of the injectable formulation and 53.0 ± 6.0 and 53.0 ± 16.0% for the R(−) KTP and S(+) KTP, respectively, following administration of KTP paste.",Pharmacokinetics of ketoprofen enantiomers following intravenous and oral administration to exercised Thoroughbred horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27152386/),%,53.0,158310,DB01009,Ketoprofen
,27152386,Oral bioavailability,"Oral bioavailability was calculated as 69.5 ± 10.3% and 88.2 ± 15.9% for R(−) KTP and S(+) KTP, respectively, following administration of the injectable formulation and 53.0 ± 6.0 and 53.0 ± 16.0% for the R(−) KTP and S(+) KTP, respectively, following administration of KTP paste.",Pharmacokinetics of ketoprofen enantiomers following intravenous and oral administration to exercised Thoroughbred horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27152386/),%,53.0,158311,DB01009,Ketoprofen
,21516380,AUC(0-∞),"The values of AUC(0-∞) were 11.89 ± 5.00 and 10.92 ± 4.10 mg h/L for (-)-R and (+)-S enantiomer, respectively, and were lower compared with data obtained in healthy volunteers following administration of the same dose of rac-KTP.",Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21516380/),[h·mg] / [l],11.89,158547,DB01009,Ketoprofen
,21516380,AUC(0-∞),"The values of AUC(0-∞) were 11.89 ± 5.00 and 10.92 ± 4.10 mg h/L for (-)-R and (+)-S enantiomer, respectively, and were lower compared with data obtained in healthy volunteers following administration of the same dose of rac-KTP.",Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21516380/),[h·mg] / [l],10.92,158548,DB01009,Ketoprofen
,21516380,Cl((-)-R ),"Though RA patients represented the same wild genotype, quite significant variabilities (Cl((-)-R ) = 2.37-13.50 L/h and Cl((+)-S ) = 2.44-9.90 L/h) existed in the pharmacokinetics parameters of KTP.",Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21516380/),[l] / [h],2.37-13.50,158549,DB01009,Ketoprofen
,21516380,Cl((+)-S ),"Though RA patients represented the same wild genotype, quite significant variabilities (Cl((-)-R ) = 2.37-13.50 L/h and Cl((+)-S ) = 2.44-9.90 L/h) existed in the pharmacokinetics parameters of KTP.",Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21516380/),[l] / [h],2.44-9.90,158550,DB01009,Ketoprofen
,1770096,flow-rate,The formed diastereomers were chromatographed on a reversed-phase column with a mobile phase of 0.06 M KH2PO4-acetonitrile-triethylamine (65:35:0.1) at a flow-rate of 1 ml/min and a detection wavelength of 275 nm.,Simultaneous determination of ketoprofen enantiomers and probenecid in plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770096/),[ml] / [min],1,159489,DB01009,Ketoprofen
,1770096,minimum quantifiable concentration,The minimum quantifiable concentration was 0.5 micrograms/ml in 100 microliters of rat plasma and urine samples.,Simultaneous determination of ketoprofen enantiomers and probenecid in plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770096/),[μg] / [ml],0.5,159490,DB01009,Ketoprofen
,6318342,plasma half-life,"During the initial phase, plasma half-life, which averaged 1.5 to 2 hours in study patients, was similar to that recorded in controls.",[Pharmacokinetics of ketoprofen in the synovial fluid]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6318342/),h,1.5 to 2,160081,DB01009,Ketoprofen
,6715081,peak plasma ketoprofen concentration,The peak plasma ketoprofen concentration (4.2 micrograms/ml) and apparent elimination half-life (8.4 h) did not markedly alter during the course of the study.,A pharmacokinetic study of repeated doses of a new controlled release form of ketoprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6715081/),[μg] / [ml],4.2,160403,DB01009,Ketoprofen
,6715081,apparent elimination half-life,The peak plasma ketoprofen concentration (4.2 micrograms/ml) and apparent elimination half-life (8.4 h) did not markedly alter during the course of the study.,A pharmacokinetic study of repeated doses of a new controlled release form of ketoprofen. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6715081/),h,8.4,160404,DB01009,Ketoprofen
,33134366,area under the curve (AUC),"In trout, area under the curve (AUC) levels were 115.24 μg hr/mL for IM and 135.69 μg hr/mL for IV groups with a half-life of 4.40 and 3.91 h, respectively.",Pharmacokinetics of Ketoprofen in Nile Tilapia (Oreochromis niloticus) and Rainbow Trout (Oncorhynchus mykiss). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33134366/),[h·μg] / [ml],115.24,160657,DB01009,Ketoprofen
,33134366,area under the curve (AUC),"In trout, area under the curve (AUC) levels were 115.24 μg hr/mL for IM and 135.69 μg hr/mL for IV groups with a half-life of 4.40 and 3.91 h, respectively.",Pharmacokinetics of Ketoprofen in Nile Tilapia (Oreochromis niloticus) and Rainbow Trout (Oncorhynchus mykiss). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33134366/),[h·μg] / [ml],135.69,160658,DB01009,Ketoprofen
,33134366,half-life,"In trout, area under the curve (AUC) levels were 115.24 μg hr/mL for IM and 135.69 μg hr/mL for IV groups with a half-life of 4.40 and 3.91 h, respectively.",Pharmacokinetics of Ketoprofen in Nile Tilapia (Oreochromis niloticus) and Rainbow Trout (Oncorhynchus mykiss). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33134366/),h,4.40,160659,DB01009,Ketoprofen
,33134366,half-life,"In trout, area under the curve (AUC) levels were 115.24 μg hr/mL for IM and 135.69 μg hr/mL for IV groups with a half-life of 4.40 and 3.91 h, respectively.",Pharmacokinetics of Ketoprofen in Nile Tilapia (Oreochromis niloticus) and Rainbow Trout (Oncorhynchus mykiss). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33134366/),h,3.91,160660,DB01009,Ketoprofen
,33134366,AUC,"AUC values of the S- and R-enantiomers were 510 and 194 μg hr/Ml, respectively, corresponding to a faster clearance for the R-enantiomer.",Pharmacokinetics of Ketoprofen in Nile Tilapia (Oreochromis niloticus) and Rainbow Trout (Oncorhynchus mykiss). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33134366/),[h·μg] / [Ml],510,160661,DB01009,Ketoprofen
,33134366,AUC,"AUC values of the S- and R-enantiomers were 510 and 194 μg hr/Ml, respectively, corresponding to a faster clearance for the R-enantiomer.",Pharmacokinetics of Ketoprofen in Nile Tilapia (Oreochromis niloticus) and Rainbow Trout (Oncorhynchus mykiss). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33134366/),[h·μg] / [Ml],194,160662,DB01009,Ketoprofen
,27107851,flow rate,The analysis was performed in less than 3min with a flow rate of 0.2mL/min.,Simultaneous determination of parecoxib sodium and its active metabolite valdecoxib in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study after intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27107851/),[ml] / [min],0.2,166246,DB01009,Ketoprofen
more,27107851,extraction recoveries,The mean extraction recoveries for all analytes obtained from three concentrations of QC plasma samples were more than 89.0% efficient.,Simultaneous determination of parecoxib sodium and its active metabolite valdecoxib in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study after intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27107851/),%·efficient,89.0,166247,DB01009,Ketoprofen
,16848323,in vitro recovery,The in vitro recovery was 28.75% by concentration difference method and the in vivo recovery was (40.3 +/- 2.7) % by retrodialysis method.,[Pharmacokinetic study of ketoprofen in rat by blood microdialysis technique]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16848323/),%,28.75,166807,DB01009,Ketoprofen
,16848323,in vivo recovery,The in vitro recovery was 28.75% by concentration difference method and the in vivo recovery was (40.3 +/- 2.7) % by retrodialysis method.,[Pharmacokinetic study of ketoprofen in rat by blood microdialysis technique]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16848323/),%,40.3,166808,DB01009,Ketoprofen
,16848323,T 1/2,"After i.v. administration of ketoprofen in rat, T 1/2, AUC and CL of unbound ketoprofen were (181 +/- 16) min, (112 +/- 27) microg x min x mL(-1) and (0.22 +/- 0.05) L x min(-1), respectively.",[Pharmacokinetic study of ketoprofen in rat by blood microdialysis technique]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16848323/),min,181,166809,DB01009,Ketoprofen
,16848323,AUC,"After i.v. administration of ketoprofen in rat, T 1/2, AUC and CL of unbound ketoprofen were (181 +/- 16) min, (112 +/- 27) microg x min x mL(-1) and (0.22 +/- 0.05) L x min(-1), respectively.",[Pharmacokinetic study of ketoprofen in rat by blood microdialysis technique]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16848323/),[min·μg] / [ml],112,166810,DB01009,Ketoprofen
,16848323,CL,"After i.v. administration of ketoprofen in rat, T 1/2, AUC and CL of unbound ketoprofen were (181 +/- 16) min, (112 +/- 27) microg x min x mL(-1) and (0.22 +/- 0.05) L x min(-1), respectively.",[Pharmacokinetic study of ketoprofen in rat by blood microdialysis technique]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16848323/),[l] / [min],0.22,166811,DB01009,Ketoprofen
,6487749,highest observed plasma ketoprofen concentrations,The mean +/- standard deviation values for highest observed plasma ketoprofen concentrations were determined by high performance liquid chromatography to be 23 +/- 11 micrograms ml-1 at 0.82 +/- 0.18 h after dosing with ketoprofen capsules and 3.5 +/- 1.0 micrograms ml-1 at 4.9 +/- 1.0 h after dosing with sustained-release pellets.,Comparative pharmacokinetics of ketoprofen derived from single oral doses of ketoprofen capsules or a novel sustained-release pellet formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487749/),[μg] / [ml],23,168001,DB01009,Ketoprofen
,6487749,highest observed plasma ketoprofen concentrations,The mean +/- standard deviation values for highest observed plasma ketoprofen concentrations were determined by high performance liquid chromatography to be 23 +/- 11 micrograms ml-1 at 0.82 +/- 0.18 h after dosing with ketoprofen capsules and 3.5 +/- 1.0 micrograms ml-1 at 4.9 +/- 1.0 h after dosing with sustained-release pellets.,Comparative pharmacokinetics of ketoprofen derived from single oral doses of ketoprofen capsules or a novel sustained-release pellet formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487749/),[μg] / [ml],3.5,168002,DB01009,Ketoprofen
,6487749,apparent ketoprofen elimination half-lives,"The apparent ketoprofen elimination half-lives after these treatments were 3.3 +/- 1.2 h and 8.4 +/- 3.4 h, respectively.",Comparative pharmacokinetics of ketoprofen derived from single oral doses of ketoprofen capsules or a novel sustained-release pellet formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487749/),h,3.3,168003,DB01009,Ketoprofen
,6487749,apparent ketoprofen elimination half-lives,"The apparent ketoprofen elimination half-lives after these treatments were 3.3 +/- 1.2 h and 8.4 +/- 3.4 h, respectively.",Comparative pharmacokinetics of ketoprofen derived from single oral doses of ketoprofen capsules or a novel sustained-release pellet formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487749/),h,8.4,168004,DB01009,Ketoprofen
,16563885,absolute recoveries,"The mean absolute recoveries of loxoprofen, trans- and cis-alcohol for human serum were 89.6 +/- 3.9, 93.5 +/- 3.2, and 93.7 +/- 4.3%, respectively.",Direct and simultaneous analysis of loxoprofen and its diastereometric alcohol metabolites in human serum by on-line column switching liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16563885/),%,89.6,168735,DB01009,Ketoprofen
,16563885,absolute recoveries,"The mean absolute recoveries of loxoprofen, trans- and cis-alcohol for human serum were 89.6 +/- 3.9, 93.5 +/- 3.2, and 93.7 +/- 4.3%, respectively.",Direct and simultaneous analysis of loxoprofen and its diastereometric alcohol metabolites in human serum by on-line column switching liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16563885/),%,93.5,168736,DB01009,Ketoprofen
,16563885,absolute recoveries,"The mean absolute recoveries of loxoprofen, trans- and cis-alcohol for human serum were 89.6 +/- 3.9, 93.5 +/- 3.2, and 93.7 +/- 4.3%, respectively.",Direct and simultaneous analysis of loxoprofen and its diastereometric alcohol metabolites in human serum by on-line column switching liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16563885/),%,93.7,168737,DB01009,Ketoprofen
,16563885,total analytical time,"This analytical method showed excellent sensitivity with small sample volume (50 microl), good precision, accuracy, and speed (total analytical time 18 min), without any loss in chromatographic efficiency.",Direct and simultaneous analysis of loxoprofen and its diastereometric alcohol metabolites in human serum by on-line column switching liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16563885/),min,18,168738,DB01009,Ketoprofen
,16801989,cumulative urinary excretion,"The cumulative urinary excretion of unchanged dexketoprofen, assessed up to 24 hours postdose, was similar in all groups (median values of 7.0%, 8.1% and 9.7% of the administered dose).",Pharmacokinetics of dexketoprofen trometamol in subjects with mild and moderate chronic renal insufficiency. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801989/),%,7.0,169287,DB01009,Ketoprofen
,16801989,cumulative urinary excretion,"The cumulative urinary excretion of unchanged dexketoprofen, assessed up to 24 hours postdose, was similar in all groups (median values of 7.0%, 8.1% and 9.7% of the administered dose).",Pharmacokinetics of dexketoprofen trometamol in subjects with mild and moderate chronic renal insufficiency. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801989/),%,8.1,169288,DB01009,Ketoprofen
,16801989,cumulative urinary excretion,"The cumulative urinary excretion of unchanged dexketoprofen, assessed up to 24 hours postdose, was similar in all groups (median values of 7.0%, 8.1% and 9.7% of the administered dose).",Pharmacokinetics of dexketoprofen trometamol in subjects with mild and moderate chronic renal insufficiency. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801989/),%,9.7,169289,DB01009,Ketoprofen
,9225435,mean residence time,"The absorption rate of ketoprofen administered as the lysine salt was rather low: the mean residence time increased from 31.7 min after IV injection to 128.9 min (after IM injection), and the bioavailability was high (mean 92.4%).",Intramuscular bioavailability of ketoprofen lysine salt in horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9225435/),min,31.7,170696,DB01009,Ketoprofen
,9225435,mean residence time,"The absorption rate of ketoprofen administered as the lysine salt was rather low: the mean residence time increased from 31.7 min after IV injection to 128.9 min (after IM injection), and the bioavailability was high (mean 92.4%).",Intramuscular bioavailability of ketoprofen lysine salt in horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9225435/),min,128.9,170697,DB01009,Ketoprofen
,9225435,bioavailability,"The absorption rate of ketoprofen administered as the lysine salt was rather low: the mean residence time increased from 31.7 min after IV injection to 128.9 min (after IM injection), and the bioavailability was high (mean 92.4%).",Intramuscular bioavailability of ketoprofen lysine salt in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9225435/),%,92.4,170698,DB01009,Ketoprofen
,9769898,oral bioavailability,"The oral bioavailability, evaluated by the area under the K serum concentration curve, was not modified, those of FSR was significantly lower than FR (6%, p < 0.05).",[Impact of the method and timing of administration on the systemic transport of ketoprofen]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9769898/),%,6,176449,DB01009,Ketoprofen
,3604255,Tmax,"Administration of ketoprofen immediately following the heavy meal slightly, but significantly, delayed the absorption of the drug, as evidenced by mean (+/- S.D.)Tmax values of 6.7 (+/- 1.0) and 9.0 (+/- 1.4) hours respectively.",Effect of meal size and composition on the bioavailability of ketoprofen (Oruvail). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604255/),h,6.7,177034,DB01009,Ketoprofen
,3604255,Tmax,"Administration of ketoprofen immediately following the heavy meal slightly, but significantly, delayed the absorption of the drug, as evidenced by mean (+/- S.D.)Tmax values of 6.7 (+/- 1.0) and 9.0 (+/- 1.4) hours respectively.",Effect of meal size and composition on the bioavailability of ketoprofen (Oruvail). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604255/),h,9.0,177035,DB01009,Ketoprofen
,3346825,S:R ratios,"In plasma, small but significant differences were found between concentrations of the enantiomers (mean S:R ratios of 0.81 +/- 0.19 after single and 0.87 +/- 0.11 after repeated doses).",Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3346825/),,0.81,177994,DB01009,Ketoprofen
,3346825,S:R ratios,"In plasma, small but significant differences were found between concentrations of the enantiomers (mean S:R ratios of 0.81 +/- 0.19 after single and 0.87 +/- 0.11 after repeated doses).",Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3346825/),,0.87,177995,DB01009,Ketoprofen
,3346825,S:R ratios,"More than 80% of the given doses was found in urine as conjugated S- and R-KT, the predominant enantiomer being S-KT (mean S:R ratios of 1.19 +/- 0.05 after single and 1.17 +/- 0.05 after repeated doses).",Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3346825/),,1.19,177996,DB01009,Ketoprofen
,3346825,S:R ratios,"More than 80% of the given doses was found in urine as conjugated S- and R-KT, the predominant enantiomer being S-KT (mean S:R ratios of 1.19 +/- 0.05 after single and 1.17 +/- 0.05 after repeated doses).",Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3346825/),,1.17,177997,DB01009,Ketoprofen
,27757013,terminal elimination half-life in blood,Frovatriptan is a second-generation triptan with a longer terminal elimination half-life in blood than other triptans (~26 hours).,Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27757013/),h,26,182748,DB01009,Ketoprofen
,9549653,fractional inversion (Finv),The fractional inversion (Finv) of (R)- ketoprofen was 8.9 +/- 3.3% using plasma data and 10.0 +/- 2.2% using urine data.,Stereoselective pharmacokinetics and inversion of (R)- ketoprofen in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549653/),%,8.9,186222,DB01009,Ketoprofen
,9549653,fractional inversion (Finv),The fractional inversion (Finv) of (R)- ketoprofen was 8.9 +/- 3.3% using plasma data and 10.0 +/- 2.2% using urine data.,Stereoselective pharmacokinetics and inversion of (R)- ketoprofen in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549653/),%,10.0,186223,DB01009,Ketoprofen
,9549653,Half-lives,Half-lives were 130-144 minutes for (R)- ketoprofen and 132-209 minutes for (S)- ketoprofen.,Stereoselective pharmacokinetics and inversion of (R)- ketoprofen in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549653/),min,130-144,186224,DB01009,Ketoprofen
,9549653,Half-lives,Half-lives were 130-144 minutes for (R)- ketoprofen and 132-209 minutes for (S)- ketoprofen.,Stereoselective pharmacokinetics and inversion of (R)- ketoprofen in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549653/),min,132-209,186225,DB01009,Ketoprofen
,7629924,terminal elimination half-life,"The harmonic mean of the terminal elimination half-life of ketoprofen after the first and last dose was 98.2 and 78.0 min, respectively.",Pharmacokinetics of ketoprofen after multiple intravenous doses to mares. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7629924/),min,98.2,186520,DB01009,Ketoprofen
,7629924,terminal elimination half-life,"The harmonic mean of the terminal elimination half-life of ketoprofen after the first and last dose was 98.2 and 78.0 min, respectively.",Pharmacokinetics of ketoprofen after multiple intravenous doses to mares. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7629924/),min,78.0,186521,DB01009,Ketoprofen
,7629924,total plasma clearance,"The median values of the total plasma clearance and the renal clearance after the first dose were 4.81 and 1.93 mL/min/kg, respectively.",Pharmacokinetics of ketoprofen after multiple intravenous doses to mares. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7629924/),[ml] / [kg·min],4.81,186522,DB01009,Ketoprofen
,7629924,renal clearance,"The median values of the total plasma clearance and the renal clearance after the first dose were 4.81 and 1.93 mL/min/kg, respectively.",Pharmacokinetics of ketoprofen after multiple intravenous doses to mares. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7629924/),[ml] / [kg·min],1.93,186523,DB01009,Ketoprofen
,7629924,plasma protein binding,Plasma protein binding of ketoprofen was extensive; the mean plasma protein binding of ketoprofen was 92.8% (SD 3.0%) at 500 ng/mL and 91.6% (SD 0.60%) at 10.0 micrograms/mL.,Pharmacokinetics of ketoprofen after multiple intravenous doses to mares. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7629924/),%,92.8,186524,DB01009,Ketoprofen
,7629924,plasma protein binding,Plasma protein binding of ketoprofen was extensive; the mean plasma protein binding of ketoprofen was 92.8% (SD 3.0%) at 500 ng/mL and 91.6% (SD 0.60%) at 10.0 micrograms/mL.,Pharmacokinetics of ketoprofen after multiple intravenous doses to mares. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7629924/),%,91.6,186525,DB01009,Ketoprofen
,3234462,AUC,AUC of ketoprofen was slightly but significantly larger following multiple (21.2 micrograms.h.ml-1) as compared to single dose administration (19.0 micrograms.h.ml-1).,Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234462/),[h·μg] / [ml],21.2,188834,DB01009,Ketoprofen
,3234462,AUC,AUC of ketoprofen was slightly but significantly larger following multiple (21.2 micrograms.h.ml-1) as compared to single dose administration (19.0 micrograms.h.ml-1).,Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234462/),[h·μg] / [ml],19.0,188835,DB01009,Ketoprofen
,3234462,plasma clearance,"As a result, plasma clearance of ketoprofen was slightly but significantly reduced following multiple dose administration (80.6 ml/min vs 89.3 ml/min).",Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234462/),[ml] / [min],80.6,188836,DB01009,Ketoprofen
,3234462,plasma clearance,"As a result, plasma clearance of ketoprofen was slightly but significantly reduced following multiple dose administration (80.6 ml/min vs 89.3 ml/min).",Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234462/),[ml] / [min],89.3,188837,DB01009,Ketoprofen
,3234462,Total 12-h,Total 12-h urinary recovery of ketoprofen (mostly in the form of ketoprofen glucuronide) was 83.5% of the dose following single dose administration and was significantly greater following multiple dose administration (93.1%).,Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234462/),%,83.,188838,DB01009,Ketoprofen
,3234462,Total 12-h,Total 12-h urinary recovery of ketoprofen (mostly in the form of ketoprofen glucuronide) was 83.5% of the dose following single dose administration and was significantly greater following multiple dose administration (93.1%).,Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234462/),%,93.1,188839,DB01009,Ketoprofen
,3234462,urinary recovery,Total 12-h urinary recovery of ketoprofen (mostly in the form of ketoprofen glucuronide) was 83.5% of the dose following single dose administration and was significantly greater following multiple dose administration (93.1%).,Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234462/),%,83.,188840,DB01009,Ketoprofen
,3234462,urinary recovery,Total 12-h urinary recovery of ketoprofen (mostly in the form of ketoprofen glucuronide) was 83.5% of the dose following single dose administration and was significantly greater following multiple dose administration (93.1%).,Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234462/),%,93.1,188841,DB01009,Ketoprofen
,17890028,bioavailability,"By comparing the AUC0-infinity following oral and intravenous administrations, ketoprofen bioavailability was approximately 100%.",Possibility of enterohepatic recycling of ketoprofen in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17890028/),%,100,189599,DB01009,Ketoprofen
up to,28163223,enhancement ratios,"The studies revealed that the synthesized peptide dendrimers considerably increased the transdermal permeation of ketoprofen and displayed enhancement ratios of up to 3.25 (with A16 dendrimer), compared to passive diffusion of drug alone in vitro.",Influence of peptide dendrimers and sonophoresis on the transdermal delivery of ketoprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28163223/),,3.25,189605,DB01009,Ketoprofen
up to,28163223,enhancement ratios,"Moreover, the combination of peptide dendrimer treatment and ultrasound application worked in synergy and gave enhancement ratios of up to 1369.15 (with ketoprofen-A16 dendrimer complex).",Influence of peptide dendrimers and sonophoresis on the transdermal delivery of ketoprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28163223/),,1369.15,189606,DB01009,Ketoprofen
greater,6418181,bioavailability,The slow-release preparation had a bioavailability greater than 90% as compared with the conventional capsule and produced lower and longer lasting ketoprofen serum levels.,Pharmacokinetics of a slow-release preparation of ketoprofen lysine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6418181/),%,90,192475,DB01009,Ketoprofen
,20840388,T(max),"In an in vivo pharmacokinetic ex vivo pharmacodynamic study, after both p.o. (1-2 mg/kg) and subcutaneous (2 mg/kg) dosing, robenacoxib achieved peak blood concentrations rapidly (T(max) = 1 h for both administration routes) and was cleared from blood relatively rapidly (mean residence time was 1.70 h after p.o. and 1.79 h after subcutaneous dosing).",In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840388/),h,1,196332,DB01009,Ketoprofen
,20840388,mean residence time,"In an in vivo pharmacokinetic ex vivo pharmacodynamic study, after both p.o. (1-2 mg/kg) and subcutaneous (2 mg/kg) dosing, robenacoxib achieved peak blood concentrations rapidly (T(max) = 1 h for both administration routes) and was cleared from blood relatively rapidly (mean residence time was 1.70 h after p.o. and 1.79 h after subcutaneous dosing).",In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840388/),h,1.70,196333,DB01009,Ketoprofen
,20840388,mean residence time,"In an in vivo pharmacokinetic ex vivo pharmacodynamic study, after both p.o. (1-2 mg/kg) and subcutaneous (2 mg/kg) dosing, robenacoxib achieved peak blood concentrations rapidly (T(max) = 1 h for both administration routes) and was cleared from blood relatively rapidly (mean residence time was 1.70 h after p.o. and 1.79 h after subcutaneous dosing).",In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840388/),h,1.79,196334,DB01009,Ketoprofen
,27169284,recovery rate,The recovery rate was 93.1% to 100.4%.,[Plasma ibuprofen enantiomers and their pharmacokinetics in Beagle dogs determined by HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169284/),%,93.1,199121,DB01009,Ketoprofen
,27169284,recovery rate,The recovery rate was 93.1% to 100.4%.,[Plasma ibuprofen enantiomers and their pharmacokinetics in Beagle dogs determined by HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169284/),%,100.4,199122,DB01009,Ketoprofen
,27169284,C(max),"The C(max) of S-ibuprofen in Beagle dog plasma after a single intravenous administration of racemic-ibuprofen, S-ibuprofen and R-ibuprofen were 30.8 ± 4.7, 46.1 ± 5.9 and 20.0 ± 2.6 μg x mL(-1), respectively.",[Plasma ibuprofen enantiomers and their pharmacokinetics in Beagle dogs determined by HPLC]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169284/),[μg] / [ml],30.8,199123,DB01009,Ketoprofen
,27169284,C(max),"The C(max) of S-ibuprofen in Beagle dog plasma after a single intravenous administration of racemic-ibuprofen, S-ibuprofen and R-ibuprofen were 30.8 ± 4.7, 46.1 ± 5.9 and 20.0 ± 2.6 μg x mL(-1), respectively.",[Plasma ibuprofen enantiomers and their pharmacokinetics in Beagle dogs determined by HPLC]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169284/),[μg] / [ml],46.1,199124,DB01009,Ketoprofen
,27169284,C(max),"The C(max) of S-ibuprofen in Beagle dog plasma after a single intravenous administration of racemic-ibuprofen, S-ibuprofen and R-ibuprofen were 30.8 ± 4.7, 46.1 ± 5.9 and 20.0 ± 2.6 μg x mL(-1), respectively.",[Plasma ibuprofen enantiomers and their pharmacokinetics in Beagle dogs determined by HPLC]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169284/),[μg] / [ml],20.0,199125,DB01009,Ketoprofen
,27169284,chiral inversion,"Comparing the pharmacokinetic parameters at different doses, chiral inversion were 70.1% ± 36.6% and 76.4% ± 36.2%, respectively, after intravenous administration of racemic- and R-ibuprofen.",[Plasma ibuprofen enantiomers and their pharmacokinetics in Beagle dogs determined by HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169284/),%,70.1,199126,DB01009,Ketoprofen
,27169284,chiral inversion,"Comparing the pharmacokinetic parameters at different doses, chiral inversion were 70.1% ± 36.6% and 76.4% ± 36.2%, respectively, after intravenous administration of racemic- and R-ibuprofen.",[Plasma ibuprofen enantiomers and their pharmacokinetics in Beagle dogs determined by HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169284/),%,76.4,199127,DB01009,Ketoprofen
,24746290,Steady-state volume of distribution (Vss),"Steady-state volume of distribution (Vss) and clearance (Cl) of S-(+)-ketoprofen after IV administration were 0.22 ± 0.07 and 0.19 ± 0.03 L/kg, and 0.10 ± 0.02 and 0.09 ± 0.01 L/h/kg, at 1 and 3 mg/kg, respectively.",Pharmacokinetics of the individual enantiomer S-(+)-ketoprofen after intravenous and oral administration in dogs at two dose levels. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24746290/),[l] / [kg],0.22,200694,DB01009,Ketoprofen
,24746290,Steady-state volume of distribution (Vss),"Steady-state volume of distribution (Vss) and clearance (Cl) of S-(+)-ketoprofen after IV administration were 0.22 ± 0.07 and 0.19 ± 0.03 L/kg, and 0.10 ± 0.02 and 0.09 ± 0.01 L/h/kg, at 1 and 3 mg/kg, respectively.",Pharmacokinetics of the individual enantiomer S-(+)-ketoprofen after intravenous and oral administration in dogs at two dose levels. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24746290/),[l] / [h·kg],0.10,200695,DB01009,Ketoprofen
,24746290,clearance (Cl),"Steady-state volume of distribution (Vss) and clearance (Cl) of S-(+)-ketoprofen after IV administration were 0.22 ± 0.07 and 0.19 ± 0.03 L/kg, and 0.10 ± 0.02 and 0.09 ± 0.01 L/h/kg, at 1 and 3 mg/kg, respectively.",Pharmacokinetics of the individual enantiomer S-(+)-ketoprofen after intravenous and oral administration in dogs at two dose levels. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24746290/),[l] / [kg],0.19,200696,DB01009,Ketoprofen
,24746290,clearance (Cl),"Steady-state volume of distribution (Vss) and clearance (Cl) of S-(+)-ketoprofen after IV administration were 0.22 ± 0.07 and 0.19 ± 0.03 L/kg, and 0.10 ± 0.02 and 0.09 ± 0.01 L/h/kg, at 1 and 3 mg/kg, respectively.",Pharmacokinetics of the individual enantiomer S-(+)-ketoprofen after intravenous and oral administration in dogs at two dose levels. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24746290/),[l] / [h·kg],0.09,200697,DB01009,Ketoprofen
,24746290,maximum plasma concentrations,"Following PO administration, S-(+)-ketoprofen achieved maximum plasma concentrations of 4.91 ± 0.76 and 12.47 ± 0.62 μg/ml, at two dose levels, respectively.",Pharmacokinetics of the individual enantiomer S-(+)-ketoprofen after intravenous and oral administration in dogs at two dose levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24746290/),[μg] / [ml],4.91,200698,DB01009,Ketoprofen
,24746290,maximum plasma concentrations,"Following PO administration, S-(+)-ketoprofen achieved maximum plasma concentrations of 4.91 ± 0.76 and 12.47 ± 0.62 μg/ml, at two dose levels, respectively.",Pharmacokinetics of the individual enantiomer S-(+)-ketoprofen after intravenous and oral administration in dogs at two dose levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24746290/),[μg] / [ml],12.47,200699,DB01009,Ketoprofen
,24746290,absolute bioavailability,"The absolute bioavailability after PO route was 88.66 ± 12.95% and 85.36 ± 13.90%, respectively.",Pharmacokinetics of the individual enantiomer S-(+)-ketoprofen after intravenous and oral administration in dogs at two dose levels. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24746290/),%,88.66,200700,DB01009,Ketoprofen
,24746290,absolute bioavailability,"The absolute bioavailability after PO route was 88.66 ± 12.95% and 85.36 ± 13.90%, respectively.",Pharmacokinetics of the individual enantiomer S-(+)-ketoprofen after intravenous and oral administration in dogs at two dose levels. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24746290/),%,85.36,200701,DB01009,Ketoprofen
,17315449,clearance,"Pharmacokinetic analyses were performed and indicated that ketoprofen in iguanas administered by the intravenous route has a classical two-compartmental distribution pattern, a slow clearance (67 ml/ kg/hr) and a long terminal half-life (31 hr) compared to ketoprofen studies reported in mammals.",Pharmacokinetics of ketoprofen in the green iguana (Iguana iguana) following single intravenous and intramuscular injections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315449/),[ml] / [h·kg],67,201743,DB01009,Ketoprofen
,17315449,terminal half-life,"Pharmacokinetic analyses were performed and indicated that ketoprofen in iguanas administered by the intravenous route has a classical two-compartmental distribution pattern, a slow clearance (67 ml/ kg/hr) and a long terminal half-life (31 hr) compared to ketoprofen studies reported in mammals.",Pharmacokinetics of ketoprofen in the green iguana (Iguana iguana) following single intravenous and intramuscular injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315449/),h,31,201744,DB01009,Ketoprofen
,17315449,bioavailability,"When delivered by the intramuscular route, bioavailability was 78%.",Pharmacokinetics of ketoprofen in the green iguana (Iguana iguana) following single intravenous and intramuscular injections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315449/),%,78,201745,DB01009,Ketoprofen
,2398469,"time of maximum concentration, tmax","After oral dosing, ketoprofen was rapidly absorbed (time of maximum concentration, tmax: 0.83 +/- 0.61 h), and a comparison with the intravenous solution indicated a complete bioavailability of 0.90 +/- 0.10.","Biopharmaceutical evaluation of ketoprofen following intravenous, oral, and rectal administration in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2398469/),h,0.83,205587,DB01009,Ketoprofen
,2398469,complete bioavailability,"After oral dosing, ketoprofen was rapidly absorbed (time of maximum concentration, tmax: 0.83 +/- 0.61 h), and a comparison with the intravenous solution indicated a complete bioavailability of 0.90 +/- 0.10.","Biopharmaceutical evaluation of ketoprofen following intravenous, oral, and rectal administration in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2398469/),,0.90,205588,DB01009,Ketoprofen
,2398469,bioavailability,A high variability was observed in the plasma concentrations obtained with suppository formulations; bioavailability values were approximately 20% lower than those from the oral solutions.,"Biopharmaceutical evaluation of ketoprofen following intravenous, oral, and rectal administration in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2398469/),%,20,205589,DB01009,Ketoprofen
,8807016,apparent volume of distribution at steady state,"Harmonic mean apparent volume of distribution at steady state was 0.11 (range, 0.095 to 0.13) L/kg, elimination half-life was 0.49 (range, 0.40 to 0.67) hour, and total clearance was 0.17 (range, 0.14 to 0.19) L/kg/h.",Ketoprofen concentrations in plasma and milk after intravenous administration in dairy cattle. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807016/),[l] / [kg],0.11,205646,DB01009,Ketoprofen
,8807016,elimination half-life,"Harmonic mean apparent volume of distribution at steady state was 0.11 (range, 0.095 to 0.13) L/kg, elimination half-life was 0.49 (range, 0.40 to 0.67) hour, and total clearance was 0.17 (range, 0.14 to 0.19) L/kg/h.",Ketoprofen concentrations in plasma and milk after intravenous administration in dairy cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807016/),h,0.49,205647,DB01009,Ketoprofen
,8807016,total clearance,"Harmonic mean apparent volume of distribution at steady state was 0.11 (range, 0.095 to 0.13) L/kg, elimination half-life was 0.49 (range, 0.40 to 0.67) hour, and total clearance was 0.17 (range, 0.14 to 0.19) L/kg/h.",Ketoprofen concentrations in plasma and milk after intravenous administration in dairy cattle. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807016/),[l] / [h·kg],0.17,205648,DB01009,Ketoprofen
,19296517,recoveries,"The recoveries of loxoprofen and ketoprofen were 69.7 and 67.6%, respectively.",Liquid chromatography-tandem mass spectrometry method of loxoprofen in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19296517/),%,69.7,209341,DB01009,Ketoprofen
,19296517,recoveries,"The recoveries of loxoprofen and ketoprofen were 69.7 and 67.6%, respectively.",Liquid chromatography-tandem mass spectrometry method of loxoprofen in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19296517/),%,67.6,209342,DB01009,Ketoprofen
,7439263,t1/2,No significant difference in the mean t1/2 (1.13-1.27 h) was observed after the different modes of administration.,"Pharmacokinetics of ketoprofen following single oral, intramuscular and rectal doses and after repeated oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439263/),h,1.13-1.27,215431,DB01009,Ketoprofen
,7439263,steady-state concentration,The mean steady-state concentration of ketoprofen in plasma ranged from 0.43 to 5.62 microgram/ml after the final dose of a 50 mg q. i. d. regimen.,"Pharmacokinetics of ketoprofen following single oral, intramuscular and rectal doses and after repeated oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439263/),[μg] / [ml],0.43 to 5.62,215432,DB01009,Ketoprofen
,7439263,accumulation ratio,The accumulation ratio was 1.08 +/- 0.08.,"Pharmacokinetics of ketoprofen following single oral, intramuscular and rectal doses and after repeated oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439263/),,1.08,215433,DB01009,Ketoprofen
,8668669,relative bioavailabilities,"The relative bioavailabilities of ketoprofen gel were 0.90 +/- 0.50, 1.08 +/- 0.63, and 0.74 +/- 0.38 when applied to the back, arm, and knee, respectively.",Percutaneous absorption of ketoprofen from different anatomical sites in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668669/),,0.90,215802,DB01009,Ketoprofen
,8668669,relative bioavailabilities,"The relative bioavailabilities of ketoprofen gel were 0.90 +/- 0.50, 1.08 +/- 0.63, and 0.74 +/- 0.38 when applied to the back, arm, and knee, respectively.",Percutaneous absorption of ketoprofen from different anatomical sites in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668669/),,1.08,215803,DB01009,Ketoprofen
,8668669,relative bioavailabilities,"The relative bioavailabilities of ketoprofen gel were 0.90 +/- 0.50, 1.08 +/- 0.63, and 0.74 +/- 0.38 when applied to the back, arm, and knee, respectively.",Percutaneous absorption of ketoprofen from different anatomical sites in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668669/),,0.74,215804,DB01009,Ketoprofen
,8668669,time to C(max),"The time to C(max) ranged from 2.7 to 4.0 hours and was similar for gel treatments on the back and arm, but no longer for the knee treatment.",Percutaneous absorption of ketoprofen from different anatomical sites in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668669/),h,2.7 to 4.0,215805,DB01009,Ketoprofen
,8668669,fraction of dose excreted,The fraction of dose excreted in urine as total S and R enantiomers ranged from 5.41 to 9.10%.,Percutaneous absorption of ketoprofen from different anatomical sites in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668669/),%,5.41 to 9.10,215806,DB01009,Ketoprofen
,31418598,constant release rate,The in vitro release profiles of both C-SSRRMT tablets and capsules showed a constant release rate of about 6 mg/h and were similar to that of the theoretical target linear release profile.,Combined site-specific release retardant mini-matrix tablets (C-SSRRMT) for extended oral delivery of dexketoprofen trometamol: in vitro evaluation and single versus multiple doses pharmacokinetic study in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31418598/),[mg] / [h],6,216249,DB01009,Ketoprofen
,7448348,maximum observed concentrations,"Following single doses, the mean maximum observed concentrations of ketoprofen in plasma (6.56 microgram ml-1) were achieved at 1.1 h; the mean elimination half-life was 1.78 h.",Pharmacokinetic characteristics of ketoprofen suppositories. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448348/),[μg] / [ml],6.56,220454,DB01009,Ketoprofen
,7448348,elimination half-life,"Following single doses, the mean maximum observed concentrations of ketoprofen in plasma (6.56 microgram ml-1) were achieved at 1.1 h; the mean elimination half-life was 1.78 h.",Pharmacokinetic characteristics of ketoprofen suppositories. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448348/),h,1.78,220455,DB01009,Ketoprofen
,1716910,absorption fractions,"Compared to the administration of an oral solution of an equivalent dose of parent ketoprofen, the average absorption fractions for the different prodrugs ranged from 100 to 67%.",Bioavailability of ketoprofen from orally administered ketoprofen-dextran ester prodrugs in the pig. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1716910/),%,100 to 67,221871,DB01009,Ketoprofen
,1716910,lag time,The ketoprofen plasma profiles for all the administered prodrugs exhibited a characteristic lag time of ketoprofen appearance in the blood (2-3 h).,Bioavailability of ketoprofen from orally administered ketoprofen-dextran ester prodrugs in the pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1716910/),h,2-3,221872,DB01009,Ketoprofen
,12667184,Emax,"Both rac-KTP and the separate enantiomers produced marked inhibition of serum thromboxane B2 (TxB2) synthesis (ex vivo) and moderate inhibition of exudate prostaglandin E2 (PGE2) synthesis (in vivo); pharmacodynamic variables for S(+) KTP were Emax (%) = 94 and 100; IC50 (microg/mL) = 0.0033 and 0.0030; N = 0.45 and 0.58, respectively, where Emax is the maximal effect, IC50 the plasma drug concentration producing 50% of Emax and N the slope of log concentration/effect relationship.","Pharmacodynamics, chiral pharmacokinetics and PK-PD modelling of ketoprofen in the goat. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667184/),%,94,224987,DB01009,Ketoprofen
,12667184,Emax,"Both rac-KTP and the separate enantiomers produced marked inhibition of serum thromboxane B2 (TxB2) synthesis (ex vivo) and moderate inhibition of exudate prostaglandin E2 (PGE2) synthesis (in vivo); pharmacodynamic variables for S(+) KTP were Emax (%) = 94 and 100; IC50 (microg/mL) = 0.0033 and 0.0030; N = 0.45 and 0.58, respectively, where Emax is the maximal effect, IC50 the plasma drug concentration producing 50% of Emax and N the slope of log concentration/effect relationship.","Pharmacodynamics, chiral pharmacokinetics and PK-PD modelling of ketoprofen in the goat. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667184/),%,100,224988,DB01009,Ketoprofen
,12667184,IC50,"Both rac-KTP and the separate enantiomers produced marked inhibition of serum thromboxane B2 (TxB2) synthesis (ex vivo) and moderate inhibition of exudate prostaglandin E2 (PGE2) synthesis (in vivo); pharmacodynamic variables for S(+) KTP were Emax (%) = 94 and 100; IC50 (microg/mL) = 0.0033 and 0.0030; N = 0.45 and 0.58, respectively, where Emax is the maximal effect, IC50 the plasma drug concentration producing 50% of Emax and N the slope of log concentration/effect relationship.","Pharmacodynamics, chiral pharmacokinetics and PK-PD modelling of ketoprofen in the goat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667184/),[μg] / [ml],0.0033,224989,DB01009,Ketoprofen
,12667184,IC50,"Both rac-KTP and the separate enantiomers produced marked inhibition of serum thromboxane B2 (TxB2) synthesis (ex vivo) and moderate inhibition of exudate prostaglandin E2 (PGE2) synthesis (in vivo); pharmacodynamic variables for S(+) KTP were Emax (%) = 94 and 100; IC50 (microg/mL) = 0.0033 and 0.0030; N = 0.45 and 0.58, respectively, where Emax is the maximal effect, IC50 the plasma drug concentration producing 50% of Emax and N the slope of log concentration/effect relationship.","Pharmacodynamics, chiral pharmacokinetics and PK-PD modelling of ketoprofen in the goat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667184/),[μg] / [ml],0.00,224990,DB01009,Ketoprofen
,12667184,IC50 ratio,"The IC50 ratio, serum TxB2:exudate PGE2 was 1.10.","Pharmacodynamics, chiral pharmacokinetics and PK-PD modelling of ketoprofen in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667184/),,1.10,224991,DB01009,Ketoprofen
,18499370,permeability,"In vitro occluded skin permeability to ketoprofen from the tape (0.086cmh(-1)) marginally exceeds the value for the drug from carriers in a gel (0.058cmh(-1)), which resembles conventional gel on open excised skin (0.057cmh(-1)); smallness of occlusion-induced permeation enhancement ( approximately 1.5x) may be due to the high tested applied dose.",Occlusion effect on transcutaneous NSAID delivery from conventional and carrier-based formulations. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499370/),1/[cmh],0.086,228903,DB01009,Ketoprofen
,18499370,permeability,"In vitro occluded skin permeability to ketoprofen from the tape (0.086cmh(-1)) marginally exceeds the value for the drug from carriers in a gel (0.058cmh(-1)), which resembles conventional gel on open excised skin (0.057cmh(-1)); smallness of occlusion-induced permeation enhancement ( approximately 1.5x) may be due to the high tested applied dose.",Occlusion effect on transcutaneous NSAID delivery from conventional and carrier-based formulations. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499370/),1/[cmh],0.058,228904,DB01009,Ketoprofen
,18499370,permeability,"In vitro occluded skin permeability to ketoprofen from the tape (0.086cmh(-1)) marginally exceeds the value for the drug from carriers in a gel (0.058cmh(-1)), which resembles conventional gel on open excised skin (0.057cmh(-1)); smallness of occlusion-induced permeation enhancement ( approximately 1.5x) may be due to the high tested applied dose.",Occlusion effect on transcutaneous NSAID delivery from conventional and carrier-based formulations. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499370/),1/[cmh],0.057,228905,DB01009,Ketoprofen
,18499370,permeability,"In contrast, open skin permeability to the drug from the carriers in vitro is approximately 15xlower (0.004cmh(-1)).",Occlusion effect on transcutaneous NSAID delivery from conventional and carrier-based formulations. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499370/),,15x,228906,DB01009,Ketoprofen
,18499370,permeability,"In contrast, open skin permeability to the drug from the carriers in vitro is approximately 15xlower (0.004cmh(-1)).",Occlusion effect on transcutaneous NSAID delivery from conventional and carrier-based formulations. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499370/),1/[cmh],0.004,228907,DB01009,Ketoprofen
,25410631,area under the plasma concentration-time curve (AUC(0→∞)),"More in specific, a greater value for the mean area under the plasma concentration-time curve (AUC(0→∞)) (46.92 ± 7.75 and 11.13 ± 2.18 μg·h/mL for the S(+) and R(-) enantiomer, respectively), a lower apparent clearance (Cl/F) (32.8 ± 5.7 and 139.0 ± 25.1 mL/h·kg for the S(+) and R(-) enantiomer, respectively) and a lower apparent volume of distribution (V(d)/F) (139 ± 14.7 and 496 ± 139.4 mL/kg for the S(+) and R(-) enantiomer, respectively) were calculated for the S(+) enantiomer, indicating enantioselective pharmacokinetics for ketoprofen in calves following i.m. administration.",Enantioselective pharmacokinetics of ketoprofen in calves after intramuscular administration of a racemic mixture. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25410631/),[h·μg] / [ml],46.92,229016,DB01009,Ketoprofen
,25410631,area under the plasma concentration-time curve (AUC(0→∞)),"More in specific, a greater value for the mean area under the plasma concentration-time curve (AUC(0→∞)) (46.92 ± 7.75 and 11.13 ± 2.18 μg·h/mL for the S(+) and R(-) enantiomer, respectively), a lower apparent clearance (Cl/F) (32.8 ± 5.7 and 139.0 ± 25.1 mL/h·kg for the S(+) and R(-) enantiomer, respectively) and a lower apparent volume of distribution (V(d)/F) (139 ± 14.7 and 496 ± 139.4 mL/kg for the S(+) and R(-) enantiomer, respectively) were calculated for the S(+) enantiomer, indicating enantioselective pharmacokinetics for ketoprofen in calves following i.m. administration.",Enantioselective pharmacokinetics of ketoprofen in calves after intramuscular administration of a racemic mixture. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25410631/),[h·μg] / [ml],11.13,229017,DB01009,Ketoprofen
,25410631,apparent clearance (Cl/F),"More in specific, a greater value for the mean area under the plasma concentration-time curve (AUC(0→∞)) (46.92 ± 7.75 and 11.13 ± 2.18 μg·h/mL for the S(+) and R(-) enantiomer, respectively), a lower apparent clearance (Cl/F) (32.8 ± 5.7 and 139.0 ± 25.1 mL/h·kg for the S(+) and R(-) enantiomer, respectively) and a lower apparent volume of distribution (V(d)/F) (139 ± 14.7 and 496 ± 139.4 mL/kg for the S(+) and R(-) enantiomer, respectively) were calculated for the S(+) enantiomer, indicating enantioselective pharmacokinetics for ketoprofen in calves following i.m. administration.",Enantioselective pharmacokinetics of ketoprofen in calves after intramuscular administration of a racemic mixture. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25410631/),[ml] / [h·kg],32.8,229018,DB01009,Ketoprofen
,25410631,apparent clearance (Cl/F),"More in specific, a greater value for the mean area under the plasma concentration-time curve (AUC(0→∞)) (46.92 ± 7.75 and 11.13 ± 2.18 μg·h/mL for the S(+) and R(-) enantiomer, respectively), a lower apparent clearance (Cl/F) (32.8 ± 5.7 and 139.0 ± 25.1 mL/h·kg for the S(+) and R(-) enantiomer, respectively) and a lower apparent volume of distribution (V(d)/F) (139 ± 14.7 and 496 ± 139.4 mL/kg for the S(+) and R(-) enantiomer, respectively) were calculated for the S(+) enantiomer, indicating enantioselective pharmacokinetics for ketoprofen in calves following i.m. administration.",Enantioselective pharmacokinetics of ketoprofen in calves after intramuscular administration of a racemic mixture. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25410631/),[ml] / [h·kg],139.0,229019,DB01009,Ketoprofen
,25410631,apparent volume of distribution (V(d)/F),"More in specific, a greater value for the mean area under the plasma concentration-time curve (AUC(0→∞)) (46.92 ± 7.75 and 11.13 ± 2.18 μg·h/mL for the S(+) and R(-) enantiomer, respectively), a lower apparent clearance (Cl/F) (32.8 ± 5.7 and 139.0 ± 25.1 mL/h·kg for the S(+) and R(-) enantiomer, respectively) and a lower apparent volume of distribution (V(d)/F) (139 ± 14.7 and 496 ± 139.4 mL/kg for the S(+) and R(-) enantiomer, respectively) were calculated for the S(+) enantiomer, indicating enantioselective pharmacokinetics for ketoprofen in calves following i.m. administration.",Enantioselective pharmacokinetics of ketoprofen in calves after intramuscular administration of a racemic mixture. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25410631/),[ml] / [kg],139,229020,DB01009,Ketoprofen
,25410631,apparent volume of distribution (V(d)/F),"More in specific, a greater value for the mean area under the plasma concentration-time curve (AUC(0→∞)) (46.92 ± 7.75 and 11.13 ± 2.18 μg·h/mL for the S(+) and R(-) enantiomer, respectively), a lower apparent clearance (Cl/F) (32.8 ± 5.7 and 139.0 ± 25.1 mL/h·kg for the S(+) and R(-) enantiomer, respectively) and a lower apparent volume of distribution (V(d)/F) (139 ± 14.7 and 496 ± 139.4 mL/kg for the S(+) and R(-) enantiomer, respectively) were calculated for the S(+) enantiomer, indicating enantioselective pharmacokinetics for ketoprofen in calves following i.m. administration.",Enantioselective pharmacokinetics of ketoprofen in calves after intramuscular administration of a racemic mixture. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25410631/),[ml] / [kg],496,229021,DB01009,Ketoprofen
,16801990,Cmax,"Following the single dose, mean (+/- SEM) Cmax were 3027.7 +/- 429.3 ng/ml (healthy subjects), 2856.3 +/- 340.3 ng/ml (Child-Pugh A) and 1937.2 +/- 328.0 ng/ml (Child-Pugh B).",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),[ng] / [ml],3027.7,229306,DB01009,Ketoprofen
,16801990,Cmax,"Following the single dose, mean (+/- SEM) Cmax were 3027.7 +/- 429.3 ng/ml (healthy subjects), 2856.3 +/- 340.3 ng/ml (Child-Pugh A) and 1937.2 +/- 328.0 ng/ml (Child-Pugh B).",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),[ng] / [ml],2856.3,229307,DB01009,Ketoprofen
,16801990,Cmax,"Following the single dose, mean (+/- SEM) Cmax were 3027.7 +/- 429.3 ng/ml (healthy subjects), 2856.3 +/- 340.3 ng/ml (Child-Pugh A) and 1937.2 +/- 328.0 ng/ml (Child-Pugh B).",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),[ng] / [ml],1937.2,229308,DB01009,Ketoprofen
,16801990,tmax,"Median tmax were 0.49 h (0.33-0.68) h, 0.50 h (0.33-0.67) h and 0.67 h (0.33-1.50) h.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),h,0.49,229309,DB01009,Ketoprofen
,16801990,tmax,"Median tmax were 0.49 h (0.33-0.68) h, 0.50 h (0.33-0.67) h and 0.67 h (0.33-1.50) h.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),h,0.50,229310,DB01009,Ketoprofen
,16801990,tmax,"Median tmax were 0.49 h (0.33-0.68) h, 0.50 h (0.33-0.67) h and 0.67 h (0.33-1.50) h.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),h,0.67,229311,DB01009,Ketoprofen
,16801990,AUC0-x,"AUC0-x averaged 3778.0 +/- 439.0 ng.h/ml, 4890.4 +/- 539.1 ng.h/ml and 3985.0 +/- 712.0 ng.h/ml.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),[h·ng] / [ml],3778.0,229312,DB01009,Ketoprofen
,16801990,AUC0-x,"AUC0-x averaged 3778.0 +/- 439.0 ng.h/ml, 4890.4 +/- 539.1 ng.h/ml and 3985.0 +/- 712.0 ng.h/ml.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),[h·ng] / [ml],4890.4,229313,DB01009,Ketoprofen
,16801990,AUC0-x,"AUC0-x averaged 3778.0 +/- 439.0 ng.h/ml, 4890.4 +/- 539.1 ng.h/ml and 3985.0 +/- 712.0 ng.h/ml.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),[h·ng] / [ml],3985.0,229314,DB01009,Ketoprofen
,16801990,CL/F,"Mean CL/F were 101.1 +/- 11.3 ml/h/kg, 73.3 +/- 9.9 ml/h/kg and 88.8 +/- 15.5 ml/h/kg and V/F averaged 0.192 +/- 0.018 l/kg, 0.162 +/- 0.006 l/kg and 0.214 +/- 0.044 l/kg.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),[ml] / [h·kg],101.1,229315,DB01009,Ketoprofen
,16801990,CL/F,"Mean CL/F were 101.1 +/- 11.3 ml/h/kg, 73.3 +/- 9.9 ml/h/kg and 88.8 +/- 15.5 ml/h/kg and V/F averaged 0.192 +/- 0.018 l/kg, 0.162 +/- 0.006 l/kg and 0.214 +/- 0.044 l/kg.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),[ml] / [h·kg],73.3,229316,DB01009,Ketoprofen
,16801990,CL/F,"Mean CL/F were 101.1 +/- 11.3 ml/h/kg, 73.3 +/- 9.9 ml/h/kg and 88.8 +/- 15.5 ml/h/kg and V/F averaged 0.192 +/- 0.018 l/kg, 0.162 +/- 0.006 l/kg and 0.214 +/- 0.044 l/kg.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),[ml] / [h·kg],88.8,229317,DB01009,Ketoprofen
,16801990,V/F,"Mean CL/F were 101.1 +/- 11.3 ml/h/kg, 73.3 +/- 9.9 ml/h/kg and 88.8 +/- 15.5 ml/h/kg and V/F averaged 0.192 +/- 0.018 l/kg, 0.162 +/- 0.006 l/kg and 0.214 +/- 0.044 l/kg.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),[l] / [kg],0.192,229318,DB01009,Ketoprofen
,16801990,V/F,"Mean CL/F were 101.1 +/- 11.3 ml/h/kg, 73.3 +/- 9.9 ml/h/kg and 88.8 +/- 15.5 ml/h/kg and V/F averaged 0.192 +/- 0.018 l/kg, 0.162 +/- 0.006 l/kg and 0.214 +/- 0.044 l/kg.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),[l] / [kg],0.162,229319,DB01009,Ketoprofen
,16801990,V/F,"Mean CL/F were 101.1 +/- 11.3 ml/h/kg, 73.3 +/- 9.9 ml/h/kg and 88.8 +/- 15.5 ml/h/kg and V/F averaged 0.192 +/- 0.018 l/kg, 0.162 +/- 0.006 l/kg and 0.214 +/- 0.044 l/kg.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),[l] / [kg],0.214,229320,DB01009,Ketoprofen
,16801990,excretions,"As related to the administered dose, median excretions of unchanged and conjugated dexketoprofen in urine were 2.1% and 67.1% in healthy subjects, 2.8% and 60.9% in Child-Pugh A subjects and 4.4% and 47.7% in Child-Pugh B volunteers.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),%,2.1,229321,DB01009,Ketoprofen
,16801990,excretions,"As related to the administered dose, median excretions of unchanged and conjugated dexketoprofen in urine were 2.1% and 67.1% in healthy subjects, 2.8% and 60.9% in Child-Pugh A subjects and 4.4% and 47.7% in Child-Pugh B volunteers.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),%,67.1,229322,DB01009,Ketoprofen
,16801990,excretions,"As related to the administered dose, median excretions of unchanged and conjugated dexketoprofen in urine were 2.1% and 67.1% in healthy subjects, 2.8% and 60.9% in Child-Pugh A subjects and 4.4% and 47.7% in Child-Pugh B volunteers.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),%,2.8,229323,DB01009,Ketoprofen
,16801990,excretions,"As related to the administered dose, median excretions of unchanged and conjugated dexketoprofen in urine were 2.1% and 67.1% in healthy subjects, 2.8% and 60.9% in Child-Pugh A subjects and 4.4% and 47.7% in Child-Pugh B volunteers.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),%,60.9,229324,DB01009,Ketoprofen
,16801990,excretions,"As related to the administered dose, median excretions of unchanged and conjugated dexketoprofen in urine were 2.1% and 67.1% in healthy subjects, 2.8% and 60.9% in Child-Pugh A subjects and 4.4% and 47.7% in Child-Pugh B volunteers.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),%,4.4,229325,DB01009,Ketoprofen
,16801990,excretions,"As related to the administered dose, median excretions of unchanged and conjugated dexketoprofen in urine were 2.1% and 67.1% in healthy subjects, 2.8% and 60.9% in Child-Pugh A subjects and 4.4% and 47.7% in Child-Pugh B volunteers.",Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801990/),%,47.7,229326,DB01009,Ketoprofen
,10797647,kt,The (R)- and (S)-kt levels were quantifiable from 0.05 to 2500 ng ml(-1) by constructing two separate curves from calibration standards covering the same range.,Determination of (R)- and (S)-ketoprofen in human plasma by liquid chromatography/tandem mass spectrometry following automated solid-phase extraction in the 96-well format. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10797647/),[ng] / [ml],0.05 to 2500,230925,DB01009,Ketoprofen
,10797647,curve,The first curve ranged from 0.05 to 100 and the second from 100 to 2500 ng ml(-1).,Determination of (R)- and (S)-ketoprofen in human plasma by liquid chromatography/tandem mass spectrometry following automated solid-phase extraction in the 96-well format. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10797647/),[ng] / [ml],0.05 to 100,230926,DB01009,Ketoprofen
,10797647,curve,The first curve ranged from 0.05 to 100 and the second from 100 to 2500 ng ml(-1).,Determination of (R)- and (S)-ketoprofen in human plasma by liquid chromatography/tandem mass spectrometry following automated solid-phase extraction in the 96-well format. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10797647/),[ng] / [ml],100 to 2500,230927,DB01009,Ketoprofen
,21369435,relative bioavailability,In vivo pharmacokinetic studies showed a level A correlation (R(2)>0.99) with 39.24 % relative bioavailability compared to immediate release tablet of ketoprofen.,"In situ formed phase transited drug delivery system of ketoprofen for achieving osmotic, controlled and level a in vitro in vivo correlation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369435/),%,39.24,231731,DB01009,Ketoprofen
,8921728,total body clearance (ClB),"The total body clearance (ClB) was 414.0 +/- 98.70 ml/h/kg (mean +/- SD), the volume of distribution at steady state (Vss) 263.10 +/- 55.43 ml/kg and the elimination half-life 1.30 +/- 0.75 h.",Pharmacokinetics of ketoprofen in the donkey (Equus asinus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8921728/),[ml] / [h·kg],414.0,232444,DB01009,Ketoprofen
,8921728,volume of distribution at steady state (Vss),"The total body clearance (ClB) was 414.0 +/- 98.70 ml/h/kg (mean +/- SD), the volume of distribution at steady state (Vss) 263.10 +/- 55.43 ml/kg and the elimination half-life 1.30 +/- 0.75 h.",Pharmacokinetics of ketoprofen in the donkey (Equus asinus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8921728/),[ml] / [kg],263.10,232445,DB01009,Ketoprofen
,8921728,elimination half-life,"The total body clearance (ClB) was 414.0 +/- 98.70 ml/h/kg (mean +/- SD), the volume of distribution at steady state (Vss) 263.10 +/- 55.43 ml/kg and the elimination half-life 1.30 +/- 0.75 h.",Pharmacokinetics of ketoprofen in the donkey (Equus asinus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8921728/),h,1.30,232446,DB01009,Ketoprofen
,17520441,relative bioavailability (frel),The relative bioavailability (frel) of the LT compared with the IR tablet was 168%.,Pilot study of relative bioavailability of two oral formulations of ketoprofen 25 mg in healthy subjects. A fast-dissolving lyophilized tablet as compared to immediate release tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520441/),%,168,232780,DB01009,Ketoprofen
,12648027,maximum plasma concentration,"In the intravenous group, the maximum plasma concentration of ketoprofen ranged between 10.5 and 22.2 mg/L, and in the suppository group, following dose normalisation to 1 mg/kg of ketoprofen, between 3.8 and 7.4 mg/L.",Pharmacokinetics of intravenous and rectal ketoprofen in young children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648027/),[mg] / [l],10.5 and 22.2,235642,DB01009,Ketoprofen
,12648027,maximum plasma concentration,"In the intravenous group, the maximum plasma concentration of ketoprofen ranged between 10.5 and 22.2 mg/L, and in the suppository group, following dose normalisation to 1 mg/kg of ketoprofen, between 3.8 and 7.4 mg/L.",Pharmacokinetics of intravenous and rectal ketoprofen in young children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648027/),[mg] / [l],3.8 and 7.4,235643,DB01009,Ketoprofen
,12648027,area under the concentration-time curve from zero to infinity,"In the intravenous group, area under the concentration-time curve from zero to infinity ranged between 9.2 and 23.5 mg x h/L, and in the suppository group after dose normalisation between 8.8 and 12.9 mg x h/L.",Pharmacokinetics of intravenous and rectal ketoprofen in young children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648027/),[h·mg] / [l],9.2 and 23.5,235644,DB01009,Ketoprofen
,12648027,bioavailability,The bioavailability of ketoprofen from the suppository was about 73%.,Pharmacokinetics of intravenous and rectal ketoprofen in young children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648027/),%,73,235645,DB01009,Ketoprofen
,12648027,Volume of distribution,Volume of distribution was 0.04-0.10 L/kg in the intravenous group and 0.08-0.16 L/kg in the suppository group.,Pharmacokinetics of intravenous and rectal ketoprofen in young children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648027/),[l] / [kg],0.04-0.10,235646,DB01009,Ketoprofen
,12648027,Volume of distribution,Volume of distribution was 0.04-0.10 L/kg in the intravenous group and 0.08-0.16 L/kg in the suppository group.,Pharmacokinetics of intravenous and rectal ketoprofen in young children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648027/),[l] / [kg],0.08-0.16,235647,DB01009,Ketoprofen
,12648027,terminal half-life,"The terminal half-life was comparable in both study groups, ranging between 0.7 and 3.0 hours in the intravenous group and between 1.2 and 2.9 hours in the suppository group.",Pharmacokinetics of intravenous and rectal ketoprofen in young children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648027/),h,0.7 and 3.0,235648,DB01009,Ketoprofen
,12648027,terminal half-life,"The terminal half-life was comparable in both study groups, ranging between 0.7 and 3.0 hours in the intravenous group and between 1.2 and 2.9 hours in the suppository group.",Pharmacokinetics of intravenous and rectal ketoprofen in young children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648027/),h,1.2 and 2.9,235649,DB01009,Ketoprofen
,32104369,size,"The size and zeta potential of prepared CD-g-NMCS nanoparticles were 179.2~274.0 nm and 36.2~42.4 mV, respectively.",Preparation and characterization of β-cyclodextrin grafted N-maleoyl chitosan nanoparticles for drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104369/),nm,179.2,237312,DB01009,Ketoprofen
,32104369,zeta potential,"The size and zeta potential of prepared CD-g-NMCS nanoparticles were 179.2~274.0 nm and 36.2~42.4 mV, respectively.",Preparation and characterization of β-cyclodextrin grafted N-maleoyl chitosan nanoparticles for drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104369/),mv,36.2,237313,DB01009,Ketoprofen
,32104369,zeta potential,"The size and zeta potential of prepared CD-g-NMCS nanoparticles were 179.2~274.0 nm and 36.2~42.4 mV, respectively.",Preparation and characterization of β-cyclodextrin grafted N-maleoyl chitosan nanoparticles for drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104369/),mv,42.4,237314,DB01009,Ketoprofen
,32104369,drug loading efficiency,The drug loading efficiency of CD-g-NMCS20 nanoparticles were 14.8% for KTP.,Preparation and characterization of β-cyclodextrin grafted N-maleoyl chitosan nanoparticles for drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104369/),%,14.8,237315,DB01009,Ketoprofen
,12086732,C(max),"Differently, Orudis retard 200 produced a delayed, higher C(max) (5.91+/-0.66 vs. 4.51+/-0.65 microg/ml; P<0.01) and disappeared more quickly.",Bioavailability of a new ketoprofen formulation for once-daily oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12086732/),[μg] / [ml],5.91,237514,DB01009,Ketoprofen
,12086732,C(max),"Differently, Orudis retard 200 produced a delayed, higher C(max) (5.91+/-0.66 vs. 4.51+/-0.65 microg/ml; P<0.01) and disappeared more quickly.",Bioavailability of a new ketoprofen formulation for once-daily oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12086732/),[μg] / [ml],4.51,237515,DB01009,Ketoprofen
,12833392,flow rate,"The analytes were separated using an acetonitrile-phosphate buffer gradient at a flow rate of 1 mL/min, and UV detection at 282 nm.",Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12833392/),[ml] / [min],1,239549,DB01009,Ketoprofen
,12833392,retention times,"The retention times for aceclofenac, diclofenac, 4'-hydroxy-aceclofenac, 4'-hydroxy-diclofenac and ketoprofen (internal standard) were 69.1, 60.9, 46.9, 28.4 and 21.2 min, respectively.",Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12833392/),min,69.1,239550,DB01009,Ketoprofen
,12833392,retention times,"The retention times for aceclofenac, diclofenac, 4'-hydroxy-aceclofenac, 4'-hydroxy-diclofenac and ketoprofen (internal standard) were 69.1, 60.9, 46.9, 28.4 and 21.2 min, respectively.",Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12833392/),min,60.9,239551,DB01009,Ketoprofen
,12833392,retention times,"The retention times for aceclofenac, diclofenac, 4'-hydroxy-aceclofenac, 4'-hydroxy-diclofenac and ketoprofen (internal standard) were 69.1, 60.9, 46.9, 28.4 and 21.2 min, respectively.",Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12833392/),min,46.9,239552,DB01009,Ketoprofen
,12833392,retention times,"The retention times for aceclofenac, diclofenac, 4'-hydroxy-aceclofenac, 4'-hydroxy-diclofenac and ketoprofen (internal standard) were 69.1, 60.9, 46.9, 28.4 and 21.2 min, respectively.",Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12833392/),min,28.4,239553,DB01009,Ketoprofen
,12833392,retention times,"The retention times for aceclofenac, diclofenac, 4'-hydroxy-aceclofenac, 4'-hydroxy-diclofenac and ketoprofen (internal standard) were 69.1, 60.9, 46.9, 28.4 and 21.2 min, respectively.",Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12833392/),min,21.2,239554,DB01009,Ketoprofen
,12518887,F,"The enantiomers of ketoprofen were absorbed well after oral administration, with median F of 101% for R-ketoprofen and 85% for S-ketoprofen.",Oral bioavailability and pharmacokinetic characteristics of ketoprofen enantiomers after oral and intravenous administration in Asian elephants (Elephas maximus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518887/),%,101,242244,DB01009,Ketoprofen
,12518887,F,"The enantiomers of ketoprofen were absorbed well after oral administration, with median F of 101% for R-ketoprofen and 85% for S-ketoprofen.",Oral bioavailability and pharmacokinetic characteristics of ketoprofen enantiomers after oral and intravenous administration in Asian elephants (Elephas maximus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518887/),%,85,242245,DB01009,Ketoprofen
,12518887,half-life,"Harmonic mean half-life ranged from 3.8 to 5.5 hours, depending on route of administration and enantiomer.",Oral bioavailability and pharmacokinetic characteristics of ketoprofen enantiomers after oral and intravenous administration in Asian elephants (Elephas maximus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518887/),h,3.8 to 5.5,242246,DB01009,Ketoprofen
,8773953,recirculation ratios,"The recirculation ratios of (R)- and (S)-ketoprofen for the single EHC were estimated to be 15.4% and 63.6%, respectively.",Moment analysis of stereoselective enterohepatic circulation and unidirectional chiral inversion of ketoprofen enantiomers in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773953/),%,15.4,243305,DB01009,Ketoprofen
,8773953,recirculation ratios,"The recirculation ratios of (R)- and (S)-ketoprofen for the single EHC were estimated to be 15.4% and 63.6%, respectively.",Moment analysis of stereoselective enterohepatic circulation and unidirectional chiral inversion of ketoprofen enantiomers in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773953/),%,63.6,243306,DB01009,Ketoprofen
,8773953,absorption ratios,"The absorption ratios of (R)- and (S)-ketoprofen for the absorption process from the gastrointestinal tract into the systemic circulation were 87.0% and 83.8%, respectively.",Moment analysis of stereoselective enterohepatic circulation and unidirectional chiral inversion of ketoprofen enantiomers in rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773953/),%,87.0,243307,DB01009,Ketoprofen
,8773953,absorption ratios,"The absorption ratios of (R)- and (S)-ketoprofen for the absorption process from the gastrointestinal tract into the systemic circulation were 87.0% and 83.8%, respectively.",Moment analysis of stereoselective enterohepatic circulation and unidirectional chiral inversion of ketoprofen enantiomers in rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773953/),%,83.8,243308,DB01009,Ketoprofen
,8773953,biliary excretion rations,"The biliary excretion rations of (R)- and (S)-ketoprofen for the disposition process through the systemic circulation into the bile were 17.7% and 75.8%, respectively.",Moment analysis of stereoselective enterohepatic circulation and unidirectional chiral inversion of ketoprofen enantiomers in rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773953/),%,17.7,243309,DB01009,Ketoprofen
,8773953,biliary excretion rations,"The biliary excretion rations of (R)- and (S)-ketoprofen for the disposition process through the systemic circulation into the bile were 17.7% and 75.8%, respectively.",Moment analysis of stereoselective enterohepatic circulation and unidirectional chiral inversion of ketoprofen enantiomers in rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773953/),%,75.8,243310,DB01009,Ketoprofen
,22998765,maximum S-ketoprofen concentration,"The mean (± SD) maximum S-ketoprofen concentration in plasma (7.42 mg/L ± 2.35 in PO and 7.32 mg/L ± 0.75 in IM) was more than twice as high as that of R-ketoprofen (2.55 mg/L ± 0.99 in PO and 3.23 mg/L ± 0.70 in IM), and the terminal half-life was three times longer for S-ketoprofen (3.40 h ± 0.91 in PO and 2.89 h ± 0.85 in IM) than R-ketoprofen (1.1 h ± 0.90 in PO and 0.75 h ± 0.48 in IM).",Enantiospecific ketoprofen concentrations in plasma after oral and intramuscular administration in growing pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998765/),[mg] / [l],7.42,243423,DB01009,Ketoprofen
,22998765,maximum S-ketoprofen concentration,"The mean (± SD) maximum S-ketoprofen concentration in plasma (7.42 mg/L ± 2.35 in PO and 7.32 mg/L ± 0.75 in IM) was more than twice as high as that of R-ketoprofen (2.55 mg/L ± 0.99 in PO and 3.23 mg/L ± 0.70 in IM), and the terminal half-life was three times longer for S-ketoprofen (3.40 h ± 0.91 in PO and 2.89 h ± 0.85 in IM) than R-ketoprofen (1.1 h ± 0.90 in PO and 0.75 h ± 0.48 in IM).",Enantiospecific ketoprofen concentrations in plasma after oral and intramuscular administration in growing pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998765/),[mg] / [l],7.32,243424,DB01009,Ketoprofen
,22998765,maximum S-ketoprofen concentration,"The mean (± SD) maximum S-ketoprofen concentration in plasma (7.42 mg/L ± 2.35 in PO and 7.32 mg/L ± 0.75 in IM) was more than twice as high as that of R-ketoprofen (2.55 mg/L ± 0.99 in PO and 3.23 mg/L ± 0.70 in IM), and the terminal half-life was three times longer for S-ketoprofen (3.40 h ± 0.91 in PO and 2.89 h ± 0.85 in IM) than R-ketoprofen (1.1 h ± 0.90 in PO and 0.75 h ± 0.48 in IM).",Enantiospecific ketoprofen concentrations in plasma after oral and intramuscular administration in growing pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998765/),[mg] / [l],2.55,243425,DB01009,Ketoprofen
,22998765,maximum S-ketoprofen concentration,"The mean (± SD) maximum S-ketoprofen concentration in plasma (7.42 mg/L ± 2.35 in PO and 7.32 mg/L ± 0.75 in IM) was more than twice as high as that of R-ketoprofen (2.55 mg/L ± 0.99 in PO and 3.23 mg/L ± 0.70 in IM), and the terminal half-life was three times longer for S-ketoprofen (3.40 h ± 0.91 in PO and 2.89 h ± 0.85 in IM) than R-ketoprofen (1.1 h ± 0.90 in PO and 0.75 h ± 0.48 in IM).",Enantiospecific ketoprofen concentrations in plasma after oral and intramuscular administration in growing pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998765/),[mg] / [l],3.23,243426,DB01009,Ketoprofen
,22998765,terminal half-life,"The mean (± SD) maximum S-ketoprofen concentration in plasma (7.42 mg/L ± 2.35 in PO and 7.32 mg/L ± 0.75 in IM) was more than twice as high as that of R-ketoprofen (2.55 mg/L ± 0.99 in PO and 3.23 mg/L ± 0.70 in IM), and the terminal half-life was three times longer for S-ketoprofen (3.40 h ± 0.91 in PO and 2.89 h ± 0.85 in IM) than R-ketoprofen (1.1 h ± 0.90 in PO and 0.75 h ± 0.48 in IM).",Enantiospecific ketoprofen concentrations in plasma after oral and intramuscular administration in growing pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998765/),h,3.40,243427,DB01009,Ketoprofen
,22998765,terminal half-life,"The mean (± SD) maximum S-ketoprofen concentration in plasma (7.42 mg/L ± 2.35 in PO and 7.32 mg/L ± 0.75 in IM) was more than twice as high as that of R-ketoprofen (2.55 mg/L ± 0.99 in PO and 3.23 mg/L ± 0.70 in IM), and the terminal half-life was three times longer for S-ketoprofen (3.40 h ± 0.91 in PO and 2.89 h ± 0.85 in IM) than R-ketoprofen (1.1 h ± 0.90 in PO and 0.75 h ± 0.48 in IM).",Enantiospecific ketoprofen concentrations in plasma after oral and intramuscular administration in growing pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998765/),h,2.89,243428,DB01009,Ketoprofen
,22998765,terminal half-life,"The mean (± SD) maximum S-ketoprofen concentration in plasma (7.42 mg/L ± 2.35 in PO and 7.32 mg/L ± 0.75 in IM) was more than twice as high as that of R-ketoprofen (2.55 mg/L ± 0.99 in PO and 3.23 mg/L ± 0.70 in IM), and the terminal half-life was three times longer for S-ketoprofen (3.40 h ± 0.91 in PO and 2.89 h ± 0.85 in IM) than R-ketoprofen (1.1 h ± 0.90 in PO and 0.75 h ± 0.48 in IM).",Enantiospecific ketoprofen concentrations in plasma after oral and intramuscular administration in growing pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998765/),h,1.1,243429,DB01009,Ketoprofen
,22998765,terminal half-life,"The mean (± SD) maximum S-ketoprofen concentration in plasma (7.42 mg/L ± 2.35 in PO and 7.32 mg/L ± 0.75 in IM) was more than twice as high as that of R-ketoprofen (2.55 mg/L ± 0.99 in PO and 3.23 mg/L ± 0.70 in IM), and the terminal half-life was three times longer for S-ketoprofen (3.40 h ± 0.91 in PO and 2.89 h ± 0.85 in IM) than R-ketoprofen (1.1 h ± 0.90 in PO and 0.75 h ± 0.48 in IM).",Enantiospecific ketoprofen concentrations in plasma after oral and intramuscular administration in growing pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998765/),h,0.75,243430,DB01009,Ketoprofen
,22998765,relative bioavailability,"The mean (± SD) relative bioavailability (PO compared to IM) was 83 ± 20% and 63 ± 23% for S-ketoprofen and R-ketoprofen, respectively.",Enantiospecific ketoprofen concentrations in plasma after oral and intramuscular administration in growing pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998765/),%,83,243431,DB01009,Ketoprofen
,22998765,relative bioavailability,"The mean (± SD) relative bioavailability (PO compared to IM) was 83 ± 20% and 63 ± 23% for S-ketoprofen and R-ketoprofen, respectively.",Enantiospecific ketoprofen concentrations in plasma after oral and intramuscular administration in growing pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998765/),%,63,243432,DB01009,Ketoprofen
,3608343,peak plasma concentration,The peak plasma concentration was twice as high after drug administration at 07.00 hours (13.4 +/- 1 mg/L) than after other administration times (13.00 hours: 6.9 +/- 1; 19.00 hours: 7.2 +/- 0.7; 01.00 hours: 6.3 +/- 0.5 mg/L) [p less than 0.001].,Circadian changes in the pharmacokinetics of oral ketoprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608343/),[mg] / [l],13.4,249156,DB01009,Ketoprofen
,3608343,peak plasma concentration,The peak plasma concentration was twice as high after drug administration at 07.00 hours (13.4 +/- 1 mg/L) than after other administration times (13.00 hours: 6.9 +/- 1; 19.00 hours: 7.2 +/- 0.7; 01.00 hours: 6.3 +/- 0.5 mg/L) [p less than 0.001].,Circadian changes in the pharmacokinetics of oral ketoprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608343/),[mg] / [l],7.2,249157,DB01009,Ketoprofen
,3608343,peak plasma concentration,The peak plasma concentration was twice as high after drug administration at 07.00 hours (13.4 +/- 1 mg/L) than after other administration times (13.00 hours: 6.9 +/- 1; 19.00 hours: 7.2 +/- 0.7; 01.00 hours: 6.3 +/- 0.5 mg/L) [p less than 0.001].,Circadian changes in the pharmacokinetics of oral ketoprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608343/),[mg] / [l],6.3,249158,DB01009,Ketoprofen
,3608343,time to reach peak concentration,"The time to reach peak concentration was much longer after drug administration at 01.00 hours (135 +/- 16.7 min) than at 07.00 (73.1 +/- 14.1 min), 13.00 (75 +/- 16.5 min) or 19.00 hours (82.5 +/- 12.7 min) [p less than 0.05].",Circadian changes in the pharmacokinetics of oral ketoprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608343/),min,135,249159,DB01009,Ketoprofen
,3608343,time to reach peak concentration,"The time to reach peak concentration was much longer after drug administration at 01.00 hours (135 +/- 16.7 min) than at 07.00 (73.1 +/- 14.1 min), 13.00 (75 +/- 16.5 min) or 19.00 hours (82.5 +/- 12.7 min) [p less than 0.05].",Circadian changes in the pharmacokinetics of oral ketoprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608343/),min,73.1,249160,DB01009,Ketoprofen
,3608343,time to reach peak concentration,"The time to reach peak concentration was much longer after drug administration at 01.00 hours (135 +/- 16.7 min) than at 07.00 (73.1 +/- 14.1 min), 13.00 (75 +/- 16.5 min) or 19.00 hours (82.5 +/- 12.7 min) [p less than 0.05].",Circadian changes in the pharmacokinetics of oral ketoprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608343/),min,13.00,249161,DB01009,Ketoprofen
,3608343,time to reach peak concentration,"The time to reach peak concentration was much longer after drug administration at 01.00 hours (135 +/- 16.7 min) than at 07.00 (73.1 +/- 14.1 min), 13.00 (75 +/- 16.5 min) or 19.00 hours (82.5 +/- 12.7 min) [p less than 0.05].",Circadian changes in the pharmacokinetics of oral ketoprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608343/),min,75,249162,DB01009,Ketoprofen
,3608343,time to reach peak concentration,"The time to reach peak concentration was much longer after drug administration at 01.00 hours (135 +/- 16.7 min) than at 07.00 (73.1 +/- 14.1 min), 13.00 (75 +/- 16.5 min) or 19.00 hours (82.5 +/- 12.7 min) [p less than 0.05].",Circadian changes in the pharmacokinetics of oral ketoprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608343/),h,19.00,249163,DB01009,Ketoprofen
,3608343,time to reach peak concentration,"The time to reach peak concentration was much longer after drug administration at 01.00 hours (135 +/- 16.7 min) than at 07.00 (73.1 +/- 14.1 min), 13.00 (75 +/- 16.5 min) or 19.00 hours (82.5 +/- 12.7 min) [p less than 0.05].",Circadian changes in the pharmacokinetics of oral ketoprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608343/),min,82.5,249164,DB01009,Ketoprofen
,3608343,lag time,The lag time was significantly longer at 01.00 hours than at 13.00 hours (p less than 0.01).,Circadian changes in the pharmacokinetics of oral ketoprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608343/),h,01,249165,DB01009,Ketoprofen
,3608343,lag time,The lag time was significantly longer at 01.00 hours than at 13.00 hours (p less than 0.01).,Circadian changes in the pharmacokinetics of oral ketoprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608343/),h,13.,249166,DB01009,Ketoprofen
,27086319,highest measured concentration (C max),"In CSF the highest measured concentration (C max) of dexketoprofen was 4.0 (median) ng/mL (minimum-maximum 1.9-13.9) and time to the highest concentration (t max) 3 h (2-5), and for etoricoxib C max 73 ng/mL (36-127) and t max 5 h (1-24), respectively.",The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27086319/),[ng] / [ml],4.0,251471,DB01009,Ketoprofen
,27086319,time to the highest concentration (t max),"In CSF the highest measured concentration (C max) of dexketoprofen was 4.0 (median) ng/mL (minimum-maximum 1.9-13.9) and time to the highest concentration (t max) 3 h (2-5), and for etoricoxib C max 73 ng/mL (36-127) and t max 5 h (1-24), respectively.",The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27086319/),h,3,251472,DB01009,Ketoprofen
,27086319,C max,"In CSF the highest measured concentration (C max) of dexketoprofen was 4.0 (median) ng/mL (minimum-maximum 1.9-13.9) and time to the highest concentration (t max) 3 h (2-5), and for etoricoxib C max 73 ng/mL (36-127) and t max 5 h (1-24), respectively.",The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27086319/),[ng] / [ml],73,251473,DB01009,Ketoprofen
,27086319,t max,"In CSF the highest measured concentration (C max) of dexketoprofen was 4.0 (median) ng/mL (minimum-maximum 1.9-13.9) and time to the highest concentration (t max) 3 h (2-5), and for etoricoxib C max 73 ng/mL (36-127) and t max 5 h (1-24), respectively.",The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27086319/),h,5,251474,DB01009,Ketoprofen
,2670397,elimination half-life,"Even though diclofenac has a relatively short elimination half-life in plasma (1.5 hours), it persists in synovial fluid.",Diclofenac sodium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670397/),h,1.5,252500,DB01009,Ketoprofen
,17184895,accumulative bile excretion,"It was observed that there was significant difference in the accumulative bile excretion of KPGs between the CCl(4) intoxicated rats and the normal rats (54+/-18.3% versus 90+/-6.9%), while it was extremely inhibited in ANIT intoxicated rats (2.0+/-3.1% versus 90+/-6.9%).",Ketoprofen glucuronidation and bile excretion in carbon tetrachloride and alpha-naphthylisothiocyanate induced hepatic injury rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17184895/),%,54,252663,DB01009,Ketoprofen
,17184895,accumulative bile excretion,"It was observed that there was significant difference in the accumulative bile excretion of KPGs between the CCl(4) intoxicated rats and the normal rats (54+/-18.3% versus 90+/-6.9%), while it was extremely inhibited in ANIT intoxicated rats (2.0+/-3.1% versus 90+/-6.9%).",Ketoprofen glucuronidation and bile excretion in carbon tetrachloride and alpha-naphthylisothiocyanate induced hepatic injury rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17184895/),%,90,252664,DB01009,Ketoprofen
,17184895,accumulative bile excretion,"It was observed that there was significant difference in the accumulative bile excretion of KPGs between the CCl(4) intoxicated rats and the normal rats (54+/-18.3% versus 90+/-6.9%), while it was extremely inhibited in ANIT intoxicated rats (2.0+/-3.1% versus 90+/-6.9%).",Ketoprofen glucuronidation and bile excretion in carbon tetrachloride and alpha-naphthylisothiocyanate induced hepatic injury rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17184895/),%,2.0,252665,DB01009,Ketoprofen
,8364755,S(+)/R(-) ratio,"The S(+)/R(-) ratio of the ""areas under the curves"" during the time course of the kinetics, is: 0.60 in dogs, 0.53 in Yucatan micro-pigs, 0.48 in mini-goats, 0.67 in calves and 0.19 in horses.","[Comparative enantioselectivity of the disposition of two non-steroidal anti-inflammatory agents, ketoprofen and carprofen, in man and animals]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364755/),,0.60,254562,DB01009,Ketoprofen
,8364755,S(+)/R(-) ratio,"The S(+)/R(-) ratio of the ""areas under the curves"" during the time course of the kinetics, is: 0.60 in dogs, 0.53 in Yucatan micro-pigs, 0.48 in mini-goats, 0.67 in calves and 0.19 in horses.","[Comparative enantioselectivity of the disposition of two non-steroidal anti-inflammatory agents, ketoprofen and carprofen, in man and animals]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364755/),,0.53,254563,DB01009,Ketoprofen
,8364755,S(+)/R(-) ratio,"The S(+)/R(-) ratio of the ""areas under the curves"" during the time course of the kinetics, is: 0.60 in dogs, 0.53 in Yucatan micro-pigs, 0.48 in mini-goats, 0.67 in calves and 0.19 in horses.","[Comparative enantioselectivity of the disposition of two non-steroidal anti-inflammatory agents, ketoprofen and carprofen, in man and animals]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364755/),,0.48,254564,DB01009,Ketoprofen
,8364755,S(+)/R(-) ratio,"The S(+)/R(-) ratio of the ""areas under the curves"" during the time course of the kinetics, is: 0.60 in dogs, 0.53 in Yucatan micro-pigs, 0.48 in mini-goats, 0.67 in calves and 0.19 in horses.","[Comparative enantioselectivity of the disposition of two non-steroidal anti-inflammatory agents, ketoprofen and carprofen, in man and animals]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364755/),,0,254565,DB01009,Ketoprofen
,32154277,Time to peak concentration (Tmax),"Time to peak concentration (Tmax) of meloxicam, flunixin, and S(-)-ketoprofen in plasma were 1.21, 0.85, and 0.59 h, compared to 2.81, 3.64, and 2.98 h in the ISF, respectively.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,1.21,254566,DB01009,Ketoprofen
,32154277,Time to peak concentration (Tmax),"Time to peak concentration (Tmax) of meloxicam, flunixin, and S(-)-ketoprofen in plasma were 1.21, 0.85, and 0.59 h, compared to 2.81, 3.64, and 2.98 h in the ISF, respectively.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,0.85,254567,DB01009,Ketoprofen
,32154277,Time to peak concentration (Tmax),"Time to peak concentration (Tmax) of meloxicam, flunixin, and S(-)-ketoprofen in plasma were 1.21, 0.85, and 0.59 h, compared to 2.81, 3.64, and 2.98 h in the ISF, respectively.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,0.59,254568,DB01009,Ketoprofen
,32154277,Time to peak concentration (Tmax),"Time to peak concentration (Tmax) of meloxicam, flunixin, and S(-)-ketoprofen in plasma were 1.21, 0.85, and 0.59 h, compared to 2.81, 3.64, and 2.98 h in the ISF, respectively.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,2.81,254569,DB01009,Ketoprofen
,32154277,Time to peak concentration (Tmax),"Time to peak concentration (Tmax) of meloxicam, flunixin, and S(-)-ketoprofen in plasma were 1.21, 0.85, and 0.59 h, compared to 2.81, 3.64, and 2.98 h in the ISF, respectively.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,3.64,254570,DB01009,Ketoprofen
,32154277,Time to peak concentration (Tmax),"Time to peak concentration (Tmax) of meloxicam, flunixin, and S(-)-ketoprofen in plasma were 1.21, 0.85, and 0.59 h, compared to 2.81, 3.64, and 2.98 h in the ISF, respectively.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,2.98,254571,DB01009,Ketoprofen
,32154277,apparent terminal half-life,"The apparent terminal half-life of meloxicam, flunixin and S(-)-ketoprofen were 4.39, 7.69, and 3.50 h, compared to 11.26, 16.34, and 5.54 h, respectively in the ISF.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,4.39,254572,DB01009,Ketoprofen
,32154277,apparent terminal half-life,"The apparent terminal half-life of meloxicam, flunixin and S(-)-ketoprofen were 4.39, 7.69, and 3.50 h, compared to 11.26, 16.34, and 5.54 h, respectively in the ISF.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,7.69,254573,DB01009,Ketoprofen
,32154277,apparent terminal half-life,"The apparent terminal half-life of meloxicam, flunixin and S(-)-ketoprofen were 4.39, 7.69, and 3.50 h, compared to 11.26, 16.34, and 5.54 h, respectively in the ISF.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,3.50,254574,DB01009,Ketoprofen
,32154277,apparent terminal half-life,"The apparent terminal half-life of meloxicam, flunixin and S(-)-ketoprofen were 4.39, 7.69, and 3.50 h, compared to 11.26, 16.34, and 5.54 h, respectively in the ISF.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,11.26,254575,DB01009,Ketoprofen
,32154277,apparent terminal half-life,"The apparent terminal half-life of meloxicam, flunixin and S(-)-ketoprofen were 4.39, 7.69, and 3.50 h, compared to 11.26, 16.34, and 5.54 h, respectively in the ISF.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,16.34,254576,DB01009,Ketoprofen
,32154277,apparent terminal half-life,"The apparent terminal half-life of meloxicam, flunixin and S(-)-ketoprofen were 4.39, 7.69, and 3.50 h, compared to 11.26, 16.34, and 5.54 h, respectively in the ISF.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,5.54,254577,DB01009,Ketoprofen
,12489253,plasma,An average plasma value of 52.8 +/- 30.1 (SD) ng/ml of ketoprofen was obtained in the 10 patients.,Tissue absorption and distribution of ketoprofen after patch application in subjects undergoing knee arthroscopy or endoscopic carpal ligament release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489253/),[ng] / [ml],52.8,254993,DB01009,Ketoprofen
,12489253,tissue concentrations,The tissue concentrations of ketoprofen in the 5 subjects undergoing knee arthroscopy were 27.9 +/- 26.1 ng/g (range 7.2-67.1 ng/g) in the anterior fat pad and 239.0 +/- 163.0 ng/g (range 20.0-430.5 ng/g) in the synovial tissue.,Tissue absorption and distribution of ketoprofen after patch application in subjects undergoing knee arthroscopy or endoscopic carpal ligament release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489253/),[ng] / [g],27.9,254994,DB01009,Ketoprofen
,12489253,tissue concentrations,The tissue concentrations of ketoprofen in the 5 subjects undergoing knee arthroscopy were 27.9 +/- 26.1 ng/g (range 7.2-67.1 ng/g) in the anterior fat pad and 239.0 +/- 163.0 ng/g (range 20.0-430.5 ng/g) in the synovial tissue.,Tissue absorption and distribution of ketoprofen after patch application in subjects undergoing knee arthroscopy or endoscopic carpal ligament release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489253/),[ng] / [g],239.0,254995,DB01009,Ketoprofen
,3677544,equilibrium time,The equilibrium time was about 3 1/2 hours.,Total and free ketoprofen in serum and synovial fluid after intramuscular injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677544/),h,3 1/2,255584,DB01009,Ketoprofen
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),[ng] / [ml],1051.8,256545,DB01009,Ketoprofen
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),[ng] / [ml],335.9,256546,DB01009,Ketoprofen
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),[ng] / [ml],11150,256547,DB01009,Ketoprofen
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,4,256548,DB01009,Ketoprofen
,26512724,Tmax,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,5.3,256549,DB01009,Ketoprofen
,26512724,half-life of elimination,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,13.3,256550,DB01009,Ketoprofen
,26512724,half-life of elimination,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,1.8,256551,DB01009,Ketoprofen
,26512724,half-life of elimination,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,18.7,256552,DB01009,Ketoprofen
,11836052,AUC(F),"AUC(T) of ketoprofen-loaded NCs in plasma was similar to that of the reference solution, while AUC(F) of the former (5.41 mg/l x h) was higher than that produced by the latter (4.03 mg/l x h).",Influence of a polymeric formulation of ketoprofen on its diffusion into cerebrospinal fluid in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11836052/),[mg] / [h·l],5.41,257687,DB01009,Ketoprofen
,11836052,AUC(F),"AUC(T) of ketoprofen-loaded NCs in plasma was similar to that of the reference solution, while AUC(F) of the former (5.41 mg/l x h) was higher than that produced by the latter (4.03 mg/l x h).",Influence of a polymeric formulation of ketoprofen on its diffusion into cerebrospinal fluid in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11836052/),[mg] / [h·l],4.03,257688,DB01009,Ketoprofen
,11836052,unbound fraction (f(u)),"Accordingly, the unbound fraction (f(u)) was higher after administration of NCs than that of the solution (2.5 and 1.8%, respectively).",Influence of a polymeric formulation of ketoprofen on its diffusion into cerebrospinal fluid in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11836052/),%,2.5,257689,DB01009,Ketoprofen
,11836052,unbound fraction (f(u)),"Accordingly, the unbound fraction (f(u)) was higher after administration of NCs than that of the solution (2.5 and 1.8%, respectively).",Influence of a polymeric formulation of ketoprofen on its diffusion into cerebrospinal fluid in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11836052/),%,1.8,257690,DB01009,Ketoprofen
,4091989,peak plasma concentrations,"Mean +/- s.d. peak plasma concentrations (5.6 +/- 1.75 micrograms ml-1 and 6.3 +/- 2.7 micrograms ml-1 on day 1 and day 10, respectively) were higher than those reported in young volunteers given similar treatment, but similar to those reported in young volunteers following 50 mg four times daily of conventionally formulated ketoprofen, and markedly lower than reported following a single 100 mg dose of ketoprofen.",Pharmacokinetic profile of controlled release ketoprofen in elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091989/),[μg] / [ml],5.6,259355,DB01009,Ketoprofen
,4091989,peak plasma concentrations,"Mean +/- s.d. peak plasma concentrations (5.6 +/- 1.75 micrograms ml-1 and 6.3 +/- 2.7 micrograms ml-1 on day 1 and day 10, respectively) were higher than those reported in young volunteers given similar treatment, but similar to those reported in young volunteers following 50 mg four times daily of conventionally formulated ketoprofen, and markedly lower than reported following a single 100 mg dose of ketoprofen.",Pharmacokinetic profile of controlled release ketoprofen in elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091989/),[μg] / [ml],6.3,259356,DB01009,Ketoprofen
,4091989,half-life for drug release,The half-life for drug release (mean +/- s.d.) from the controlled release formulation (8.5 +/- 7.4 h) and accumulation upon repeated dosing (28%) were essentially the same as reported for young volunteers.,Pharmacokinetic profile of controlled release ketoprofen in elderly patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091989/),h,8.5,259357,DB01009,Ketoprofen
,4091989,half-life for drug release,The half-life for drug release (mean +/- s.d.) from the controlled release formulation (8.5 +/- 7.4 h) and accumulation upon repeated dosing (28%) were essentially the same as reported for young volunteers.,Pharmacokinetic profile of controlled release ketoprofen in elderly patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091989/),%,28,259358,DB01009,Ketoprofen
,17955456,AUC(0-24h),"AUC(0-24h) and C(max) of Ketotop-P were 260.92 microg.h/ml and 25.09 microg/ml, respectively, which were about twice the values of Ketotop-L.",Pharmacokinetics and pharmacodynamics of ketoprofen plasters. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17955456/),[h·μg] / [ml],260.92,259901,DB01009,Ketoprofen
,17955456,C(max),"AUC(0-24h) and C(max) of Ketotop-P were 260.92 microg.h/ml and 25.09 microg/ml, respectively, which were about twice the values of Ketotop-L.",Pharmacokinetics and pharmacodynamics of ketoprofen plasters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17955456/),[μg] / [ml],25.09,259902,DB01009,Ketoprofen
,17955456,area under the time-response curve (AUR),"The hind paw edema induced by carrageenan injection was measured for 6 h after applying a 2 x 2 cm(2) plaster, and the area under the time-response curve (AUR) value was significantly lower in Ketotop-P attached rats (180.70%.h) than in those with the Ketotop-L (298.65%.h) and the control (407.04%.h) groups, indicating a stronger anti-inflammatory action of Ketotop-P.",Pharmacokinetics and pharmacodynamics of ketoprofen plasters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17955456/),%·h,180.70,259903,DB01009,Ketoprofen
,17955456,area under the time-response curve (AUR),"The hind paw edema induced by carrageenan injection was measured for 6 h after applying a 2 x 2 cm(2) plaster, and the area under the time-response curve (AUR) value was significantly lower in Ketotop-P attached rats (180.70%.h) than in those with the Ketotop-L (298.65%.h) and the control (407.04%.h) groups, indicating a stronger anti-inflammatory action of Ketotop-P.",Pharmacokinetics and pharmacodynamics of ketoprofen plasters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17955456/),%·h,298.65,259904,DB01009,Ketoprofen
,17955456,area under the time-response curve (AUR),"The hind paw edema induced by carrageenan injection was measured for 6 h after applying a 2 x 2 cm(2) plaster, and the area under the time-response curve (AUR) value was significantly lower in Ketotop-P attached rats (180.70%.h) than in those with the Ketotop-L (298.65%.h) and the control (407.04%.h) groups, indicating a stronger anti-inflammatory action of Ketotop-P.",Pharmacokinetics and pharmacodynamics of ketoprofen plasters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17955456/),%·h,407.04,259905,DB01009,Ketoprofen
,3244610,flow rate,The formed diastereoisomers are chromatographed on a reversed-phase HPLC with a mobile phase consisting of monopotassium phosphate solution:acetonitrile:triethylamine (65:35:0.02) at a flow rate of 1 ml/min.,Stereospecific high-performance liquid chromatographic (HPLC) assay of fenoprofen enantiomers in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3244610/),[ml] / [min],1,260102,DB01009,Ketoprofen
,3244610,UV wavelength,"The detection UV wavelengths are 232 and 275 for the drug and IS, respectively.",Stereospecific high-performance liquid chromatographic (HPLC) assay of fenoprofen enantiomers in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3244610/),,232,260103,DB01009,Ketoprofen
,3244610,UV wavelength,"The detection UV wavelengths are 232 and 275 for the drug and IS, respectively.",Stereospecific high-performance liquid chromatographic (HPLC) assay of fenoprofen enantiomers in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3244610/),,275,260104,DB01009,Ketoprofen
,26364041,plasma oxycodone concentrations (MEC),"At the onset of pain, the plasma oxycodone concentrations (MEC) were similar in the two groups: median 60 ng/mL (range 37-73) in the 10 mg group and median 52 ng/mL (range 24-79) in the 50 mg group.",A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364041/),[ng] / [ml],60,260908,DB01009,Ketoprofen
,26364041,plasma oxycodone concentrations (MEC),"At the onset of pain, the plasma oxycodone concentrations (MEC) were similar in the two groups: median 60 ng/mL (range 37-73) in the 10 mg group and median 52 ng/mL (range 24-79) in the 50 mg group.",A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364041/),[ng] / [ml],52,260909,DB01009,Ketoprofen
,26364041,MEACs,"At the time of pain relief, the MEACs were 98 ng/mL (range 59-150) in the 10 mg group and 80 ng/mL (range 45-128) in the 50 mg group.",A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364041/),[ng] / [ml],98,260910,DB01009,Ketoprofen
,26364041,MEACs,"At the time of pain relief, the MEACs were 98 ng/mL (range 59-150) in the 10 mg group and 80 ng/mL (range 45-128) in the 50 mg group.",A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364041/),[ng] / [ml],80,260911,DB01009,Ketoprofen
,17227721,limit of detection,The quantification range is 25-5000 ng/ml with a limit of detection of 3 ng/ml using only 10 microl sample volume.,Rapid online-SPE-MS/MS method for ketoprofen determination in dermal interstitial fluid samples from rats obtained by microdialysis or open-flow microperfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17227721/),[ng] / [ml],3,262603,DB01009,Ketoprofen
,21781136,internal volume,"Four cylindrical silicon tissue cages (TC, internal volume: 6.7 ± 0.11 cm(3)) were inserted subcutaneously in 29 young healthy cats.",Development and validation of a tissue cage model of acute inflammation in the cat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781136/),cm(3),6.7,262625,DB01009,Ketoprofen
<,18337027,bioavailability,"The drug from Gabrilen diffuses into body with low bioavailability (<10%) and limited regio-selectivity (AUC(deep muscle/plasma) approximately 45/0.8 (t=0-8h), reaching maximum concentration in subcutaneous tissues and plasma at similar time (t(max) approximately 3-4h).",Preclinical characterisation of NSAIDs in ultradeformable carriers or conventional topical gels. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18337027/),%,10,262638,DB01009,Ketoprofen
,18337027,AUC,"The drug from Gabrilen diffuses into body with low bioavailability (<10%) and limited regio-selectivity (AUC(deep muscle/plasma) approximately 45/0.8 (t=0-8h), reaching maximum concentration in subcutaneous tissues and plasma at similar time (t(max) approximately 3-4h).",Preclinical characterisation of NSAIDs in ultradeformable carriers or conventional topical gels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18337027/),,45,262639,DB01009,Ketoprofen
,18337027,t(max),"The drug from Gabrilen diffuses into body with low bioavailability (<10%) and limited regio-selectivity (AUC(deep muscle/plasma) approximately 45/0.8 (t=0-8h), reaching maximum concentration in subcutaneous tissues and plasma at similar time (t(max) approximately 3-4h).",Preclinical characterisation of NSAIDs in ultradeformable carriers or conventional topical gels. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18337027/),h,3-4,262640,DB01009,Ketoprofen
,18337027,"t1/2,a)","The apparent drug elimination half-life is then similar to oral ketoprofen (t1/2,a) approximately 2 h).",Preclinical characterisation of NSAIDs in ultradeformable carriers or conventional topical gels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18337027/),h,2,262641,DB01009,Ketoprofen
,18337027,AUC,"In contrast, Diractin containing ultradeformable carriers (Transfersome vesicles) delivers the drug more efficiently (>50%) and more directly into peripheral muscles (AUC(deep muscle/plasma) approximately 447/0.7 (652/1.4) for t=0-8 (0-24)h; tmax approximately 1 h), arguably in non-diffusive fashion.",Preclinical characterisation of NSAIDs in ultradeformable carriers or conventional topical gels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18337027/),,447,262642,DB01009,Ketoprofen
,18337027,AUC,"In contrast, Diractin containing ultradeformable carriers (Transfersome vesicles) delivers the drug more efficiently (>50%) and more directly into peripheral muscles (AUC(deep muscle/plasma) approximately 447/0.7 (652/1.4) for t=0-8 (0-24)h; tmax approximately 1 h), arguably in non-diffusive fashion.",Preclinical characterisation of NSAIDs in ultradeformable carriers or conventional topical gels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18337027/),,0.7,262643,DB01009,Ketoprofen
,18337027,AUC,"In contrast, Diractin containing ultradeformable carriers (Transfersome vesicles) delivers the drug more efficiently (>50%) and more directly into peripheral muscles (AUC(deep muscle/plasma) approximately 447/0.7 (652/1.4) for t=0-8 (0-24)h; tmax approximately 1 h), arguably in non-diffusive fashion.",Preclinical characterisation of NSAIDs in ultradeformable carriers or conventional topical gels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18337027/),,652/,262644,DB01009,Ketoprofen
,18337027,tmax,"In contrast, Diractin containing ultradeformable carriers (Transfersome vesicles) delivers the drug more efficiently (>50%) and more directly into peripheral muscles (AUC(deep muscle/plasma) approximately 447/0.7 (652/1.4) for t=0-8 (0-24)h; tmax approximately 1 h), arguably in non-diffusive fashion.",Preclinical characterisation of NSAIDs in ultradeformable carriers or conventional topical gels. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18337027/),h,1,262645,DB01009,Ketoprofen
,18337027,"t1/2,a)","Ketoprofen from Diractin moreover disappears from body periphery slower (t1/2,a) approximately 4-6 h), owing to sustained drug release from the carriers in target tissue.",Preclinical characterisation of NSAIDs in ultradeformable carriers or conventional topical gels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18337027/),h,4-6,262646,DB01009,Ketoprofen
,18337027,tmax,Final clearance always proceeds via plasma (tmax approximately 4 h).,Preclinical characterisation of NSAIDs in ultradeformable carriers or conventional topical gels. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18337027/),h,4,262647,DB01009,Ketoprofen
,681491,absolute retention times,"The absolute retention times of the internal standard and ketoprofen are 11.6 and 12.8 min, respectively.",[Determination of ketoprofen in plasma using high-performance liquid chromatography. Comparison with gas--liquid chromatography (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/681491/),min,11.6,263758,DB01009,Ketoprofen
,681491,absolute retention times,"The absolute retention times of the internal standard and ketoprofen are 11.6 and 12.8 min, respectively.",[Determination of ketoprofen in plasma using high-performance liquid chromatography. Comparison with gas--liquid chromatography (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/681491/),min,12.8,263759,DB01009,Ketoprofen
,681491,lower detection limit,The precision of the methods is +/- 4% and the lower detection limit ranges from 0.06 to 0.10 microgram/ml.,[Determination of ketoprofen in plasma using high-performance liquid chromatography. Comparison with gas--liquid chromatography (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/681491/),[μg] / [ml],0.06 to 0.10,263760,DB01009,Ketoprofen
>,11177649,extraction efficiency,The extraction efficiency was >87%.,High performance liquid chromatographic determination of cyclooxygenase II inhibitor rofecoxib in rat and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11177649/),%,87,264655,DB01009,Ketoprofen
,11177649,minimum quantifiable concentration,The minimum quantifiable concentration was set at 10 ng/mL (correlation coefficient of <10%).,High performance liquid chromatographic determination of cyclooxygenase II inhibitor rofecoxib in rat and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11177649/),[ng] / [ml],10,264656,DB01009,Ketoprofen
,9106043,flow-rate,"Following extraction with a disposable C18 solid-phase extraction column, separation of ketoprofen enantiomers and I.S. (3,4-dimethoxy benzoic acid) was achieved using a chiral column [Chirex 3005; (R)-1-naphthylglycine 3,5-dinitrobenzoic acid] with the mobile phase, 0.02 M ammonium acetate in methanol, set at a flow-rate of 1.2 ml/min.",Quantification of ketoprofen enantiomers in human plasma based on solid-phase extraction and enantioselective column chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9106043/),[ml] / [min],1.2,266882,DB01009,Ketoprofen
,23829165,absolute bioavailability (F),3. Pharmacokinetic analysis of Inh-1 revealed an absolute bioavailability (F) of 21% and a short t1/2 of <1 h.,"Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23829165/),%,21,273116,DB01009,Ketoprofen
<,23829165,t1/2,3. Pharmacokinetic analysis of Inh-1 revealed an absolute bioavailability (F) of 21% and a short t1/2 of <1 h.,"Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23829165/),h,1,273117,DB01009,Ketoprofen
,9114902,percentage unbound,6. The mean +/- s.d. percentage unbound of (S)-ketoprofen in plasma (0.801 +/- 0.194%) exceeded (P < 0.05) the corresponding value for its optical antipode (0.724 +/- 0.149%).,The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114902/),%,0.801,273246,DB01009,Ketoprofen
,9114902,percentage unbound,6. The mean +/- s.d. percentage unbound of (S)-ketoprofen in plasma (0.801 +/- 0.194%) exceeded (P < 0.05) the corresponding value for its optical antipode (0.724 +/- 0.149%).,The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114902/),%,0.724,273247,DB01009,Ketoprofen
,9114902,EC50,The mean +/- s.d. EC50 was 0.216 +/- 0.143 ng ml-1.,The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114902/),[ng] / [ml],0.216,273248,DB01009,Ketoprofen
,8568633,absolute bioavailability,The absolute bioavailability of propentofylline from gel preparations was almost 100%.,[Studies on development of pharmaceutical preparation with the purpose of improving controlled-release and bioavailability]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8568633/),%,100,273388,DB01009,Ketoprofen
,9571227,overall degradation rate constants,"The overall degradation rate constants (hr-1) of (R)- and (S)-KP glucuronides were 1.07 +/- 0.154 and 0.55 +/- 0.034, respectively.",Studies on the stereoselective internal acyl migration of ketoprofen glucuronides using 13C labeling and nuclear magnetic resonance spectroscopy. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571227/),1/[h],1.07,274041,DB01009,Ketoprofen
,9571227,overall degradation rate constants,"The overall degradation rate constants (hr-1) of (R)- and (S)-KP glucuronides were 1.07 +/- 0.154 and 0.55 +/- 0.034, respectively.",Studies on the stereoselective internal acyl migration of ketoprofen glucuronides using 13C labeling and nuclear magnetic resonance spectroscopy. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571227/),1/[h],0.55,274042,DB01009,Ketoprofen
,9571227,rate constants,"The rate constants (hr-1) for 1beta-->2beta migration of (R)- and (S)-KP glucuronides were 1.04 +/- 0.158 and 0. 52 +/- 0.029, respectively.",Studies on the stereoselective internal acyl migration of ketoprofen glucuronides using 13C labeling and nuclear magnetic resonance spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571227/),1/[h],1.04,274043,DB01009,Ketoprofen
,9571227,rate constants,"The rate constants (hr-1) for 1beta-->2beta migration of (R)- and (S)-KP glucuronides were 1.04 +/- 0.158 and 0. 52 +/- 0.029, respectively.",Studies on the stereoselective internal acyl migration of ketoprofen glucuronides using 13C labeling and nuclear magnetic resonance spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571227/),1/[h],0. 52,274044,DB01009,Ketoprofen
,24072487,solubility,"The coupling of ketoprofen with β-CD resulted in increased solubility (100% in 60 min) of the newly-formed product, which further resulted in a higher bioavailability compared with ketoprofen (<40% in 120 min).",Comparative assessment of effectiveness of ketoprofen and ketoprofen/beta-cyclodextrin complex in two experimental models of inflammation in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24072487/),%,100,274249,DB01009,Ketoprofen
<,24072487,bioavailability,"The coupling of ketoprofen with β-CD resulted in increased solubility (100% in 60 min) of the newly-formed product, which further resulted in a higher bioavailability compared with ketoprofen (<40% in 120 min).",Comparative assessment of effectiveness of ketoprofen and ketoprofen/beta-cyclodextrin complex in two experimental models of inflammation in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24072487/),%,40,274250,DB01009,Ketoprofen
